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Summary 
Patients with end stage  renal disease (ESRD) have a 20-100 fold risk  of premature 
cardiovascular death compared to age matched controls from the general population. 
These patients have many ‘conventional’ cardiovascular risk factors such as diabetes, 
ischaemic  heart  disease,  hypertension,  cigarette  smoking  and  hyperlipidaemia. 
However, the relationship between the presence of these risk factors and cardiovascular 
outcomes  is  less  clear  in  ESRD  than  in  the  general  population.  In  the  cases  of 
hyperlipidaemia  and  hypertension  a  paradoxical  relationship  has  been  demonstrated 
where  lower  cholesterol  or  blood  pressure  is  associated  with  an  increased  risk  of 
cardiovascular events. One factor previously demonstrated to be associated with poor 
prognosis is the presence of uraemic cardiomyopathy, found in approximately 70% of 
ESRD patients at initiation of dialysis therapy, usually defined echocardiographically as 
the  presence  of  left  ventricular  (LV)  abnormalities,  including  left  ventricular 
hypertrophy  (LVH),  LV  dilatation  and  LV  systolic  dysfunction.  However, 
echocardiography  makes  assumptions  regarding  LV  geometry,  which  is  frequently 
distorted in patients with ESRD. Furthermore any errors in measurements are amplified 
by the changes in hydration status which occur during the dialysis cycle, leading to 
changes  in  LV  chamber  dimensions.  For  these  reasons,  cardiac  magnetic  resonance 
imaging (CMR), by providing high fidelity measurements, potentially offers a ‘volume 
independent’ method of quantifying LV dimensions. Furthermore, by using gadolinium 
based contrast agents, tissue abnormalities particularly myocardial fibrosis, indicated by 
late gadolinium enhancement (LGE) may by identified.  
 
The  work  contained  in  this  thesis  examines  the  relationship  between  cardiac 
dimensions, as defined by CMR and cardiovascular risk factors (both conventional and 
specific  to  uraemia).    In  a  study  of  145  patients  with  ESRD  using  CMR  with 35 
gadolinium, two specific pathological processes were demonstrated. First, the presence 
of subendocardial LGE indicating previous myocardial infarction was associated with 
the  presence  of  conventional  cardiovascular  risk  factors  such  as  previous  ischaemic 
heart  disease  and  diabetes.  Patients  with  subendocardial  LGE  frequently  had  LV 
systolic dysfunction. Second, diffuse LGE, representing fibrosis throughout the LV wall 
was  identified  in  patients  with  LVH.  This  was  an  unexpected  finding  and  appears 
specific  to  uraemia.  Using  CMR,  isolated  LV  dilatation  was  rare.  These  findings 
suggest that in uraemia two forms of cardiomyopathy exist- LV systolic dysfunction 
due  to  underling  myocardial  ischaemia  and  LVH  which  is  a  true  ‘uraemic 
cardiomyopathy’ associated with diffuse myocardial fibrosis. Attempts were made to 
reassess  the  relationship  between  CMR  and  echocardiographic  measures  of  cardiac 
dimensions.  In  keeping  with  a  previous  study,  it  was  demonstrated  that  M-mode 
echocardiography overestimates LV mass compared to CMR in this population. Thus, 
CMR  may  be  used  to  optimise  echocardiographic  formulae  to  calculate  LV  mass. 
Furthermore,  it  appeared  that  either  by  echocardiography  or  by  CMR  the  chief 
determinant of LVH in this population was blood pressure, in particular systolic blood 
pressure.  This  has  implications  for  treatment  as  recent  studies  aimed  at  correcting 
anaemia,  previously  associated  with  LVH,  either  to  reduce  LV  mass  or  to  improve 
survival,  have  generally  demonstrated  increased  cardiovascular  events  with  higher 
haemoglobin. Therefore, if LV mass is a goal of treatment, attempts should be made to 
reduce blood pressure further in this population. 
 
The patients studied in these investigations were candidates for renal transplantation, 
the definitive treatment for chronic renal failure. Cardiovascular disease is the leading 
cause of death both in patients on the renal transplant list, as well as post successful 
transplantation.  There  is  a  great  deal  of  interest  in  identifying  patients  at  high 36 
cardiovascular risk, to allow strategies to be adopted to minimise this risk, frequently by 
undertaking invasive investigation such as coronary angiography. In a survival study of 
300  potential  renal  transplant  recipients,  factors  associated  with  increased  risk  of 
mortality were increased age, ischaemic heart disease whilst receipt of a renal transplant 
was protective. Although the presence of LGE was associated with poorer outcome, this 
finding was not independent of other variables. One interesting finding was that patients 
with greater exercise tolerance, measured objectively using the full Bruce exercise test 
had better outcomes. This observation represents a simple pragmatic method to risk-
stratify such patients. A study using the biomarker brain natriuretic peptide (BNP) a 
peptide released from the LV in response to stretch and hypertrophy, in 114 patients, 
demonstrated that whilst BNP has potential as a diagnostic tool for the presence of 
uraemic cardiomyopathy, in particular LVH, this peptide added little prognostic value.   
 
As familiarity with CMR techniques developed, it became clear that vascular function 
could  be  investigated  with  this  imaging  modality.  Previous  studies  using  alternative 
measures  of  vascular  function  have  suggested  that  arterial  stiffness  is  an  important 
predictor of long term outcome in patients with ESRD. A study of 147 uraemic patients 
using aortic distensibilty and aortic volumetric arterial strain as CMR measures of aortic 
stiffness demonstrated that both these parameters were associated with an increased risk 
of cardiovascular events and mortality. To date there do not appear to be any similar 
outcome studies using these measures, although a number of authors have noted an 
association between aortic distensibilty and cardiovascular risk factors. These factors 
may represent potential targets for therapy aimed at reduction of cardiovascular risk in 
patients with ESRD.  
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One  unfortunate  development  during  the  period  during  which  these  studies  were 
undertaken, was the emergence of a link between exposure to gadolinium based contrast 
agents  and  nephrogenic  systemic  fibrosis  (NSF),  a  potentially  life  threatening  skin 
disorder in patients with advanced renal failure. This finding lead to the cessation of 
contrast CMR studies. A retrospective investigation of factors present  in patients in 
North Glasgow affected by NSF, confirmed that patients with NSF were more likely to 
have undergone contrast based imaging than unaffected patients, frequently undergoing 
multiple scans, with high doses of gadodiamide used. Until this issue is clarified, future 
scans using these agents in this population should be undertaken with caution. 
 
These studies have characterised for the first time the relationship between both uraemic 
cardiomyopathy and uraemic arterial stiffness and both cardiovascular risk factors and 
long  term  outcome.  CMR  measures  of  cardiac  dimensions  and  vascular  function 
represent  future  targets  for  interventions  aimed  at  reducing  cardiovascular  risk  in 
patients with advanced renal failure.  
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1.1    Epidemiology of cardiovascular disease in end stage renal failure 
Premature cardiovascular disease is the leading cause of death in patients with end stage 
renal  disease  (ESRD)  requiring  dialysis  therapy  with  approximate  risk  age  adjusted 
cardiovascular  risk  and  cardiovascular  mortality  rates  around  20  times  those  of  the 
general population(1;2). Prior to the development of haemodialysis (and subsequently 
peritoneal dialysis) as treatment for advanced renal failure, pericarditis and pericardial 
effusions  were  common  and  often  fatal  cardiac  manifestations  of  the  syndrome  of 
terminal uraemia.  With the advent of dialysis therapy, it became evident that premature 
cardiovascular  disease  was  reported  as  cause  of  death  in  a  disproportionately  large 
number of patients on dialysis programmes, despite the young age of patients selected 
for dialysis treatment during the early years of this treatment. In 1974, the Seattle group 
led  by  Belding  Scribner,  a  pioneer  in  early  haemodialysis  treatment,  reported  the 
presence  of  accelerated  atherosclerosis  in  patients  treated  with  dialysis  treatment(3). 
Whilst undeniably a contributory factor to the excess cardiovascular mortality in ESRD 
patients,  this  is  unlikely  to  be  the  sole  mechanism,  and  further  analysis  of  the 
relationship  between  conventional  cardiovascular  risk  factors  and  outcome  in  this 
population  reveals  stark  differences  between  patients  with  ESRD  and  the  general 
population. 
 
Using data from the United States Renal Data Services (USRDS), approximately 60% 
of deaths amongst dialysis patients in the United States can be attributed to myocardial 
infarction,  cardiac  arrest,  cerebrovascular  disease  and  other  cardiac  causes(4),  with 
similar figures reported to European renal registries. Whilst the most common mode of 
cardiovascular death in  the general population is myocardial infarction, one striking 
finding in the ESRD population is the extremely high proportion of deaths attributed to 
sudden (and therefore presumed arrhythmic) cardiac death (Figure 1.1).  40 
 
 
 
Figure 1.1 
Cause specific death rates for all dialysis patients by age, 1995-97 from the USRDS 
report 1999.  
 
One dilemma here is the difficultly is ascertaining the cause of death in such patients, to 
then  identify  reversible  risk  factors  to  improve  treatment.  Nonetheless,  as  this  is  a 
consistent finding, it suggests differences in the pathogenesis of fatal cardiovascular 
events in patients with ESRD compared to those in the general population. Moreover, 
although many ‘conventional’ cardiovascular risk factors are present in patients with 
ESRD, the relationship between these risk factors and outcome is less clear than in the 
general population, and additionally there are cardiovascular risk factors either specific 
to  the  uraemic  milieu  which  carry  a  more  influential  role  on  future  cardiovascular 
events than in the general population. Table 1.1 lists some of these risk factors which 
will be discussed in greater detail. 
 41 
Risk factors for CVD – gen. population  Risk factors for CVD - ESRD 
Older age  Haemodynamic and metabolic factors of CRF 
Hypertension  Proteinuria 
Hyperlipidaemia  ↑extracellular fluid (ECF) volume 
Diabetes  Electrolyte imbalance 
Physical inactivity  Anaemia 
Previous MI/CAD/PVD/CVD  Homocysteine 
Smoking  ↑PTH/calcium-phosphate  
Oxidative stress  Arterial calcification 
LVH/LVSD  Inflammation 
 
Table 1.1 
Risk factors for cardiovascular disease in the general population and in ESRD 
 
1.2  Risk  factors  for  cardiovascular  disease  in  the  general  population  and  in 
ESRD 
In the later part of the 20
th century it became clear from an abundance of large clinical 
trials,  that  by  intervention  on  a  specific  risk  factor,  previously  identified  from 
observational studies, the risk of future cardiovascular events could be reduced. Focus 
has directed on which patients derive most benefit from these interventions, frequently 
dependent on their baseline probability of a certain event occurring. For example, in the 
case of lipid lowering therapy post myocardial infarction(5), the clinical benefit is now 
clear  and  has  translated  into  widespread  changes  in  clinical  practice.    As  the  same 
evidence  is  not  present  in  the  ESRD  population,  it  is  tempting  to  extrapolate  these 
findings  from  trials  in  the  general  population  to  this  group.  However,  these 
epidemiological associations from observational studies do not demonstrate the same 
relationship in ESRD as in the general population and to date interventional trials aimed 42 
at such risk factors in ESRD patients have given conflicting results. It is also clear that 
some of these risk factors are closely interrelated (e.g. haemodynamic/ metabolic factors 
of  chronic  renal  failure  and  extracellular  fluid  volume).  A  number  of  the  factors 
displayed in Table 1.1 are discussed.  
 
1.2.1   Hypertension 
In the  general population, it has been demonstrated that lowering blood pressure in 
patients with hypertension reduces cardiovascular risk(6;7). Initially studies suggested 
that the agent used to treat blood pressure may not be as important as the blood pressure 
target  itself,  with  certain  exceptions.  Treatment  with  diuretics(8),  calcium  channel 
antagonists(9),  beta  blockers(10),  angiotensin  converting  enzyme  inhibitors(11)  and 
angiotensin receptor blockers(12) have all been shown to be effective at reducing risk of 
cardiovascular events in hypertensive individuals. To date, no minimum blood pressure 
target  has  been  identified  and  although  there  is  some  evidence  from  observational 
studies that a ‘U’ or ‘J’ shaped curve relationship between diastolic blood pressure and 
outcome  exists(13),  suggesting  that  low  diastolic  blood  pressure  may  compromise 
perfusion  of  vascular  beds  distal  to  a  stenotic  vessel.  Nonetheless,  this  is  less  of  a 
problem in clinical practice, where frequently achieving target blood pressure is more of 
an  issue.  Additionally,  it  has  been  clearly  demonstrating  that  reduction  of  blood 
pressure is a major modifiable risk factor in patients with chronic kidney disease, both 
in preventing progression to ESRD and in preventing cardiovascular events(14;15). 
The story is more complex in patients with ESRD. Several observational studies have 
demonstrated  that  low  blood  pressure  is  independently  associated  with  increased 
mortality in ESRD. Zager et al demonstrated that whilst pre-dialysis blood pressure was 
unrelated to cardiovascular mortality, a clear ‘U’ shaped curve relationship between 
post-dialysis  blood  pressure  was  seen  with  post-dialysis  systolic  blood 43 
pressure>180mmHg  and  <110mmHg  both  associated  with  adverse  outcome(16). 
Similar findings have been demonstrated in other observational studies, with Port et al 
also  observing  that  a  low  pre-dialysis  blood  pressure  being  associated  with 
mortality(17).  However,  intriguingly  Mazzuchi  et  al  observed  that  once  incident 
dialysis patients were followed up for greater than two years, risk of early mortality 
(after < 2years on dialysis therapy) demonstrated a ‘U’ shaped relationship with pre-
dialysis systolic blood pressure (patients with systolic blood pressure >160mmHg or 
<110mmHg were most at risk), whilst later mortality (after >2 years on dialysis therapy) 
demonstrated a linear relationship with increasing blood pressure(18). The inference 
from this study is that low blood pressure in incident dialysis patients may represent left 
ventricular systolic dysfunction, hence increasing these patients risk of early death.  
 
There few trials to inform how best to achieve blood pressure targets in ESRD, and 
observational  data  supports  the  use  of  long-duration  dialysis  sessions,  with  slow 
ultrafiltration as pioneered by Charra et al in Tassain, France(19). More recent data 
have  shown  similar  benefits  with  nocturnal  haemodialysis  (allowing  for  longer 
treatment sessions)(20). There is a pressing need for large randomised controlled trials 
in ESRD (both haemodialysis and peritoneal dialysis) to determine both optimal blood 
pressure  targets  and  strategies  to  achieve  those  targets,  with  either  dialysis, 
pharmacological intervention or a combination of these methods. 
 
1.2.2  Hyperlipidaemia 
In the general population, hypercholesterolaemia and dyslipidaemia are interchangeable 
in terms of prevalence and risk implication. In ESRD, however, this is not the case. 
ESRD patients typically have either normal or slightly increased low-density lipoprotein 
(LDL),  increased  very  low-density  lipoprotein  (VLDL)  and  intermediate-density 44 
lipoprotein (IDL) leading to elevated triglyceride levels, and decreased levels of high-
density lipoprotein (HDL). There are also qualitative changes in dyslipidaemia with a 
shift to a more atherogenic LDL particle size toward a small, dense apo-B-rich LDL 
predominance(21). The prevalence of dyslipidaemia in chronic kidney disease patients 
is very high.  In one study of patients of both  haemodialysis  and peritoneal dialysis 
patients,  the  prevalence  of  dyslipidaemia  was  approximately  67%(22),  where 
dyslipidaemia was defined as at least one abnormal lipid parameter. In fact, peritoneal 
dialysis seems to be associated with a relatively more atherogenic lipid profile than 
haemodialysis(23).  
 
In the general population the relationship between hyperlipidaemia (dyslipidaemia) and 
cardiovascular disease (predominantly coronary artery disease) is well established and 
there  are  proven  benefits  of  lipid-lowering  with  statins(5;24-28).  Only  limited 
epidemiological  and  even  more  limited  interventional,  data  exist  on  the  relationship 
between  dyslipidaemia  and  cardiovascular  disease  in  ESRD.  In  patients  receiving 
maintenance  haemodialysis,  reports  suggest  either  no  relationship  or  paradoxical 
correlations, the so called “reverse epidemiology”, where a lower total cholesterol level 
has been associated with a higher risk of death (29-31), or conversely, a higher serum 
cholesterol level has been found in long-term dialysis survivors(32). These studies have 
often used registry data, and either all cause mortality or unspecified  CV mortality. 
Similar  inverse,  “J”  or  “U”-shaped  relationships  between  lipid  levels  and  all  cause 
mortality  have  been  reported  in  other  populations  and  are  thought  to  reflect  a  high 
prevalence of co-morbid disease (specifically malignancy and associated malnutrition) 
in  patients  with  low  cholesterol  levels.  These  observations  highlight  the  need  for 
interventional trials and may have led to under-treatment of dyslipidaemia. Amongst 
patients starting dialysis, almost 40% are diabetic and 25% have known coronary artery 45 
disease  and  30%  of  dialysis  patients  have  cholesterol  levels  higher  than 
5.18mmol/L(33).  Despite  these  observations,  and  studies  showing  effective  lipid-
lowering  and  safety  of  statins,  less  than  10%  of  patients  commencing  maintenance 
dialysis  receive  statins(34;35).  The  impetus  now  lies  in  clarifying  the  therapeutic 
benefit, and unravelling the mechanisms that underlie the cholesterol paradox.   
 
The  “4D  Trial”  (Deutsche  Diabetes  Dialyse  Studie)  perhaps  unexpectedly,  failed  to 
show a significant reduction in cardiovascular events in haemodialysis patients given 
atorvastatin for a median of four years(36). It was a randomised, placebo-controlled 
study in 1,255 type II diabetic patients on chronic haemodialysis, who had been on 
dialysis for less than two years. Atorvastatin lowered mean LDL-cholesterol levels by 
42%, to 1.9 mmol/L. However, there was no significant reduction in the primary end 
point (a composite of cardiac death, nonfatal myocardial infarction, and fatal or nonfatal 
stroke).  The investigators speculated that the negative results could be in part due to a 
different pathogenesis of vascular events in diabetic patients with ESRD compared to 
other  groups,  and  that  the  intervention  was  too  late  in  the  natural  history  of  such 
complex disease. Atorvastatin therapy did, however, lower the incidence of myocardial 
infarction.  Thus,  an  alternative  explanation  is  that  in  the  complex  mixture  of 
cardiovascular  disease  that  affects  patients  with  ESRD  the  relationship  between 
cholesterol and myocardial infarction is present (and lipid-lowering reduces this end-
point) but that myocardial infarction is not the dominant cardiovascular end-point.  
 
This  hypothesis  has  been  explored  in  patients  with  ESRD  who  received  renal 
transplants in the Assessment of LEscol in Renal Transplantation (ALERT) trial. In this 
related population, all lipid parameters are associated strongly with the development of 
myocardial infarction but much less so with cardiac death, which is more dependent on 46 
left ventricular hypertrophy (LVH) and hypertension(37). The differences in cardiac 
outcomes in the 4S study in patients with conventional CVD, the 4D study and the 
ALERT study are illustrated in Table 1.2. The 4S (Scandinavian Simvastatin Survival 
Study)  study  randomised  patients  to  simvastatin  40mg  or  placebo  post  myocardial 
infarction and demonstrated a significant reduction in both myocardial infarction and 
cardiovascular death(5). In the general population (4S) patients are more likely to have a 
non-fatal  MI  than  a  cardiac  death,  whereas  in  patients  receiving  haemodialysis  the 
relationship is reversed. Additionally it is clear that the cardiac event rate in the 4D 
exceeds even a very high risk group such as post myocardial infarction patients. In the 
general population, a minimum threshold for lowering LDL has not yet been defined 
and safety concerns regarding intensive statin therapy have not been founded. To date 
only  less  aggressive  statin  therapy  has  been  trialled  in  the  ESRD  population  and 
although the risk of adverse affects such rhabdomyolysis in this population is higher, so 
far the safety record in these clinical trials has been good.  
 
LDL-cholesterol 
  n 
mmol/L 
baseline 
mmol/L 
change 
% change 
CD+MI 
annual 
rate 
Non-
fatal 
MI % 
CD+MI % 
reduction 
CD % of 
reduction 
4S  4444  4.9  1.7  -35  5.2  16.9  34  42 
ALERT  2102  4.1  1.0  -32  2.0  5.2  35  38 
4D  1255  3.1  1.2  -42  8.2  11.8  14  19 
 
Table 1.2 
Comparison of the 4S study with the 4D and ALERT studies. Abbreviations n= number 
of patients studied, CD – cardiac death, MI – myocardial infarction 
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1.2.3   Diabetes mellitus 
Diabetic nephropathy is the cause of ESRD in 15-30% of patients with approximately 
equal  proportions  of  patients  having  type  I  and  type  II  diabetes(38).    Extra-renal 
complications of diabetes include macrovascular disease and microvascular disease. The 
overall  risk  of  death  from  myocardial  infarction  in  a  patient  with  diabetes  is 
approximately three times that of the general population, with younger patients at higher 
risk(39).  However  the  development  of  nephropathy,  heralded  by  the  presence  of 
albuminuria, enhances the risks of further macrovascular complications as well as the 
risk of progressing to ESRD(40). Data from the Diabetes Control and Complications 
trial  has  shown  that  tight  diabetic  and  blood  pressure  control  reduce  the  risk  of 
progression to ESRD and cardiovascular events in type I diabetics(41;42). However in 
the United Kingdom Prospective Diabetes Study tight glycaemic control was not shown 
to reduce risk of myocardial infarction in type II diabetics(43). Better glycaemic control 
was shown to reduce risk of microvascular complications and better blood pressure 
control has been demonstrated to reduce risk of cardiovascular events and progression 
of  diabetic  nephropathy(44).  Once  established  on  dialysis  therapy,  the  survival  for 
diabetic patients is considerably worse than for patients with other causes of ESRD with 
a median survival on dialysis survival of 2.5 years(45). This is mainly attributable to the 
excess  risk  of  vascular  disease.  Studies  screening  diabetic  patients  for  kidney 
transplantation have suggested that over half of diabetic renal transplant candidates will 
have at least one greater than 50% coronary artery stenosis(46).  
 
Once established on dialysis therapy, the options for type I diabetic patients include 
both simultaneous kidney-pancreas transplantation and kidney only transplantation with 
or  without  pancreas  after  kidney  transplantation.  Islet  cell  transplantation  has  been 
performed successfully but the long success has to date been relatively disappointing 48 
with  <50%  of  patients  insulin  independent  at  2-3  years(47).  Although  less  widely 
established  than  kidney  only  transplants,  kidney-pancreas  transplantation  in  suitable 
recipients has been demonstrated to have good outcomes for the patient with 85% 1 
year  graft  (kidney  and  pancreas)  survival.  Crude  analyses  have  suggested  that 
simultaneous kidney-pancreas transplantation offers a survival advantage compared to 
cadaveric renal transplantation for type I diabetic patients with ESRD(48). 
 
1.2.4   Ischaemic heart disease 
Although  sudden  cardiac  death  is  a  more  dominant  manifestation  of  cardiovascular 
disease in patients with ESRD, there is no question that the prevalence and severity of 
ischaemic  heart  disease  in  the  ESRD  is  a  key  factor  in  explaining  the  dramatically 
increased  risk  of  cardiovascular  death  in  this  population.  In  some  patients,  the 
underlying cause of ESRD will share a common pathogenesis as that of accelerated 
atherosclerosis (e.g. in diabetic nephropathy or atherosclerotic renal artery stenosis). It 
is difficult to accurately categorise what proportion of excess cardiovascular morbidity 
can be attributed to obstructive coronary artery disease in ESRD patients. Some of the 
sudden cardiac deaths, out of hospital, may be due to acute myocardial infarction, whilst 
others  may  be  inappropriately  labelled  as  myocardial  infarction  when  primary 
arrhythmia  was  the  underlying  cause.  Studies  assessing  the  prevalence  of  coronary 
artery disease in patients with advanced renal disease have tended to focus on potential 
renal transplant candidates who tend to have less co morbidity than the whole ESRD 
population.  Nonetheless,  Sharma  et  al  reported  that  in  a  series  of  126  consecutive 
patients screened with coronary angiography significant coronary artery disease in at 
least one vessel was found in 30% of patients(49). On the other hand, symptomatic 
angina  is  common  in  patients  with  ESRD  with  angiographically  normal  coronary 
arteries.  Rostand et al reported that of 44 ESRD patients with symptomatic angina, 49 
only 53% had obstructive coronary artery disease at angiography(50). Explanations for 
this phenomenon include subendocardial ischaemia due to left ventricular hypertrophy 
(LVH), microvascular dysfunction with impaired vasodilator reserve and/or limitations 
of oxygen delivery.  
 
About 20% of deaths in dialysis patients are attributed to acute myocardial infarction. In 
patients  with  ESRD,  acute  myocardial  infarction  is  associated  with  extremely  poor 
survival. Herzog et al reported a 1-yr 59% mortality and 2-yr 73% mortality in 34,189 
dialysis patients with acute myocardial infarction in the US from 1977 to 1995(51). In 
the ‘post thrombolysis’ era, 1-yr and 2-yr mortalities of have improved little at 62% and 
74% in 1990–95, and 2-yr mortality of 78% in 1991–97(52). Although ESRD is a risk 
for poor outcome post myocardial infarction, ESRD patients are less likely to receive 
treatments proven to improve outcome in this setting such as aspirin, thrombolytics and 
beta blockers(53). Additionally, the presence of advanced kidney failure is frequently an 
exclusion  criterion  for  clinical  trials  in  myocardial  infarction.  Therefore,  the    poor 
outcome of ESRD patients with myocardial infarction may be partially attributable to 
undertreatment,  either  due  to  fear  of  potential  complications  such  as  haemorrhage, 
particularly  from  arteriovenous  fistulae  used  for  dialysis,  and  the  unavailability  of 
clinical trial outcome data due to the exclusion of ESRD patients from all AMI trials. 
 
In  ESRD  patients  with  critical  coronary  artery  stenosis  there  is  a  relative  survival 
advantage associated with coronary artery bypass grafting compared to percutaneous 
coronary intervention (angioplasty or stent) in dialysis patients. USRDS data reports 
that for dialysis patients receiving their first coronary revascularisation procedure in 
1995–98: 4836 dialysis patients treated with angioplasty, 4280 with angioplasty plus 
stent, and 6668 coronary artery bypass grafting, the 2-yr all-cause survival was 48% in 50 
both percutaneous coronary intervention groups and 56% after coronary artery bypass 
grafting(54). In a multivariate analysis, the risk of all-cause death was 20% lower for 
bypass  grafting  compared  to  percutaneous  intervention  and  6%  lower  for  stenting 
compared  with  angioplasty.  This  must  be  balanced  with  the  higher  than  normal  in 
hospital mortality for bypass (4.1% for stenting, 6.4% for angioplasty and 8.6% for 
bypass  grafting).  However,  the  restenosis  rates  of  coronary  stents  are  unknown  in 
dialysis  patients,  but  are  likely  to  be  no  lower  than  in  the  general  population,  and 
probably  higher.  Drug  eluting  stents  (using  sirolimus  or  paclitaxel)  have  offered 
promising  results  with  extremely  low  restenosis  rates  (0%  at  6  months  for  patients 
receiving  sirolimus-  coated  stents  for  native  coronary  lesions  compared  to  a  26.6% 
restenosis  rate  in  the  Randomized  Study  with  the  Sirolimus-  Coated  Bx  Velocity 
Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary 
Artery Lesions (RAVEL) trial)(55). Whether these results will translate to benefits in 
the dialysis population is unclear, particularly in light of some evidence suggesting that 
late  stenosis  after  one  year  is  more  common  with  both  sirolimus-eluting  stents  and 
paclitaxel-eluting stents than with bare-metal stents(56).  
 
Whilst  in  patients  with  critical  coronary  disease  revascularisation  is  imperative,  the 
presence of renal failure is a predictor of adverse outcome after percutaneous coronary 
intervention. Rubenstein et al compared the immediate and long-term outcomes of 362 
renal failure patients (creatinine >132.6 µmol/L, 27 dialysis patients) with 2972 patients 
with normal renal function undergoing PCI in 1994–97(57). The in-hospital mortality 
was  significantly  higher  in  the  patients  with  renal  dysfunction  (10.8%  for  the  renal 
patients and 1.1% in the controls) with significantly more blood transfusions in the renal 
patients. The 1-yr actuarial survival was significantly lower at 75% for the renal group 
compared to 97% for the matched controls. These data suggest that once a patient with 51 
advanced renal disease develops a significant burden of atherosclerotic coronary artery 
disease, there is paucity of randomised controlled data to inform best practise. Current 
observational evidence suggests that outcomes are considerably poorer than the general 
population both in the setting of acute myocardial ischaemia as well as for coronary 
revascularisation. 
 
1.2.5   Physical inactivity 
Evidence from observational studies of the general population suggests that increased 
physical activity is associated with reduced cardiovascular mortality.  Physical activity 
is frequently limited in ESRD patients. One epidemiological study from the Dialysis 
Morbidity and Mortality Wave 2 study has demonstrated that limitations in physical 
activity are common among new patients with ESRD in the United States and correlate 
highly with increased mortality risk. Frequent exercise of up to 4 to 5 times per week 
correlate with improved survival. Daily exercise was not associated with any additional 
protective benefit(58). Although direct benefits of an interventional exercise programme 
on long term outcome are difficult to demonstrate, in a small single centre study of 
haemodialysis patients, Mustata et al demonstrated that a 3 month exercise programme 
improved  arterial  stiffness,  a  surrogate  marker  of  increased  cardiovascular  risk  in 
ESRD. A typical class consisted of a 5- to 10-minute warm-up period, 40 to 50 minutes 
of conditioning  exercise (either treadmill running or exercise bicycle),  and a 5- 10-
minute cool-down(59). It is not clear how this approach would translate to the entire 
ESRD population. 
 
1.2.6   Cigarette smoking 
Of potentially modifiable risk cardiovascular risk factors in ESRD patients, perhaps less 
attention has been paid to cigarette smoking than other factors. In the USRDS Wave 2 52 
study studying 4024 new dialysis patients smoking at the time of inception of dialysis 
was associated with a 37% increase in mortality, even after adjustment for co-morbidity. 
Ex-smokers  had  event  rates  similar  to  non  smokers(60).  Cigarette  smoking  also 
accelerates the progression of chronic renal failure. There are no trials to support which 
smoking cessation strategy is most effective in ESRD, but meta-analyses suggest that 
nicotine  replacement  therapy  is  part  of  an  effective  strategy  in  the  general 
population(61). 
 
1.2.7   Oxidative stress 
Conditions  predisposing  to  atherosclerosis,  including  hypercholesterolemia,  diabetes 
mellitus, cigarette smoking and chronic kidney disease are associated with increased 
oxidative  stress.  The  atherogenicity  of  low-density  lipoprotein  (LDL)  is  greatly 
increased  upon  oxidative  modification(62)  as,  once  oxidised,  LDL  is  taken  up  by 
scavenger receptors on monocytes, leading to the conversion of monocytes into foam 
cells, one of the earliest steps in the development of atherosclerosis. Reactive oxygen 
species can also directly promote LDL oxidation, stimulate vascular smooth muscle cell 
proliferation and migration(63). Reactive oxygen species also activate several matrix 
metalloproteinases, which contribute to atherosclerotic plaque instability and rupture, 
thereby  precipitating  acute  cardiovascular  events(64).  Oberg  et  al  demonstrated  that 
biomarkers of oxidative stress (plasma protein carbonyl group content, plasma free F2-
isoprostane content, plasma protein reduced thiol content) were significantly elevated in 
patients  with  chronic  renal  failure  compared  to  healthy  subjects(65).  Haemodialysis 
(HD) may induce oxidative stress, primarily through membrane bio-incompatibility and 
endotoxin challenge. One study examining the relationship between haemodialysis and 
cardiovascular disease on serum malondialdehyde levels, a marker of oxidative stress 
found  mean  serum  malondialdehyde  levels  were  significantly  elevated  in  dialysis 53 
patients with cardiovascular disease(66). However to date no study exists examining the 
relationship between oxidative stress and long term outcome in ESRD patients.  
 
A number of studies have addressed the issue  of whether using antioxidant therapy 
would  reduce  the  risk  of  cardiovascular  events,  both  in  patients  at  high  risk  of 
cardiovascular  events  in  the  general  population  and  in  ESRD.  The  Heart  Protection 
Study  randomised  20,536  UK  adults  (aged  40-80)  with  coronary  disease,  other 
occlusive arterial disease, or diabetes to receive antioxidant vitamin supplementation 
(600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching 
placebo. None of these interventions produced any significant reductions in the 5-year 
mortality from, or incidence of, any type of vascular disease, cancer, or other major 
outcome(67). Similarly in the Heart Outcomes Prevention Evaluation  (HOPE) Study 
treatment with vitamin E had no apparent effect on cardiovascular outcomes(68). By 
contrast  in  the  Cambridge  Heart  Antioxidant  Study  (CHAOS)  in  patients  with 
angiographically  proven  coronary  atherosclerosis,  alpha-tocopherol  (vitamin  E) 
substantially reduced the rate of non-fatal myocardial infarction at one year(69). This 
study is out of keeping with the larger trials with longer follow up.  
 
Interestingly in ESRD, alpha-tocopherol decreases LDL oxidation in ESRD patients. 
The benefit appears to be greater in patients on PD, which may be of clinical importance 
given  the  greater  atherogenicity  of  lipid  abnormalities  in  peritoneal  dialysis(70). 
Building  on  this  observation,  the  Secondary  Prevention  with  Antioxidants  of 
Cardiovascular  disease  in  End  stage  renal  disease  study  (SPACE),  assigned 
haemodialysis  patients  with  cardiovascular  disease  to  high  dose  (800  IU/day)  oral 
vitamin  E  or  placebo.   Vitamin  E  reduced  the  risk  of  the  composite  cardiovascular 
disease  endpoints  (myocardial  infarction  (fatal  and  non-fatal),  ischaemic  stroke, 54 
peripheral  vascular  disease  and  unstable  angina)(71).  A  similar  large  scale  trial  of 
antioxidant therapy as primary cardiovascular disease prevention is required in ESRD. 
 
1.2.8   Uraemic cardiomyopathy as a cardiovascular risk factor 
Cardiac abnormalities, specifically hypertrophy of the left ventricular wall, were first 
noted in ESRD by Richard Bright in 1827, where he postulated that it was caused by 
‘the unusual efforts to which the heart has been impelled’(72). The presence of uraemic 
cardiomyopathy is strongly  associated with adverse outcome in patients will ESRD. 
Echocardiographic  studies  report  three  patterns  of  cardiomyopathy  –  left  ventricular 
hypertrophy (LVH) and LV dilatation and left ventricular systolic dysfunction (LVSD) - 
that affect up to 90% of patients starting dialysis therapy(73). Each is associated with 
reduced  survival  compared  with  unaffected  patients;  effects  that  persist  even  after 
successful  transplantation(74).  Parfrey  et  al  have  demonstrated  that  the 
echocardiographic prevalence of LVH is 50-80%, with left ventricular dilatation in 20-
40%  and  LVSD  present  in  approximately  16%  of  patients  in  incident  ESRD 
patients(75).  When  followed  up  over  a  2  year  period,  these  abnormalities  were 
associated with a cumulatively poorer survival compared to those patients with normal 
ventricles after adjustment for other variables such as age, diabetes and ischaemic heart 
disease(76).  Data  from  the  USRDS  registry  has  demonstrated  similar  findings  with 
LVH  a  risk  factor  for  poor  outcome  in  incident  dialysis  patients(77).  A  schematic 
diagram of the potential relationships between ischaemic heart disease, sudden cardiac 
death and LVH is demonstrated in Figure 1.2. 
 
LVH develops early in  the course of chronic kidney  disease and is associated with 
stiffening  of  the  LV  wall,  a  precursor  to  diastolic  heart  failure(78;79).  The  various 
permissive factors promoting LVH in uraemia will be discussed in detail in Chapter 5 55 
but hypertension, anaemia, hyperparathyroidism and hypoalbuminaemia have all been 
associated with its development(80). Volume status is a key factor in determining blood 
pressure in ESRD and may make definition of LV chamber dimensions difficult(81).  
 
Histological analysis of the heart in animal models of experimental renal failure shows 
that LVH is associated with an increase in cardiomyocyte volume(82). This, in turn, 
results in increased oxygen diffusion distance and subsequent cardiomyocyte ischaemia. 
Cardiomyocyte number may increase initially but subsequently is reduced(83). In sub-
totally  nephrectomised  rats,  reduced  capillary  density  per  volume  of  myocardium  is 
seen(84).  Similar  findings  have  been  demonstrated  in  post  mortem  specimens  of 
patients with ESRD(85). It is likely that apoptosis is triggered and increased fibrosis 
follows progressive myocyte death(82). Electrophysiological abnormalities in calcium 
handling  have  been  demonstrated  with  abnormal  sarcoplasmic  calcium  uptake,  and 
increased  cytosolic  calcium  concentrations  of  calcium  in  diastole(86-88).  These 
electrophysiological  changes  lower  the  threshold  for  arrhythmia  and  underpin  the 
evolution of diastolic heart failure. 
 
LVH may be considered an adaptive process in response to increased myocardial work 
due to pressure and volume overload. Pressure overload tends to cause increased wall 
thickness with an unchanged or reduced LV cavity diameter (concentric hypertrophy), 
whilst  volume  overload  promotes  LV  dilatation,  with  additional  changes  in  wall 
thickness as an adaptive mechanism to reduce wall stress(89;90). This phenomenon is 
called eccentric hypertrophy. Both eccentric and concentric remodelling are common in 
ESRD patients. These remodelling processes are initially beneficial as dilatation allows 
an  increase  in  stroke  volume  without  increased  inotropy,  as  well  as  permitting 
maintenance  of  stroke  volume  and  cardiac  output  in  the  presence  of  decreased 56 
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contractility(91).    Physiological  hypertrophy  may  additionally  occur  in  response  to 
increased cardiac work, and the increase in LV mass is appropriate to LV volume such 
as  in  highly  conditioned  athletes(92).  However,  in  dialysis  patients  the  degree  of 
hypertrophy may be inappropriate for the given ventricular stresses, either volume or 
pressure load, both of which are dramatically elevated(76). This has led to the term 
‘inadequate  hypertrophy’,  and  LVH  may  be  either  a  precursor  to  the  evolution  of 
cardiac failure or arrhythmia in ESRD patients(93). 
 
 
Figure 1.2 Schematic view of the relationship between ischaemic heart disease, LVH 
and sudden cardiac death in ESRD. Abbreviations CRF- chronic renal failure, RRT –
renal replacement therapy, Tx - transplant 
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1.2.9   Sudden cardiac death 
Sudden cardiac death is the cause of up to 60% of cardiovascular deaths in patients with 
ESRD.  The  risk  of  such  an  event  increased  with  increasing  time  spent  on  renal 
replacement therapy. Although, high risk patients potentially can be identified- patients 
with LVH or LVSD, previous ischaemic heart disease or potentially using biomarkers 
such as brain natriuretic peptide (BNP) or troponin T(94), no proven strategy exists to 
reduce risk of this catastrophic event. Haemodialysis specific risks include pre-dialysis 
hyperkalaemia and intra-dialytic or post dialysis hypokalaemia.  In a large retrospective 
analysis of dialysis related cardiac arrests (in centre up to 2 hours post dialysis), a low 
potassium dialysate (0 or 1 mmol/L) was identified as a risk factor for cardiac arrest. 
More cardiac arrests took place on Mondays, suggestive that fluid overload may also be 
a risk factor, after the ‘long gap’ of 2 days since the antecedent dialysis session(95). 
Evidence is emerging from patients with ischaemic heart disease and cardiac failure that 
implantable cardiac defibrillators, as a prophylaxis for sudden cardiac death, improve 
survival(96).  Currently  these  are  underused  in  the  ESRD  post  cardiac  arrest  despite 
apparent  association  with  improved  survival(97).  A  prospective  trial  of  implantable 
defibrillators for reduction of mortality in dialysis patients is warranted.   
 
1.2.10  Haemodynamic and metabolic factors of CRF 
Additional to electrolyte shifts related to dialysis, alterations in volume status and hence 
blood pressure, may cause haemodynamic instability in the dialysis patient. Intermittent 
haemodialysis  leads  to  rapid  changes  in  fluid  and  solute  status.  Hypotension  in 
particular, is a common cardiovascular complication of haemodialysis, which may vary 
in severity from minor, if troublesome side-effects such as nausea or dizziness, through 
to more severe cardiac or cerebral ischaemia. The pathogenesis of haemodialysis related 
hypertension  is  multi-factorial.  The  initial  trigger  is  hypotension  as  the  patient  is 58 
connected  to  the  dialysis  circuit.  The  main  determinants  of  blood  pressure  control, 
which are deranged in ESRD, are intravascular volume preservation, vasoconstriction 
leading to increased systemic vascular resistance and maintenance of cardiac output by 
appropriate inotropic and chronotropic response(98).  
 
During haemodialysis, fluid is removed from the intravascular space by ultrafiltration. 
As intravascular pressure drops, fluid is drawn from the interstitial space in an attempt 
to  maintain  intravascular  volume.  This  however  is  incomplete  and  limited  by  the 
relative increase in extravascular osmotic pressure. Blood volume decreases leading to 
hypotension(99). Factors influencing this include ultrafiltration rate(100), fluid status of 
the  patient(101),  dialysate  sodium(102),  dialysate  buffer(103),  temperature(104), 
venous compliance and food intake which may lead to splanchnic blood pooling(105).  
 
The  appropriate  response  to  dialysis  related  hypovolaemia  is  normally  to  increase 
systemic vascular resistance, by constriction of precapillary vessels. However in ESRD 
this  mechanism  is  blunted.  Although  autonomic  neuropathy  affecting  efferent 
sympathetic pathways may contribute to this disturbance (primarily found in diabetic 
patients), the dialysis treatment itself is a greater factor for impaired vascular response 
in this setting.  Haemodialysis appears to be associated with impaired vascular reactivity 
during  hypovolaemia.  The  secretion  of  vasoconstrictive  peptides  such  as 
catecholamines, vasopressin and renin is less pronounced with haemodialysis compared 
to  say  haemofiltration  or  isolated  ultrafiltration(106).  Other  factors  associated  with 
vasodilatation related to haemodialysis include excess secretion of cytokines such as 
tumour  necrosis  factor-α  and  interleukin-1,  perhaps  related  to  the  degree  of 
biocompatibility  of  the  dialysis  membrane,  although  this  remains 
controversial(107;108). The temperature of the dialysate in the extracorporeal circuit is 59 
an  additional  feature  influencing  haemodynamic  stability  and  control  of  systemic 
vascular  resistance.  Both  the  blood  pressure  response  and  vascular  reactivity  are 
improved  with  the  use  of  cool  (35-36
0C)  compared  to  standard  (37-38
0C)  dialysate 
(104;109).  This  may  either  be  due  to  reduced  cutaneous  vasodilatation,  which  may 
occur in a bid to reduce ‘excessive’ heat when warmer standard dialysate is used or the 
constrictive  effect  of  blood  vessels  to  maintain  a  constant  core  temperature  when  a 
cooler dialysate is used.   
 
Maintenance of cardiac output in response to hypovolaemia related to dialysis is mainly 
dependent  on  pre-existing  cardiac  function  which  is  discussed  elsewhere.  Left 
ventricular diastolic or systolic dysfunction where present impair the heart’s ability to 
maintain cardiac output. Other factors such as autonomic neuropathy and drug therapy 
with  beta-blockade  may  impair  the  chronotropic  response.  Cardiac  function  may 
paradoxically improve during dialysis due to a combination of fluid removal reducing 
after load, the removal of postulated cardiodepressor uraemic toxins (or acidosis) or due 
to the use of increased dialysate calcium which has a positive inotropic effect(110;111). 
Factors  specific  to  dialysis  which  may  reduce  cardiac  output  include  impaired 
ventricular  filling  due  to  reduced  venous  return.  The  presence  of  the  arteriovenous 
fistula used for dialysis access causes increased cardiac output, promoting LVH and 
may lead to high output cardiac failure(112). 
 
For the period when the patient is not on dialysis therapy, the relationship between 
volume status, blood pressure and systemic vascular response is complex with debate 
about  the  relative  importance  of  increased  peripheral  resistance  and  increased 
intravascular volume on the development of hypertension in ESRD. In one pilot study 
from our group, cardiac output was lower in haemodialysis patients than in a small 60 
group of normal subjects, because of a lower stroke volume in the dialysis group(113). 
As the blood pressure was the same, calculated peripheral resistance was thus higher in 
the  dialysis  group  compared  with  controls.  In  the  dialysis  group  there  is  a  very 
convincing  relationship  between  end  diastolic  volume  (a  reflection  of  intravascular 
volume), cardiac output and blood pressure. No such relationship was found between 
calculated  peripheral  resistance  and  any  blood  pressure  variable,  suggesting  that 
intravascular  volume  plays  a  larger  role  than  increased  vascular  resistance  in  the 
determination of blood pressure in patients on haemodialysis, or is at least the most 
variable factor. This is consistent with the effects of reduction of intravascular volume 
(‘dry  weight’)  and  improved  blood  pressure  control  on  dialysis(114;115).  Although 
there  was  no  correlation  between  systemic  vascular  resistance  and  blood  pressure 
parameters, systemic vascular resistance was higher in haemodialysis patients. Thus, for 
a  given  cardiac  output,  the  achieved  blood  pressure  is  substantially  greater  in 
haemodialysis  patients  than  in  controls.  Whether  this  increase  in  systemic  vascular 
resistance  is  a  functional  consequence  of  increased  vascular  tone  or  of  structural 
changes in the vessel wall is unclear, although it is clearly important as vasodilators are 
likely  to  be  effective  against  the  former,  whereas  reversal  of  strategies  structural 
changes (e.g. associated with calcification) are likely to be more difficult. 
 
1.2.11  Proteinuria 
Microalbuminuria  (30  to  300mg/day)  was  first  identified  as  risk  factor  for 
cardiovascular disease in patients with diabetes in 1984(116). Subsequently, data from 
the Framingham studies have shown that proteinuria is a risk factor for cardiovascular 
mortality  in  the  general  population(117).  Similar  findings  have  emerged  from  other 
large epidemiological studies that either proteinuria or microalbuminuria are not only 
predictive of progression of renal disease but also of future cardiovascular events(118). 61 
Analyses from the Prevention of Vascular and End Stage Renal Disease (PREVEND) 
study  shows  clearly  that  urinary  albumin  acts  as  a  continuous  risk  factor  for 
cardiovascular events with no lower limit(119). Microalbuminuria and proteinuria have 
been accepted to represent a consequence of renal damage. However,  Deckert et al 
proposed in 1989 that albumin leakage is a reflection of widespread vascular damage, 
with  the  kidney  as  a  ‘window’  to  the  vasculature(120).  This  hypothesis  has  been 
reinforced by studies demonstrating that microalbuminuria is associated with changes in 
endothelial dysfunction in patients with diabetes(121). The Irbesartan in Patients with 
Type 2 Diabetes and Microalbuminuria (IRMA-2) study, evaluating the effect of the 
angiotensin  II  antagonist  irbesartan,  demonstrated  that  reduction  of  albuminuria  in 
microalbuminuric hypertensive patients with type II diabetes was associated with renal 
protection and some degree of cardiovascular protection although this study was not 
powered to address the effect on cardiovascular events(122). From the standpoint of the 
patient with ESRD, as albuminuria or proteinuria are both markers of cardiovascular 
risk and of progression of renal disease towards ESRD, it seems likely that proteinuria 
is a cardiovascular risk factor, which whilst present in some patients in the general 
population, is grossly overrepresented in patients at the onset of dialysis therapy.  
 
1.2.12  Anaemia 
The presence of anaemia, secondary to erythropoietin deficiency is an almost universal 
finding in patients with ESRD. This is strongly associated with increased mortality and 
morbidity  in  patients  on  maintenance  haemodialysis(123).  Anaemia  has  been 
consistently linked with the development and progression of cardiac structural changes 
in patients with chronic renal failure. In patients with chronic renal failure, haemoglobin 
starts to fall as glomerular filtration rate drops to between 25 and 50 ml/min and Levin 
et al demonstrated that in patients with advanced pre-dialysis renal failure each 0.5g/dL 62 
fall  in  haemoglobin  was  associated  with  a  increased  LV  mass(124).  However,  the 
outcome of studies directed at haemoglobin correction, either to reduce progression of 
LVH or to reduce cardiovascular events have generally been associated with increased 
mortality in patients randomised to achieve a higher haemoglobin with erythropoietin 
therapy(125-128).  Lower haemoglobin is likely to be found in ‘sicker’ patients with 
more evidence of inflammation and malnutrition, and therefore it is not surprising that 
anaemia is associated with increased mortality. What is less clear is what the target 
haemoglobin  should  be  in  dialysis  patients,  and  the  optimum  time  to  commence 
correctional  therapy  with  erythropoietin.  The  relationship  between  haemoglobin  and 
uraemic cardiomyopathy and outcome is further discussed in Chapter 5. 
 
1.2.13  Homocysteine 
Homocysteine  is  a  sulphur  containing  amino  acid,  formed  during  the  conversion  of 
methionine to cysteine. The concept of homocysteine being atherogenic arose from the 
observation  that  patients  with  homocystinuria,  an  autosomal  recessive  condition, 
characterised  by  the  accumulation  of  homocysteine  experienced  premature 
cardiovascular  death.  Epidemiological  studies  have  demonstrated  an  association 
between  hyperhomocysteinaemia  and  atherosclerotic  vascular  disease.  Normal 
metabolism  of  homocysteine  is  either  by  transsulfuration  to  cysteine  (vitamin  B6 
dependent) or remethylation to methionine (vitamin B12 and folate dependent). In renal 
failure  it  is  suggested  that  remethylation  is  impaired  leading  to  accumulation  of 
homocysteine.  Hyperhomocysteinaemia  has  been  associated  with  increased  risk  of 
cardiovascular events in patients with ESRD in a number of observational studies(129-
131).  
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One large trial of B vitamin (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of 
vitamin B12) supplementation in the general population to reduce cardiovascular events 
was  disappointing,  with  no  significant  reduction  in  risk(132).  In  dialysis  patients, 
despite evidence that reduction of serum homocysteine levels can be achieved with folic 
acid, randomised controlled trials have demonstrated that folic acid supplementation in 
ESRD is not associated with reduction of cardiovascular events(133) or a reduction in 
atheroma progression(134). Indeed, further analysis have suggested paradoxically that 
some patients with higher homocysteine levels are at reduced risk(133;135) forwarding 
the hypothesis, that homocysteine levels may be a nutritional marker in dialysis patients 
in  the  absence  of  inflammation,  a  frequent  confounder  of  other  markers  of  
interpretation of nutritional status (albumin) in ESRD. This represents a further example 
of the ‘reverse epidemiology’ (akin to cholesterol) of cardiovascular risk factors where 
conventional  cardiovascular  risk  factors  in  the  general  population  have  the  reverse 
relationship with outcome in the ESRD population. 
 
1.2.14  Hyperparathyroidism,  calcium-phosphate  metabolism  and  arterial 
calcification 
Hyperparathyroidism is one of the hallmarks of chronic renal failure and is a result of 
chronic  hyperphosphataemia  and  hypocalcaemia.  Secondary  and  tertiary 
hyperparathyroidism  result  in  the  spectrum  of  renal  bone  disease  including  osteitis 
fibrosa cystica and mixed renal osteodystrophy. Observational studies demonstrate that 
as well as being a risk factor for fractures (136), raised serum PTH levels are a risk 
factor for mortality in dialysis patients(137;138). It is now recognised that parathyroid 
hormone (PTH) has potentially negative cardiovascular effects. In animal models of 
uraemia  PTH  has  been  demonstrated  to  promote  cardiac  interstitial  fibrosis  and 
arteriolar thickening(139). PTH has also been shown to stimulate cardiac accumulation 64 
of calcium in myocytes leading to scarring(140). The role of PTH in promoting LVH is 
further discussed in Chapter 5. 
 
Like  hyperparathyroidism,  hyperphosphataemia  is  almost  inevitable  in  patients  with 
ESRD and registry data supports that even mild hyperphosphataemia is an independent 
predictor  of  mortality  in  dialysis  patients(137;138;141).  Although  poor  phosphate 
control  may  be  a  reflection  of  under  dialysis,  it  has  become  clear  that  phosphorus 
retention  promotes  vascular  calcification,  perhaps  by  inducing  transformation  of 
vascular  smooth  muscle  cells  into  an  osteoblast-like  phenotype(142).  Total  body 
calcium or calcium phosphate product as well as PTH have been recognised to be the 
other  key  determinants  of  vascular  calcification.  Other  clinical  factors  consistently 
associated with the development of vascular calcification include age, duration on renal 
replacement therapy, PTH, homocysteine and degree of inflammation(143-147).  
 
Although  patients  with  ESRD,  if  left  untreated,  would  be  calcium  deficient  due  to 
failure of synthesis of 1,25-dihydroxyvitamin D3, the combination of treatment with 
vitamin D analogues to suppress PTH, combined with calcium containing phosphate 
binders may lead to overall normalised or high body calcium levels. The presence and 
degree of coronary artery calcification, demonstrated in young adult dialysis patients by 
electron  beam  computed  tomography,  has  been  associated  with  ingestion  of  large 
amounts of calcium containing phosphate binders and a greater elevation in the calcium-
phosphate product(144). Until fairly recently, options for controlling phosphate with 
phosphate binding medication were limited to compounds containing either calcium or 
aluminium.  The  non-calcium  containing  binder  sevelamer  hydrochloride  has  been 
demonstrated to be associated with a lesser degree of progression of coronary artery 
calcification  in  patients  new  to  haemodialysis  therapy,  compared  to  those  taking 65 
calcium containing phosphate binders(143). It has been suggested that this reduction in 
vascular calcification using non calcium containing phosphate binders  may translate 
into a survival benefit for these patients(148). 
 
1.2.15  Inflammation and C-Reactive protein 
Chronic inflammation is indicated by raised serum C-reactive protein (CRP), a hepatic 
derived acute phase protein. CRP is raised in response to a number of conditions where 
inflammation may be present including infection, trauma, infarction and malignancy. 
The acute phase response is driven by cytokines including interleukin-1, interleukin-6, 
interferon-gamma,  tumour  necrosis  factor-α,  and  transforming  growth  factor-β.    In 
healthy individuals elevated CRP is a risk factor for future coronary events(149;150) as 
well  as  in  patients  with  diabetes(151),  whilst  in  patients  with  acute  myocardial 
infarction, CRP predicts mortality within the first 30 days post infarct (152). Whether 
CRP  is  simply  an  additional  marker  for  established  coronary  risk  factors,  such  as 
dyslipidaemia  or  perhaps  the  inflammatory  nature  of  the  high  risk  atherosclerotic 
coronary plaque, or represents a further additive risk factor is less clear.  The is no doubt 
that  raised  CRP  correlates  with  the  cluster  of  atherogenic  risk  factors  found  in  the 
metabolic syndrome(153). Supporting the notion that CRP is directly atherogenic, in 
vitro  studies  have  demonstrated  the  presence  of  CRP  in  atherosclerotic  coronary 
plaque(154),  whilst  CRP  and  matrix  metalloproteinase  co-localise  in  the  endothelial 
layer and macrophage-rich areas in atherosclerotic plaques suggesting that CRP has a 
role in rupture of the ‘vulnerable’ plaque(155). Finally, statins have been demonstrated 
to lower serum CRP, with greatest clinical benefit derived in patients  with a larger 
magnitude of CRP reduction in response to therapy(156).  
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Patients  with  ESRD  tend  to  have  higher  CRP  levels,  and  this  is  predictive  of 
cardiovascular  outcome  in  both  haemodialysis  and  peritoneal  dialysis 
patients(157;158)whilst  higher  levels  interleukin-6  have  also  been  associated    with 
increased  mortality(159).  Possible  explanations  for  elevated  CRP  in  ESRD  include 
direct  inflammatory  effects  of  uraemia,  chronic  infection  of  vascular  access,  the 
presence of indwelling peritoneal or vascular dialysis catheters, bio-incompatibility of 
haemodialysis membranes or peritoneal dialysis fluids or impurities of water supply 
used for dialysis.  
 
The  association  between  atherosclerosis  and  inflammation  (together  with  associated 
poor nutritional status) in dialysis patients have given rise to the hypothesis of the so 
called malnutrition, inflammation, and atherosclerosis (MIA) syndrome(160). If truly 
present this relationship may explain the cholesterol paradox in ESRD patients. One 
intriguing study addressing this issue performed by Liu and colleagues followed up 823 
chronic haemodialysis patients for a median of 2.4  years, and categorised the study 
population into 2 subgroups based on the presence or absence of inflammation and/or 
malnutrition (defined as achievement of specified cut-offs for any of serum albumin, 
CRP  and  interleukin-6)(35).  Overall,  77%  of  the  patients  had  evidence  of 
inflammation/malnutrition,  which  was  associated  with  older  age,  increased  co-
morbidity,  prevalent  CV  disease,  diabetes,  and  lower  total  cholesterol  levels.  A  U-
shaped  association  between  cholesterol  levels  and  mortality  was  seen  in  the  overall 
cohort and in the subgroup with inflammation/malnutrition. However, in the absence of 
inflammation/malnutrition,  total  cholesterol  was  positively  associated  with  all-cause 
mortality  and  even  more  strongly  associated  with  CV  mortality.  These  results  give 
insights into novel methods to address the frequently perplexing issue of the reverse 
epidemiology of cardiovascular disease in patients with renal failure. 67 
1.3  Assessment of uraemic cardiomyopathy with echocardiography 
Echocardiography involves the application of ultrasound in the frequency range of 2 to 
10  MHz.  The  technique  requires  an  ultrasound  transducer  consisting  of  a  series  of 
piezoelectric  crystals,  that  when  electrically  activated,  emit  ultrasound  energy. 
Returning  ultrasound  energy  is  converted  by  the  piezoelectric  crystal  into 
radiofrequency  energy  which  is  processed  to  digital  information  by  high-speed  by 
digital converters within the ultrasound platform.  
 
The simplest image is the M-mode echocardiogram. An M-mode echocardiogram is 
acquired  by  interrogating  returning  ultrasound  signals  along  a  single  plane  with  the 
images  generated recorded on a scrolling video screen. The operator  can select this 
plane to obtain an M-mode image. This plane line can be swept through an area of 
cardiac anatomy and the image then displayed as a series of concurrent M-mode images. 
M-mode echocardiography was once the foundation of anatomical diagnosis but has 
been  to  an  extent  abandoned  in  favour  of  90-degree  two-dimensional  scanning. 
However,  M-mode  does  confer  higher  temporal  resolution  than  two-dimensional 
echocardiography and may provide a higher degree of resolution than two-dimensional 
scanning. In general, however, its clinical role, as a stand-alone technique, has been 
largely supplanted by two-dimensional echocardiography. It remains widely used as a 
method for estimation of LV mass, both for clinical practise as well as in interventional 
studies. Conventionally “cube” methods, which using M-mode septal, posterior wall, 
and left ventricular internal dimensions have been used to measure LV mass. These 
methods assume normal ventricular geometry. More recently, several two-dimensional 
methods  have  been  shown  to  provide  enhanced  accuracy,  especially  in  abnormally 
shaped ventricles(161). 68 
Echocardiography  provides  an  excellent  method  for  quantification  of  ventricular 
function. Linear measurements such as LV wall thickness, internal chamber dimensions, 
and derived parameters such as fractional shortening traditionally have been obtained 
from M-mode echocardiography. Normal values for adults are well established(162-
164). Global ventricular function and cardiac volumes can be measured with a variety of 
methods using two-dimensional echocardiography, with Simpson’s rule being the most 
commonly  used  for  quantification  of  ventricular  volume.  Determination  of  left 
ventricular volume requires manual tracings of the endocardial border in diastole and 
systole.  Once  the  chamber  volumes  have  been  determined,  ejection  fraction  can  be 
calculated. Echocardiographic methods will be discussed in greater detail in Chapters 2 
and 4.  
 
Echocardiographic abnormalities have been described in patients with ESRD as early as 
the 1970s. Initially, as uraemic pericarditis was one of the cardinal features of advanced 
presentation  of  ESRD,  echocardiography  was  a  key  tool  in  the  diagnosis  and 
management of haemorrhagic pericardial effusions.  However, abnormal thickening of 
the  LV  wall  as  well  as  valvular  calcification,  were  soon  demonstrated 
echocardiographically(165) and the prognostic implications of these findings emerged 
with  the  expansion  of  dialysis  programmes.  Studies  from  the  Canadian  dialysis 
population  have  demonstrated  the  importance  of  LV  abnormalities  as  discussed 
previously(73;76).  However,  as  echocardiographic  measurement  of  LV  mass  and 
function is dependent on LV chamber dimensions, care must be taken in assessing LV 
structure and performance in patients with ESRD. It is well-established that changes in 
volume status in these patients during both the inter- and intra-dialytic period result in 
substantial  changes  in  LV  chamber  dimensions(81;166),  with  any  potential  error  in 
echocardiographic  measures  being  amplified  by  the  assumptions  of  cubed  formulae.  69 
Additionally changes in volume status affect both pre- and after-load. To what extent 
the changing loading conditions contribute to a change in LV function parameters is 
difficult to determine. A lower ejection fraction after dialysis may result from a decrease 
in contractility either de novo or in response to myocardial ischaemia invoked by the 
haemodynamic demands of dialysis, but also from a decreased preload, an increased 
after load or a combination thereof. 
 
A  ‘volume-independent’  assessment  of  LV  dimensions  in  ESRD  is  an  extremely 
attractive  concept.  Newer  echocardiographic  techniques  such  as  3-dimensional 
echocardiography  may  be  promising  but  are  untested  in  this  population.  Whilst  LV 
chamber dimensions remain subject to the hydration status of the patient regardless of 
imaging method, by using a high resolution method such as cardiac magnetic resonance 
imaging  (CMR)  to  delineate  myocardial  dimensions,  the  presence  of  structural 
cardiovascular disease may be more accurately defined in this population.   
 
1.4  Cardiovascular magnetic resonance imaging 
Rapid progress has been made with CMR over the past decade, and this has become 
established as a reliable and clinically important technique for assessment of cardiac 
structure  and  function.  Furthermore,  by  using  contrast  based  techniques,  myocardial 
perfusion and viability can be assessed. CMR is non-invasive and avoids the use of 
ionising  radiation.  Progress  in  CMR  technology  may  further  widen  its  clinical 
application  in  coronary  artery  imaging,  assessment  of  valvular  heart  disease  and 
identification of vulnerable atheromatous coronary plaque. 
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1.4.1  Principles of cardiac magnetic resonance imaging 
CMR  (and  all  magnetic  resonance  imaging)  is  based  on  the  principle  of  nuclear 
magnetic resonance. Images are generated from signals produced by protons (hydrogen 
nuclei). The human body consists of mainly of water, an abundant source of hydrogen 
ions. The proton behaves like a small magnet when placed in a magnetic field, aligning 
itself with the field and precessing with a frequency that depends on the magnetic field 
strength. Protons align parallel and anti-parallel to the direction of the primary field, 
with a small excess of parallel protons that gives rise to a net magnetisation vector. This 
net vector can be rotated by application of a second temporary radiofrequency (RF) 
pulse. Once this pulse ceases, the magnetisation vector recovers to its former position, 
releasing  a  signal  in  the  form  of  radio  waves.  This  relaxation  of  the  net  vector  is 
attributable  to  two  distinct  but  simultaneous  processes,  longitudinal  (T1)  and  the 
transverse (T2) relaxations(167;168) A pulse sequence consists of a series of RF pulses 
of  varying  duration  or  strength  and  application  of  magnetic-field  gradients  that  are 
adjusted to highlight desired tissue characteristics. 
 
Basic pulse sequences used in CMR are spin-echo and gradient-echo sequences. Spin-
echo sequences are often used for assessment of cardiac morphology, and flowing blood 
normally  appears  black.  Gradient-echo  sequences  have  a  lower  soft-tissue  contrast 
compared with spin-echo, and flowing blood is represented by high signal intensity and 
turbulence as areas of signal void. Gradient-echo sequences are used to assess valvular 
lesions, shunts, and great vessels as well as for measurement of ventricular function and 
wall-motion characteristics. Flowing blood across a magnetic gradient can be encoded 
to quantify flow. These phase-encoded velocity maps are based on the principle that 
magnetic vectors of flowing protons acquire a phase shift that is proportional to flow 71 
velocity. This technique is used to assess flow volumes and velocity profiles across 
valves and shunts.  
 
Cardiac and respiratory motion artefact can cause difficulty acquiring CMR images. 
Using  breath-hold  electrocardiograph-gated  techniques  to  acquire  images  minimises 
such  artefacts.  The  presence  of  cardiac  arrhythmias  such  as  atrial  fibrillation  may 
interfere with synchronised data acquisition.  
 
1.4.2  Cardiac magnetic resonance imaging for assessment of cardiac function 
Unlike echocardiography, where LV mass and dimensions are derived from one- or 
two-dimensional  data,  using  assumptions  of  cardiac  geometry,  with  CMR,  actual 
myocardial mass and volumes are obtained. A Simpson’s rule algorithm is still used, but 
acquired using three-dimensional data from a series of thin slices with no geometric 
assumptions.  Therefore,  CMR  has  become  established  as  the  ‘gold  standard’  non-
invasive  reference  standard  for  cardiac  function  and  mass.  Data  are  acquired  using  
bright blood gradient-echo sequences, obtained during a 15- to 20-s breath-hold, are 
used to cover the entire left ventricle (LV) with short-axis views from the mitral plane 
and slice thickness of 10 mm. In these studies a TrueFISP (fast imaging with steady-
state precession) sequence is used. Individual CMR scanner manufacturers have their 
own nomenclature for the various imaging sequences, with TrueFISP being that used 
for this pulsed gradient-echo sequence by Siemens (Erlangan, Germany). The actual 
CMR protocol used is described in detail in Chapter 2. 
 
Using these techniques, published normal reference ranges for cardiac dimensions and 
function have been generated(169). As CMR sequences evolve, it is important to use the 
appropriate  reference  range  for  the  sequence  used  to  acquire  the  data  as  small  but 72 
statistically  significant  differences  in  LV  dimensions  have  been  described  between 
images acquired of the same patients with TrueFISP and FLASH (fast low-angle shot), 
an alternative gradient-echo sequence(170). 
 
 
1.4.3  Gadolinium based contrast agents for cardiac magnetic resonance imaging 
All  the  currently  approved  CMR  contrast  agents  use  gadolinium  which  has 
paramagnetic  properties.  Gadolinium  based  contrast  acts  as  an  extracellular  contrast 
agent with a ‘fast wash in/slow wash out’ characteristics. Gadolinium itself is toxic, and 
therefore is chelated to a variety of molecules depending on the agent used. This chelate 
has some effect on the pharmacokinetics of the agent and in the case of Gd-BOPTA 
(Multihance), further changes the paramagnetic properties of the product. The molecular 
weights of these agents range between 650 and 2,000 Daltons and their mechanism of 
action is to shorten T1 relaxation of tissue within the magnetic field.  
 
During the first pass after rapid intravenous injection of contrast, extracellular agents 
diffuse into the interstitium of the tissues, except in the brain and testes. Approximately 
40%  of  intravenously  injected  extracellular  agents  diffuse  from  the  blood  into  the 
interstitium during the first pass(171). By tracking a bolus as it transits through a region 
of interest, time-intensity curves can be generated and used to determine myocardial 
perfusion. In the presence of altered interstitial tissue architecture, e.g. due to oedema, 
necrosis, fibrosis or inflammation (or any combination of these factors), passage of the 
gadolinium chelate will be delayed through the myocardial tissue. This will be indicated 
by the presence of late gadolinium enhancement (LGE), when this tissue is imaged, 
typically  achieved  approximately  5  minutes  after  bolus  injection.  Over  a  period 
typically  lasting  several  minutes,  the  agent  diffuses  back  into  the  blood  pool,  from 
which it is excreted by the kidneys.  73 
Gadolinium  based  agents  currently  in  use  for  cardiac  imaging  include  Omniscan 
(gadodiamide, GE Healthcare, UK), Magnevist (gadopentetate dimeglumine, Gadovist, 
Schering AG, Berlin, Germany), MultiHance (gadobenate dimeglumine, Bracco, Bracco 
S.p.A.,  Milan,  Italy),  Gadovist  (gadobutrol,  Schering  AG,  Berlin,  Germany),  
OptiMARK    (gadoversetamide,  Tyco  Healthcare,  Hazelwood,  Minnesota,  United 
States) and ProHance (gadoteridol, Bracco, Princeton, New Jersey, United States). 
 
1.4.4  Cardiac magnetic imaging for assessment of ischaemic heart disease 
CMR is an excellent technique for defining the presence and extent of both acute and 
chronic myocardial infarction. Like echocardiography, wall motion abnormalities may 
be present on cine images, suggestive of ischaemic myocardial damage. On first-pass 
perfusion  images  with  contrast,  an  area  of  hypo-enhancement  is  seen  within  the 
infarcted  region,  correlating  with  microvascular  obstruction  inside  the  infarct  zone 
(172), Figure 1.3. In the presence of chronic myocardial infarction the presence of LGE 
5 to 30 min after contrast injection is seen using a turbo FLASH inversion-recovery 
sequence,  Figure  1.4.  In  acute  infarction,  LGE  reflects  myocardial  necrosis  and 
abnormal  contrast  molecule  kinetics  within  infarcts  with  associated  tissue  oedema, 
whereas in chronic infarction, it reflects increased concentration of gadolinium non-
viable, infarcted scar tissue(173;174). Combining the extent of LGE, may indicate the 
presence of viable ‘hibernating’ myocardium. A myocardial segment with a wall motion 
abnormality and no LGE may represent myocardial hibernation which may recover with 
revascularisation, whilst non viable myocardium typically has >75% thickness of tissue 
demonstrating LGE(175). 
 
Coronary angiography with CMR is an attractive concept and may yet become a non-
invasive diagnostic method. Currently, the small size of coronary arteries, their complex 74 
course,  and  constant  motion  with  cardiac  contraction  and  respiration  has  made 
angiography technically difficult. CMR however can evaluate coronary blood flow of 
myocardial  perfusion  with  first-pass  contrast  enhanced  imaging  before  and  after 
pharmacologically induced hyperaemia, usually with adenosine. This method has a have 
high  diagnostic  accuracy  for  detection  of  coronary  artery  disease  with  myocardial 
perfusion  reserve  having  a  sensitivity,  specificity,  and  diagnostic  accuracy  of  90%, 
83%, and 87%, respectively, for detection of a  >75%, coronary artery stenosis(176). 
This technique clearly has great potential for non invasive diagnosis of coronary artery 
disease. 75 
 
Figure 1.3   
First pass imaging demonstrating an area of hypoenhancemnt (arrowed) in keeping with 
a myocardial perfusion deficit in a patient with a recent lateral myocardial infarction 
 
Figure 1.4   
Late  gadolinium  enhancement  representing  infarcted  myocardial  tissue  in  the  lateral 
wall of the left ventricle in the same patient as Figure 1.3 
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1.4.5  Cardiac magnetic resonance imaging for assessment of cardiomyopathy 
CMR  allows  accurate  definition  of  cardiac  structure,  function  and  geometry  in  the 
presence  of  cardiomyopathy.  Furthermore,  the  ability  of  contrast  enhanced  CMR  to 
detect areas of tissue fibrosis has allowed detailed study of myocardial composition in a 
number of cardiomyopathies characterised by the presence of fibrotic tissue (usually 
collagen) within the myocardium. To date there has been extremely limited study of 
uraemic cardiomyopathy with CMR, with one small study with CMR from our own 
group  describing  LVH  morphologically  in  haemodialysis  patients.  Other 
cardiomyopathies have been analysed in more detail. Hypertrophic cardiomyopathy has 
been intensively studied with CMR (Figure 1.5) and CMR allows both demonstration of 
the degree of hypertrophy, the phenotypic expression of the pathological fibrosis(177), 
degree  of  left    ventricular  outflow  tract  obstruction,  systolic  anterior  motion  of  the 
mitral valve and can monitor after surgical and pharmacologic interventions(178) or 
alcohol septal artery ablation(179).  
 
Other cardiomyopathies involving myocardial fibrosis where CMR may be useful in 
either the diagnosis or long term management include arrhythmogenic right-ventricular 
cardiomyopathy  and  dilated  cardiomyopathy.  In  arrhythmogenic  right-ventricular 
cardiomyopathy CMR can demonstrate fatty infiltration of the right ventricle and by 
detecting characteristic high signal intensity of fat on spin-echo images within the right 
ventricular  myocardium,  the  presence  of  fat  in  the  right  ventricular  wall  can  be 
demonstrated and then confirmed with fat suppression techniques. Diffuse and focal 
thinning and local aneurysms of the right ventricle can be also be detected (180;181). 
Areas of myocardial fibrosis have been described in dilated cardiomyopathy, and CMR 
may be a useful method of discriminating dilated from ischaemic cardiomyopathy in 
patients with heart failure of unknown aetiology(182).  77 
Inflammatory and infiltrative cardiomyopathies have also been described using CMR. 
In sarcoidosis, infiltrates in myocardium can be are seen as areas of amplified T2 signal 
intensity (attributable to inflammation, oedema, and granulomas), which enhance after 
administration  of  gadolinium.  CMR  can  non-invasively  assess  response  to  steroid 
treatment(183). In acute myocarditis contrast enhancement is present in approximately 
90%  of  patients  and  correlates  with  active  inflammation  defined  by  histopathology 
(Figure 1.6)(184). In cardiac amyloidosis, CMR initially allows accurate demonstration 
of the presence of thickening of the right atrial and right ventricular wall. Following 
administration  of  gadolinium  in  patients  with  cardiac  amyloid,  CMR  shows  a 
characteristic pattern of global subendocardial late enhancement coupled with abnormal 
myocardial  and  blood-pool  gadolinium  kinetics(185).  Additionally,  endomyocardial 
fibrosis  (also  termed  Loeffler’s  endocarditis),  which  is  characterised  by  extensive 
subendocardial  fibrosis,  apical  thrombus  formation,  and  progressive  diastolic 
dysfunction can be quantified using CMR(186).  
 
Recently,  the  ferromagnetic  properties  attributable  to  the  deposition  of  iron  in 
myocardial tissue have been exploited to initially assess the degree of iron overload in 
the heart of patients with thalassaemia. Myocardial iron loading is assessed with the use 
of myocardial T2* relaxation characteristics at CMR. This approach has subsequently 
been used to guide iron chelation therapy in these patients and myocardial T2* has been 
used  as  an  end  point  in  a  clinical  trial  demonstrating  superiority  of  combination 
chelation treatment with deferiprone and deferoxamine in comparison to deferoxamine 
monotherapy,  in  thalassaemia  major  patients  with  mild  to  moderate  cardiac  iron 
loading(187). 
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1.4.6  Contraindications to cardiac magnetic resonance imaging 
Patients  with  claustrophobia  may  not  tolerate  study  with  CMR.  The  presence  of  a 
cardiac  pacemaker  or  implantable  cardiac  defibrillator  remains  an  absolute 
contraindication  to  study  with  CMR.  There  are  some  reports  of  patients  with 
pacemakers  undergoing  CMR  without  adverse  outcome,  but  this  should  be  only  be 
carried out in a controlled environment, with facilities for both close monitoring and 
reprogramming of the pacemaker immediately available, and for the purpose of general 
clinical  and  research  use,  a  pacemaker  remains  an  absolute  contraindication  to 
scanning(188).  The  presence  of  intraocular  metallic  shards  (e.g.  welders)  and  intra-
cerebral clips or shunts are also contraindications to scanning. Metallic implants can 
lead  to  artefacts,  which  might  degrade  images.  Most  cardiac  prosthetic  valves  and 
coronary stents presently in use are safe for CMR at available clinical field strengths.  79 
 
Figure 1.5   
Extensive  chaotic  myocardial  collagen  deposition  indicated  by  late  gadolinium 
enhancement in a patient with hypertrophic cardiomyopathy 
 
Figure 1.6   
Patchy  late  gadolinium  enhancement  demon  demonstrated  in  both  the  septum  and 
lateral walls of the left ventricle in a patient with acute myocarditis 80 
1.5  Redefinition  of  uraemic  cardiomyopathy  with  cardiovascular  magnetic 
resonance imaging 
Despite  the  dramatically  increased  cardiovascular  risk  in  ESRD,  the  relationship 
between risk factors, interventions and outcome is unclear. One of the few factors to 
have  consistently  been  demonstrated  to  indicate  poor  outcome  is  uraemic 
cardiomyopathy, defined by echocardiography.  However, as discussed,  it is possible 
that some echocardiographic abnormalities widely present in ESRD, such as LVH may 
be at best overestimated, as suggested by the one previous  report using CMR, or even 
artefactual(189).  Although  a  variety  of  myocardial  tissue  abnormalities  have  been 
described  either  in  animal  models  of  uraemia  or  in  post  mortem  studies  of  ESRD 
patients,  no  method  has  been  able  to  non  invasively  describe  this  histopathological 
finding  in  vivo.  The  previous  studies  of  other  cardiomyopathies,  with  some  similar 
histological  correlates  suggest  that  CMR  has  the  potential  to  perform  this  function. 
Furthermore, very few CMR studies have been able to assess the long term implications 
of  either  morphological  ventricular  abnormalities  or  whether  the  presence  of  LGE 
confers increased risk of cardiovascular events or mortality.  
 
All these factors suggest that there would be benefits from studying a cohort of patients 
with  ESRD  using  CMR.  Hopefully,  by  more  accurately  characterising  cardiac 
abnormalities in this patient group, novel therapeutic targets for intervention may be 
identifies. The relationship between ischaemic heart disease and uraemic heart disease is 
imprecise. If systolic dysfunction, is due primarily to uraemia, then increasing doses of 
dialysis may be beneficial, on the assumption that myocardial contractility is suppressed 
by some (potentially undiscovered or least not yet causally linked) ‘uraemic factor’. 
Renal transplantation is a definitive treatment for uraemia, but unfortunately the current 
supply of cadaveric organs is outstripped by demand. On the other hand, if as in the 81 
general population, ischaemic heart disease is the leading cause of systolic dysfunction, 
then evidenced based medical therapy with inhibitors of the renin angiotensin system 
and beta blockade would be an appropriate strategy. The question of lipid lowering 
therapy  remains  unresolved,  but  requires  further  study.  Many  of  these  agents  are 
currently underused in the ESRD population, and often poorly tolerated. 
 
One further intriguing notion would be to predict the patients at highest risk of sudden 
cardiovascular  death.  The  recent  finding  that  the  presence  of  myocardial  fibrosis 
demonstrated by CMR was associated with increased risk of ventricular arrhythmia in 
patients with dilated cardiomyopathy(190), suggests that CMR may have a role in risk 
stratification for such patients. The same may apply in ESRD, with the highest risk 
patients being candidates for implantable cardiac defibrillators.  
 
Finally as CMR technology evolves, new methods for imaging and analysis emerge, 
dependent  on  the  clinical  needs  of  the  cohorts  of  patients  examined.  Often  these 
techniques  may  be  applicable,  across  a  wider  range  of  patients  than  previously 
envisaged. As a unique group of patients at very high cardiovascular risk, patients with 
ESRD may have distinct differences in both cardiac and vascular function, allowing 
insights into factors responsible for the pathogenesis of cardiovascular disease in the 
general  population.  Abnormalities  in  these  factors  which  are  severely  distorted  in 
ESRD,  such  as  arterial  stiffness,  may  be  expressed  more  subtly  in  the  general 
population. Studying a cohort of ESRD patients may allow novel CMR methods to be 
developed  to  investigate  cardiac  and  vascular  markers  of  cardiovascular  risk,  to  the 
advantage of research into cardiovascular disease in the general population. 
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1.6  Aims of this project 
The principal aims of this project were: 
•  To  establish  the  presence  and  prevalence  of  left  ventricular  abnormalities 
(‘uraemic cardiomyopathy’), in a cohort of patients with ESRD using CMR 
•  To establish the relationship between uraemic cardiomyopathy and conventional 
cardiovascular risk factors 
•  Establish  the  prognostic  impact  of  the  presence  of  uraemic  cardiomyopathy 
described by CMR 
 
Secondary aims: 
•  To compare conventional methods of defining uraemic cardiomyopathy such as 
echocardiography with CMR  
•  To examine whether vascular function could be assessed using CMR 
•  To determine methods of identifying patients with uraemic cardiomyopathy, in 
particular  left  ventricular  hypertrophy  using  the  conventional  method  of 
echocardiography 
 
1.6.1  Hypothesis 
The studies performed are designed to test the hypothesis that specific left ventricular 
and  vascular  abnormalities  can  be  identified  in  patients  with  ESRD  and  that  these 
abnormalities have an influence on long term survival of these patients. 
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1.7  Outline of the studies contained within this thesis 
Seven principal studies were performed and are detailed in Chapters 3-9:  
 
Chapter 3 :  A study of ventricular dimensions and function in uraemia with 
contrast enhanced cardiac magnetic resonance imaging.  
Chapter 4 :  A comparative study of echocardiography and electrocardiography 
with cardiac magnetic resonance imaging.  
Chapter 5 :  A study of the determinants of uraemic cardiomyopathy.  
Chapter 6 :  Survival of patients undergoing cardiovascular screening for renal 
transplantation.  
Chapter 7 :  A study of the diagnostic utility of brain natriuretic peptide in end 
stage renal disease.  
Chapter 8 :  A  study  of  vascular  function  with  cardiovascular  magnetic 
resonance imaging in end stage renal disease. 
Chapter 9 :  A  study  of  dermatological  complications  of  contrast  enhanced 
magnetic resonance imaging. 
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Chapter 2 
 
Materials and Methods 85 
2.1   Introduction 
The  principal  technique  used  for  this  thesis  was  cardiovascular  magnetic  resonance 
imaging  (CMR).  This  was  supplemented  with  electrocardiography  (ECG), 
echocardiography  and  exercise  tolerance  testing.    In  this  chapter  the  background, 
methods, apparatus and protocols used for these techniques will be outlined. 
 
2.2   Ethics Committee approval 
The studies performed in this thesis were approved by the North Glasgow Hospitals 
University NHS Trust Ethics Committee. All subjects gave written informed consent, 
the forms being approved by the Ethics Committee. 
 
2.2.1  Subjects 
Patients with advanced renal failure were recruited from the renal transplant assessment 
clinic at the Western Infirmary. At inception of the study, patients attending the renal 
transplant assessment clinic were required to be established on dialysis therapy. The 
study extended to those patients anticipated to commence dialysis therapy within six 
months  in  keeping  with  changes  in  British  Transplant  Society  recommendations 
regarding  eligibility  for  cadaveric  renal  transplantation.  Therefore  using  KDOQI 
classification all patients studied would be classified as chronic kidney disease stage 
5(191). As cardiovascular disease is the leading cause of both early (with 30 days of 
surgery) and late patient death with a functioning renal transplant, patients considered to 
be  at  increased  cardiovascular  risk  for  renal  transplantation  were  referred  for 
cardiovascular  screening  by  the  renal  transplant  co-ordinator.  At  this  point,  patients 
were asked if they were willing to undergo CMR by the investigator (PM). Patients 
were considered to be at increased cardiovascular risk if any of the following criteria 
were present, in keeping with published guidelines(192): 86 
•  Age ≥50 
•  Presence of diabetes mellitus 
•  History of cigarette smoking 
•  Previous history of ischaemic heart disease 
•  Previous history of peripheral or cerebrovascular disease 
•  Strong family history of cardiovascular disease 
•  Documented history of left ventricular abnormalities 
•  ECG or previous cardiac stress test suggestive of underlying ischaemic heart 
disease 
•  The opinion of the consultant transplant surgeon or consultant nephrologist  
 
All subjects who underwent CMR gave written informed consent and this strategy was 
approved  by  the  consultant  nephrologists  and  surgeons  involved  in  the  transplant 
assessment  process  with  the  protocol  approved  by  the  local  ethics  committee.  All 
patients underwent conventional cardiovascular risk factor assessment including history, 
clinical  examination,  ECG  and  blood  sampling.  A  history  of  IHD  was  defined  as 
previous  myocardial  infarction  or  angina  pectoris,  and  hypercholesterolaemia  was 
defined as fasting total serum cholesterol >5.0 mmol/L or use of statin therapy. The 
decision to list a patient for transplantation was not influenced by CMR findings, and 
was made by an independent transplant surgeon and nephrologist taken on the basis of 
clinical  findings  and  additional  investigations  such  as  exercise  testing,  myocardial 
perfusion  scanning  and  coronary  angiography  as  clinically  indicated.  Due  to  ethical 
concerns  regarding  the  potential  risks  of  invasive  procedures  such  as  coronary 
angiography,  this  was  only  performed  as  clinically  indicated  as  judged  by  an 
independent cardiologist, and not as part of study protocol. 
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2.2.2  Exclusion criteria 
Exclusion criteria were contraindications to magnetic resonance scanning (permanent 
pacemaker, implanted ferromagnetic objects, pregnancy, and extreme claustrophobia). 
Two otherwise eligible patients were also screened and excluded with a documented 
history or echocardiographic evidence of hypertrophic cardiomyopathy and one further 
patient with a history of thalassaemia and repeated blood transfusions was excluded; 
both of which have been associated with characteristic CMR findings(177;187). There 
was no evidence of other cause of cardiomyopathy (e.g. amyloidosis, Fabry’s disease, 
sarcoidosis, iron overload) in study patients based on clinical (original renal disease, 
serum ferritin, and clinical review) and echocardiographic findings. 
 
2.3   Cardiovascular Magnetic Resonance Imaging  
 
2.3.1  CMR scan 
CMR  was  performed  using  a  1.5  Tesla  MRI  scanner  (Siemens  Sonata,  Erlangan, 
Germany). As described previously CMR provides a high fidelity, volume independent 
method  for  assessing  cardiac  dimensions  and  function.  To  minimise  influence  of 
hydration status on ventricular chamber dimensions CMR scanning was performed on 
the  post-dialysis  day  in  patients  on  haemodialysis,  and  with  patients  at  their  ‘dry 
weight’ in patients on peritoneal dialysis, according to clinical charts. All scanning was 
performed  by  the  investigator  (PM)  or  a  cardiac  radiographer  (Tracey  Steedman, 
Glasgow CMR Unit, Western Infirmary, Glasgow). 
 
2.3.2  Contrast agent 
The  paramagnetic  contrast  agent  used  was  gadolinium-diethylentriaminepentaacetate 
(Gd-DTPA-BMA, Omiscan, Amersham, United Kingdom). The initial dose used was 88 
0.2mmol/kg from September 2003 to March 2004. All studies after March 2004 used 
0.1mmol/kg. The change in dose was made to allow for reduction in scan time and to 
minimise any potential side effects associated with use in patients with advanced renal 
failure. 
 
2.3.3  CMR protocol- image acquisition 
 
2.3.3.i    Patient positioning 
Patients were positioned head first and supine in the scanner. Breath hold instructions 
were relayed via headphones and relaxing music played if desired. A chest coil was 
employed to optimise image acquisition.  
 
2.3.3.ii   Left ventricular mass and function 
An  ECG  gated  breath  hold  fast  imaging  with  steady-state  precession  (trueFISP) 
sequence was used to acquire cine images in long axis planes followed by sequential 
short axis left ventricular cine loops (8mm slice thickness, 2mm gap between slices) 
from the atrio-ventricular ring to the apex. In full the protocol is as follows:  
1.  The initial sequence was a multi-slice breath-hold localiser in end expiration. 
From these images select the best axial image depicting the left ventricle and 
septum was selected 
2.  This image was used to plan a vertical long axis localiser (VLA) along the long 
axis of the ventricle from the mid-point of the mitral valve to the apex.  From the 
resulting VLA scan the horizontal long axis (HLA) localiser was planned, again 
using the mid-point of the mitral valve and the apex of the ventricle to orientate 89 
3.  From this HLA view, three short axis (SA) localiser slices were produced, with 
the orientation selected as close as possible to parallel to the mitral valve plane. 
The anatomical landmark of the atrio-ventricular groove was used as a guide  
4.  The resulting SA images allow the three long axis views to be set. These were 
the 4-chamber, 2-chamber and left ventricular outflow tract (LVOT) views. Cine 
studies were acquired in these orientations 
5.  From the cine 4-chamber study acquired the short axis stack was planned. The 
first of these cine slices was positioned in an orientation across the mitral valve 
plane, again using the atrio-ventricular groove as an anatomical land-mark. The 
slice position would then be incremented and repeated until LV was completely 
covered 
Imaging parameters, which were standardized for all subjects, included repetition time 
(TR)/echo time (TE)/ flip angle (FA)/ voxel size /field of view (FoV) - 3.14 ms/ 1.6 ms/ 
60
0/ 2.2 x 1.3 x 8.0 mm/340 mm.  
 
2.3.3.iii  Aortic distensibilty and compliance 
Aortic distensibilty was assessed from cine MR images in the transverse plane of the 
ascending aorta were obtained at the level of the main pulmonary artery utilising  a 
trueFISP  sequence  (TR=3.2  ms,  TE=1.6  ms,  FA=60°,  FoV  276x340mm,  pixel 
dimensions 2.3x1.3mm, slice thickness=7 mm). The approximately 10 second breath-
hold CMR sequence resulted in prospective images with a temporal resolution of at 
least  22.5ms.  During  image  acquisition,  blood  pressure  was  measured  using  a  non-
ferromagnetic  brachial  artery  sphygmomanometer  cuff  (Schiller  instruments,  Baar, 
Switzerland).  
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2.3.3.iv  Phase encoded (Flow sensitive) CMR imaging of aortic blood flow 
To generate flow measurements along the aorta a fast low angle shot (FLASH) gradient-
echo  pulse  sequence  (TR=41  ms,  TE=3.2  ms,  FA=30°,  matrix  size=192x256,  Pixel 
Dimensions 1.5x1.5, slice thickness= 5 mm) was applied perpendicular to the aorta at 2 
levels: at the level of the crossing of the pulmonary artery through the ascending (in the 
same plane as the compliance sequence) and descending aorta and at the level of the 
diaphragm. This resulted in multiphase image pairs of modulus- and velocity encoded 
images with a temporal resolution of approximately 20.7 ms. 
 
2.3.3.v   Contrast enhanced CMR images 
Further images were acquired 10 minutes after a manual injection of a peripheral bolus 
of Gd-DTPA-BMA via a intravenous cannula flushed with 10ml of 0.9% saline.  A 
breath-hold segmented turboFLASH inversion-recovery sequence, using identical slice 
positions as the cines was used. Standardised settings were used for contrast-enhanced 
imaging including specific parameters of TR/TE/flip angle/voxel size/FoV/number of 
segments  -  11.6  ms/4.3  ms/20°/2.2  x  1.3  x  8.0  mm/  23.  Inversion  time  for  the 
turboFLASH sequence was optimized on an individual patient basis. Successful nulling 
of normal myocardium was deemed to have been achieved once the LV myocardium 
appeared black and homogenous. Generally, an inversion time of between 150 and 280 
ms was required.  
 
2.3.3.vi  CMR scan duration 
Standard  LV  mass  and  function  took  approximately  20-25  minutes.  Measures  of 
vascular  function  required  a  further  5  minutes  and  acquisition  of  contrast  enhanced 
images  added  an  additional  10  minutes  to  scan  time.  Overall,  scan  time  was 
approximately 30–40 minutes, with a maximum time of 45minutes. 91 
2.4  CMR Analysis 
 
2.4.1  Analysis of left ventricular function 
LV function was analysed from the left ventricular short axis cine loops. Epicardial and 
endocardial borders were traced manually and end-systolic and end-diastolic contours 
with  end-systolic  and  end-diastolic  volumes  and  LV  mass  were  calculated  using 
conventional  analysis  software  (Argus,  Siemens,  Erlangen).  Volumes  and  LV  mass 
were also indexed to body surface area with body surface area calculated using the 
Dubois formula: 
Body Surface Area = 0.20247 x Height(m)
0.725 x Weight(kg)
0.425 
Left ventricular ejection fraction (LVEF) was calculated as: 
 
 
2.4.2  Definition of left ventricular abnormalities 
LVSD was defined as LV ejection fraction (LVEF) <55%, with LVH defined as left 
ventricular mass index (LV mass/body surface area; LVMI) greater than 84.1 g m
-2 
(male) or 76.4  g m
-2  (female),  LV dilatation defined as  end diastolic volume/body 
surface area greater than 111.7 ml m
-2 (male) or 99.3 ml m
-2 (female) or end systolic 
volume greater than 92.8 ml (male) or 70.3 ml (female) based on based on published  
mean normal LV dimensions for healthy volunteers plus two standard deviations(169). 92 
 
Figure 2.1 
 
Figure 2.2 
Figure 2.1   Vertical long axis (2-chamber) image in end diastole in a patient with left 
ventricular hypertrophy with line demonstrating plane used to plan horizontal long axis 
(4-chamber) cine 
Figure 2.2   Horizontal  long  axis  (4-chamber)  image  in  end  diastole  in  the  same 
patient with line demonstrating plane used to plan short axis (4-chamber) cine 93 
 
 
Figure 2.3  
Short axis view of the left ventricle in end diastole with the left ventricular (LV) and 
right ventricular (RV) cavities indicated. The papillary muscles (Pap) are arrowed 
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Figure 2.4  
End diastolic (left) and end systolic (right) short axis views of the left ventricle with the 
endocardial  (red)  and  epicardial  (green)  borders  contoured  using  the  Argus  analysis 
package 95 
2.4.3  Contrast-enhanced image analysis 
Myocardial fibrosis was documented as indicated by the presence of late gadolinium 
enhancement (LGE). Images were assessed for the presence, pattern, and volume of 
gadolinium enhancement. Patients were classed as having positive LGE, if LGE was 
seen on at least two (of three) views: short axis view, long axis view, and reverse phase 
sequences, to exclude artefact. Artefact on the contrast-enhanced images was excluded 
by the acquisition of ‘reverse phase’ images through slice planes which appeared to 
demonstrate  intra-myocardial  contrast  enhancement.  This  technique  involves  the 
reversal of the phase encoding and frequency-encoding directions as the phase-encoding 
direction  is  particularly  prone  to  artefacts  caused  by  cardiac  motion  or  chest  wall 
movement. Only areas of contrast enhancement that persisted on these reversed phase 
images were included in subsequent quantification of areas of contrast enhancement. 
Areas of contrast enhancement were first identified visually and this area was contoured 
by manual planimetry to calculate volume of enhanced myocardial tissue. Volume of 
LGE mass was calculated by multiplying LGE volume by myocardial density (1.04 g 
cm
-3) and is used as the absolute measured value of contrast-enhancing tissue seen. 
 
2.4.4  Computerised assessment of areas of late gadolinium enhancement 
Mean signal intensities (+/- standard deviation) for areas of contrast enhancement and 
for an adjacent reference area of non-enhancing myocardium again using the Argus 
package. LGE was defined as an area of visually identified contrast enhancement with a 
mean signal intensity that was greater than one standard deviation higher than the mean 
signal  intensity  of  an  adjacent  area  of  reference  ventricular  myocardium,  which 
although  nulled  had  a  mean  signal  intensity  significantly  above  zero.  No  manual 
alteration of image brightness/intensity settings was made during this process to ensure 
objective visual assessment of LGE. Patterns of gadolinium enhancement were analysed 96 
both  subjectively  and  objectively  based  on  mean  signal  intensity.  LGE  volume  was 
determined by manual planimetry of any areas of contrast enhancement meeting these 
criteria.  
 
2.4.5  Analysis of vascular function 
 
2.4.5.i    Aortic distensibilty 
To calculate aortic distensibilty, the aortic volumes were measured by manual tracing of 
the cross sectional area of the vessel lumen using the Argus analysis software, which 
was multiplied by the slice thickness. Aortic distensibilty was calculated according to 
the following formula:  
 
where  (Aortic  volume)max  and  (Aortic  volume)min  are  the  maximal  and  minimal 
calculated aortic volumes obtained during the cardiac cycle (Figure 2.5). 
Aortic volumetric arterial strain (VAS- non pressure dependent) is calculated from the 
formula: 
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2.4.5.ii   Measurement of pulse wave velocity  
2.4.5.ii (a)  Assessment of aortic length 
Aortic length was measured using software developed by Dr. Gang Gao (Department of 
Computing Science, University of Glasgow). Briefly, a threshold algorithm is used to 
convert  the  original  image  to  a  binary  map  with  the  threshold  value  selected  both 
manually and automatically. The binary map highlights the aortic region since the aorta 
appears  significantly  brighter  than  other  soft  tissues  around  it.  To  locate  the  aorta, 
further manual refinements are required.  Once the aortic midline is defined, the aorta is 
‘skeletonised’, to isolate the aortic length to be measured (Figure 2.6). 
 
2.4.5.ii (b)  Interpretation  of  flow  velocity  curves  to  calculate  time  difference 
between points along the aorta 
Initial  measurement  of  blood  flow  and  velocity  was  made  using  the  Argus  CMR 
analysis  software  (Figure  2.7).  These  files  were  saved  for  off  line  plotting, 
normalisation  and  interpretation.  The  time  difference  of  initial  flow  acceleration 
between two regions of interest was calculated from normalised velocity curves using 
off-line  software  (Origin,  OriginLab  Corporation,  Northampton,  MA,  USA).  The 
upstroke velocity is approximately linear and usually contains three or more sample 
points. The location of the best cross-correlation of two partial upstroke velocity curves 
was used to estimate the time delay (Figure 2.8).  
 
2.4.5.ii (c)  Calculation of pulse wave velocity 
Pulse wave velocity was then calculated using the equation: 
Pulse wave velocity = Distance/Time 
where distance is the distance between the points along the aorta and time is the time 
difference in flow between those points. 98 
 
 
Figure 2.5 
Ascending  aorta  (AAo)  and  descending  aorta  (DAo)  shown  in  cross  section,  with 
ascending  aortic  contour  traced  for  distensibilty  and  volumetric  arterial  strain 
measurement 99 
 
Figure 2.6.1  Figure 2.6.2 
 
Figure 2.6 Using Cardiowarp to measure aortic length 
Figure 2.6.1 Sagittal planning view through the aorta with planes for measurement of 
blood flow and aortic distensibilty indicated 
Figure 2.6.2 The aortic midline has been accurately defined and skeletonised 
Figure 2.6.3 The measured aorta with regions of interest (ROI) 1-3 indicated where 
blood flow velocity will be subsequently measured 100 
 
 
 
Figure 2.7 
Ascending  aorta  (AAo)  and  descending  aorta  (DAo)  shown  in  cross  section,  with 
ascending aortic contour traced for aortic blood flow measurement 101 
 
 
 
Figure 2.8 
Representative plot of normalised blood flow plotted against time. ∆t is the time delay 
subsequently used to calculate pulse wave velocity 102 
2.5   CMR Analysis – duration 
Approximate time required analysing left ventricular mass and function was 15 minutes 
per patient, with a further five minutes required to analyse late  gadolinium images.  
Analysing the measures of vascular function took somewhat longer, with 20 minutes 
required for all the Argus based analysis and a further 10 minutes per patient to perform 
the PC based graph construction. 
 
2.6  Coronary angiography 
A  proportion  of  patients  underwent  coronary  angiography  as  part  of  assessment  for 
renal transplant listing. The decision to perform angiography and interpretation of the 
angiogram was made by a cardiologist blinded to CMR findings, and was made on 
clinical grounds, based on symptoms, LVSD, or positive stress test (exercise test or 
myocardial perfusion scanning). CMR was performed within 3 months (before or after) 
of  angiography.  Patients  were  classified  as  having  normal  coronary  arteries, 
mild/moderate  coronary  artery  disease  (presence  of  coronary  plaque  or  up  to  70% 
stenosis of any epicardial coronary artery) or severe coronary artery disease (presence of 
>70% stenosis of any epicardial coronary artery). Total atheromatous plaque burden 
was calculated by adding the percentages of the most severe lesion in each artery (thus 
the range was 0–400% as four vessels- left main stem, left anterior descending, right 
coronary and circumflex arteries were studied)(193). 
 
2.7   Echocardiography 
 
2.7.1  Echocardiography – general 
In  all  cases  echocardiography  was  carried  out  on  the  same  day  as  CMR,  either 
immediately prior to, or after the CMR scan. Echocardiography was performed using an 103 
Acuson 128 machine (Siemens Medical, Bracknell, UK) by a single cardiac technician 
(Tony Cunningham, Clinical Research Initiative, University of Glasgow) and stored on 
videotape for off line analysis. 
 
2.7.2  Echocardiography protocol – image acquisition 
Patients  were  placed  in  the  left  lateral  position  and  scanned  from  several  different 
intercostal spaces. Standard trans-thoracic views were recorded from parasternal and 
apical transducer positions as listed below:  
Parasternal Approach 
Long-axis plane 
Root of aorta—aortic valve, left atrium, left ventricular outflow tract 
Body of left ventricle—mitral valve     
Left ventricular apex     
Right ventricular inflow tract—tricuspid valve     
Short-axis plane 
Root  of  the  aorta—aortic  valve,  pulmonary  valve,  tricuspid  valve,  right  ventricular 
outflow tract, left atrium, pulmonary artery, coronary arteries 
Left ventricle—mitral valve     
Left ventricle—papillary muscles 
Left ventricle—apex     
Apical Approach 
Four-chamber plane 
Four chamber     
Four chamber with aorta     
Long-axis plane 
Two chamber—left ventricle, left atrium and with aorta      104 
Pulsed wave, continuous wave Doppler, 2-D M-mode, and colour flow mapping were 
used in each position as appropriate to assess valve flow patterns, diastolic function, 
anatomy,  dimensions  and  regurgitation  respectively.  Analysis  of  LV  mass  was 
performed as described in chapter 4. Further characterisation of LVH into concentric 
and eccentric LVH was dependent on measurements of regional wall thickness (RWT): 
RWT = [(2 x PWTd) / LVIDd) 
Concentric hypertrophy was present if the RWT ≥0.45 in the presence of LVH with 
eccentric hypertrophy present if RWT was <0.45 in the presence of LVH. 
 
2.8  Electrocardiogram 
A standard 12-lead ECG was recorded at 25 mm s
-1 and 1 mV cm
-1 standardisation. The 
ECG was considered abnormal if any of the following criteria were met in any
 of the 
standard limb leads or praecordial leads, except AVR or
 V1: pathological Q waves, 
LVH
 by Sokolow–Lyon criteria or Cornell index, ST depression
  1 mm, ST elevation  1 
mm, T wave inversion or bundle branch block
 (QRS  120 ms). 
 
2.9  Exercise tolerance testing 
All  patients  able  to  perform  treadmill  exercise  underwent  treadmill  exercise  testing 
according to standard
 Bruce protocol. The 12 lead ECG was recorded
 continuously and 
the following documented: exercise time to
 limiting symptom, maximal ST segment 
change, maximal heart rate, maximal systolic blood
 pressure, limiting symptoms.
 The 
test was stopped if any of the following occurred: limiting
 symptoms (angina, shortness 
of breath, dizziness, lethargy),
 ST depression  3 mm, ventricular tachycardia, drop in 
blood pressure
  30 mmHg, rise in systolic blood pressure  230 mmHg.
  The test was
 
described as inconclusive if stopped before 85% predicted heart
 rate could be achieved 
with no cardiac symptoms or significant
 changes at that stage. 105 
 
 
 
Figure 2.9  
M-mode  echocardiogram  of  the  left  ventricle  of  a  patient  with  left  ventricular 
hypertrophy.  IVS  (interventricular  septum),  LVPW  (left  ventricular  posterior  wall), 
LVESD (left ventricular end systolic diameter), LVEDD (left ventricular end diastolic 
diameter) 106 
 
Figure 2.10.1 
 
Figure 2.10.2 
Figure 2.10.1 
 End  diastolic  4-chamber  view  of  the  left  ventricle  with  the  endocardial  surface 
contoured 
Figure 2.10.2  
End systolic 4-chamber view of the left ventricle with the endocardial surface contoured
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2.10  Blood sampling 
Prior to CMR scanning 30ml of venous blood was drawn and analysed in the hospital 
biochemistry  and  haematology  laboratories  for  haemoglobin,  electrolytes,  urea, 
creatinine and glucose. A proportion of this blood was centrifuged and frozen within 20 
minutes of collection to -70ºC. Serum brain natriuretic peptide was measured using by a 
one  step  radioimmunoassay  (ShionoRIA,  Shinogi,  Japan).    Plasma  total  cholesterol, 
low-density lipoproteins, high-density lipoproteins, triglycerides and high sensitivity C-
reactive protein were assessed using standard biochemical methods.  
 
2.11  Follow up 
Follow up data were collected from date of the CMR scan to 30
th September 2006 using 
electronic  patient  records  from  the  Western  Infirmary  Glasgow  and  Glasgow  Royal 
Infirmary Renal Units.  108 
 
 
Chapter 3 
 
A study of ventricular dimensions and function in uraemia with contrast enhanced 
cardiac magnetic resonance imaging 109 
3.1  INTRODUCTION 
The burden of cardiovascular disease in uraemia has been outlined in Chapter 1 and its 
relationship  with  subsequent  mortality  and  morbidity  has  been  highlighted.  As 
discussed,  despite  the  presence  of  many  ‘traditional’  cardiovascular  risk  factors  for 
atherosclerosis and subsequent development of coronary artery disease as well as those 
risk factors specific to uraemia in patients with ESRD; the relationship between these 
risk factors and outcome is less clear than in the general population. However, based on 
data  from  the  early  1990s,  the  presence  of  uraemic  cardiomyopathy,  defined 
echocardiographically  by  the  presence  of  left  ventricular  abnormalities,  specifically 
LVH,  left  ventricular  dilatation  and  left  ventricular  systolic  dysfunction  have  been 
shown to be associated with poor outcome in this patient group(76). At the inception of 
the study, no large scale studies existed to establish whether these relationships between 
cardiac dimensions and outcome held true using the more accurate method of CMR to 
assess cardiac dimensions. Moreover data were limited on the use of CMR in patients 
with ESRD, with only one small pilot study published, from our own group using a 1 
Tesla scanner with less sophisticated scanning protocols(189). 
 
This study was designed to accurately characterise left ventricular mass and function in 
a cohort of patients with ESRD, firstly compared to controls and additionally to explore 
the  relationship  between  CMR  markers  of  myocardial  fibrosis,  indicated  by  late 
gadolinium enhancement (LGE), and uraemic cardiomyopathy.  110 
3.2  METHODS 
 
3.2.1  CMR technique and analysis 
All patients and controls were studied with the CMR technique described in detail in 
Chapter  2  (2.3.2).  Controls  did  not  have  contrast  enhanced  studies  with  Gd-DTPA-
BMA performed. Blood pressure was recorded at the time of scanning. 
 
3.2.2  Statistical methods 
Left ventricular dimensions, age and blood pressure were compared between control 
groups and patients with ESRD by t-test or Mann-Whitney-U as appropriate. In patients 
with  ESRD  undergoing  contrast  enhanced  CMR  the  prevalence  of  conventional 
cardiovascular  risk  factors  and  LV  abnormalities  between  those  patients  with,  and 
without, the presence of myocardial fibrosis indicated by CMR were analysed by Chi-
squared or Fisher’s exact test (as appropriate) for categorical data and paired t-test and 
Mann–Whitney–U  testing,  respectively,  for  continuous  data.  Correlations  between 
volume of myocardial fibrosis and cardiac dimensions were assessed with Pearson and 
Spearman correlation co-efficient as appropriate. All analyses were performed using the 
SPSS 11.5 statistical software package (SPSS Inc., Chicago, IL., USA). 
 
3.3   RESULTS 
 
3.3.1  Patient and control demographics 
Patient demographics and drug therapy at the time of scan are shown in Table 3.1. 
Seven (3.9%) patients consented to be studied but did not complete CMR scanning due 
to claustrophobia and were not included in the analysis. 172 patients (38 with advanced 
renal failure not on dialysis therapy and 134 established on dialysis) and 20 control 111 
subjects were studied. The groups of controls and uraemic patients had a similar age and 
sex  distribution.  No  significant  differences  in  patient  demographics  or  ventricular 
dimensions or function were exhibited between patients with advanced renal failure not 
yet on dialysis therapy and those established on renal replacement therapy and therefore 
these patients were combined as a single ‘uraemic’ group. Systolic and diastolic blood 
pressures were higher in uraemic patients than controls as expected.  
 
3.3.2  Left ventricular dimensions 
Left  ventricular  dimensions  are  shown  in  Table  3.2  for  the  uraemic  patients  and 
controls. Overall there was no significant difference in left ventricular end diastolic or 
systolic dimensions between uraemic patients and controls but, as expected, uraemic 
patients  had  significantly  higher  left  ventricular  mass.  As  an  entire  group  uraemic 
patients did not show a reduction in systolic function as indicated by left ventricular 
ejection  fraction  compared  to  controls.  Representative  CMR  images  of  control  and 
uraemic patients are shown in Figures 3.1 - 3.4. 
 
3.3.3  Reproducibility of measurement of left ventricular dimensions 
A proportion of scans (n=20) were reanalysed in a blinded fashion. The intra-observer 
variability  of  measurements  for  ejection  fraction,  LV  mass/BSA,  end  diastolic 
volume/BSA  and  end  systolic  volume/BSA  were  4.2%,  5.3,  5.3%  and  8.8%  
respectively, in keeping with previous studies within our group(189). 112 
 
  Uraemic  Control  p value 
Number  172  20  - 
Male (%)  107  (62.2)  12  (60.0)  0.847 
Age (years)  51.9  (11.1)  48.8  (9.1)  0.366 
Height (m)  168.7  (10.0)  170.4  (9.0)  0.390 
Weight (kg)  74.8  (16.2)  74.8  (10.6)  0.984 
SBP (mmHg)  140  (25)  116  (10)  <0.001 
DBP (mmHg)  82  (13)  75  (8)  0.013 
1
0 Renal Disease    -   
  Diabetes  47  (27.3) 
  APKD  19  (11.0) 
  GN  34  (19.8.) 
  CPN  19  (11.0) 
  Renovascular  7  (4.1) 
  Unknown/Other  46  (26.7) 
   
RRT time (months)  7  (47.8)     
Smoker       
  Never  97  (56.4)  13  (65.0)   
  Current  51  (29.7)  2  (10.0)  0.123 
  Ex  24  (14.0)  5  (25.0)   
Previous IHD  30  (17.4)  -  - 
TIA/CVA  14  (8.1)  -  - 
PVD  12  (7.0)  -  - 
Table 3.1 
Background demographics for uraemic patients and controls. Results are show as mean 
with  standard  deviation  in  parenthesis  or  number  with  percentage  in  parenthesis  as 
appropriate except for RRT time which is displayed as median and inter quartile range. 
Tests of significance are t-test and Chi-squared between groups  113 
 
  Uraemic  Control  p value 
LV ejection fraction (%)  66.6  (11.6)  67.4  (4.6)  0.753 
LV mass (g)  169.1  (61.4)  123.1  (29.4)  0.001 
End diastolic volume (ml)  145.0  (59.5)  137.0  (33.0)  0.556 
End systolic volume (ml)  51.7  (36.5)  45.4  (15.3)  0.444 
Stroke volume (ml)  91.3  (33.6)  91.7  (20.1)  0.961 
LV mass/BSA (g m
-2)  91.3  (29.4)  65.7  (12.9)  <0.001 
End diastolic volume/BSA (ml m
-2)
  78.6  (29.9)  72.7  (14.8)  0.398 
End systolic volume/BSA(ml m
-2)  28.0  (19.1)  24.2  (7.3)  0.391 
Stroke volume/BSA (ml m
-2)  49.6  (16.7)  48.6  (8.9)  0.792 
 
Table  3.2  Left  ventricular  dimensions  in  uraemic  patients  and  controls.  Results  are 
show as mean with standard deviation in parenthesis. Test of significance is t-test  
 114 
 
    
Figure 3.1 
Short axis mid left ventricular cavity view of images of the left and right ventricle of a 
normal control subject in end diastole (left) and end systole (right) 
 
     
Figure 3.2 
Short axis mid left ventricular cavity view of images of the left and right ventricle of a 
patient with ESRD on haemodialysis with marked left ventricular hypertrophy in end 
diastole (left) and end systole (right) 115 
   
Figure 3.3 
Horizontal long axis view of images of the left and right ventricle of a normal control 
subject in end diastole (left) and end systole (right) 
 
    
 
Figure 3.4 
Horizontal long axis view of images of the left and right ventricle of the ESRD patient 
also shown in Figure 3.2 in end diastole (left) and end systole (right) 116 
3.4  Contrast enhanced studies 
Contrast enhanced CMR studies were performed in 145 uraemic patients.  Contrast was 
not administered for the CMR scan for the following reasons: concern over precipitating 
decline  in  renal  function  in  patient  with  rapidly  deteriorating  native  renal  function 
(n=17), concern of decline in renal function in rapidly deteriorating renal transplant 
function  (4),  patient  choice  (5)  and  poor  venous  access  (1).  The  CMR  protocol  for 
image acquisition is described in detail in Chapter 2 (2.3.2.v), with analysis described in 
2.4.2. The dose of Gd-DTPA-BMA was 0.2mmol/kg used until March 2005, when it 
was reduced to 0.1mmol/kg, in light of recognition, that similar scan quality could be 
achieved with a lower dose (permitting reduced scan time and theoretically safer or less 
likely to provoke side effects).   
 
3.4.1  Baseline left ventricular dimensions in patients with and without positive 
myocardial late gadolinium enhancement 
Baseline  patient  demographics  of  patients  undergoing  contrast  enhanced  CMR  are 
displayed in Table 3.3. Results are show as mean with standard deviation in parenthesis 
or number with percentage in parenthesis as appropriate except for RRT time which is 
displayed as median and inter quartile range.   
 
There was a high prevalence of conventional cardiovascular risk factors in the overall 
patient group with 18.6% having a history of ischaemic heart disease (IHD), 31.7% 
were  diabetic  (27.6%  with  diabetic  nephropathy),  49.7%  had  hypercholesterolaemia 
(39.3%  on  statin  therapy),  and  47.6%  had  a  positive  smoking  history.  Overall,  49 
(33.8%) patients had evidence of late gadolinium enhancement (LGE) at CMR. Patients 
who had evidence of LGE (LGE positive) had greater LVMI (LGE positive – mean 
100.9 g m
-2, LGE negative – mean 86.6g m
-2, p<0.001), LV dilation (measured as end 117 
diastolic volume: LGE positive – 168.2 ml, LGE negative – 129.2ml, p<0.001) and had 
greater  evidence  of  LVSD  (ejection  fraction:  LGE  positive  –  mean  60.7%,  LGE 
negative – mean 68.8%, p<0.001) than patients with no LGE. Representative images of 
patients with and without LGE (and its subtypes are displayed in Figures 3.5-3.10). As 
fundamental  differences  emerged  between  the  functional,  clinical  and  laboratory 
correlates of different subgroups of LGE further analysis of these factors was performed 
separately. 118 
 
Male (%)  88  (60.7) 
Age (years)  51.9  (11.1) 
Height (m)  168.6  (10.0) 
Weight (kg)  74.6  (16.2) 
SBP (mmHg)  138.9  (25.3) 
DBP (mmHg)  82.4  (13.4) 
RRT   
  HD  75  (51.7) 
  PD  52  (35.9) 
  Pre-Dialysis  18  (12.4) 
Duration of RRT (months)  8  (52.5) 
1
0 Renal Disease   
  Diabetes  40  (27.6) 
  APKD  16  (11.0) 
  GN  29  (20.0) 
  CPN  15  (10.3) 
  Renovascular  6  (4.1) 
  Unknown/Other  39  (26.9) 
Smoker   
    Never  76  (52.4) 
  Current  46  (31.7) 
  Ex  23  (15.9) 
Diabetes  46  (31.7) 
    Type 1  28  (19.3) 
  Type 2  18  (12.4) 
IHD  27  (18.6) 
Hypercholesterolaemia  72  (49.7) 
Previous MI  16  (11.0) 
TIA/CVA  11   (7.6) 
PVD  12   (8.3) 
Table 3.3  
Background demographics for uraemic patients undergoing contrast enhanced CMR 119 
3.4.2  Description and functional implications of subendocardial late gadolinium 
enhancement  
Further  analysis  of  the  pattern  of  LGE  revealed  crucial  differences  between  patient 
groups.  Broadly,  there  were  two  patterns  of  LGE.  Firstly,  subendocardial  LGE 
involving  the  subendocardium  was  seen  in  24  patients  (16.6%).  This  finding  is  in 
keeping  with  the  pattern  of  LGE  previously  described  in  patients  with  myocardial 
infarction  (Figures  3.6-3.7).  Subendocardial  LGE  was  associated  with  significantly 
greater degree of ventricular dilatation (end systolic volume/BSA 47.1 vs. 22.9 ml m
-2, 
p<0.001)  as  well  as  reduced  systolic  function  indicated  by  left  ventricular  ejection 
fraction (54.1 vs.  68.8%, p<0.001) compared to patients who were LGE negative, with 
a  corresponding  greater  proportion  of  patients  with  subendocardial  LGE  having  left 
ventricular  systolic  dysfunction  (54.2%  vs.  8.3%  of  LGE  negative,  p<0.001).  These 
results  are  presented  in  Table  3.4.  In  keeping  with  this  pattern  representing  old 
myocardial infarction, the presence of subendocardial LGE was associated with a wall 
motion abnormality of the corresponding myocardial wall in nearly all cases when the 
pre-contrast  cine  images  were  reviewed  (23  of  24  scans  exhibited  wall  motion 
abnormalities  in  the  areas  affected  by  subendocardial  LGE).  In  patients  with 
subendocardial  LGE  there  was  a  significant  negative  correlation  between  mass  of 
myocardial tissue indicated by LGE and LVEF (Spearman’s R= -0.43, p=0.036).  
 
3.4.3  Clinical correlates of subendocardial late gadolinium enhancement 
Subendocardial LGE was associated with the presence of conventional cardiovascular 
risk factors (Table 3.5) and was found in significantly higher proportions in patients 
with a history of IHD (66.7% of patients with subendocardial LGE had a history of IHD 
vs.  8.3%  of  LGE  negative  patients,  Chi-  squared  p<0.001),  hypercholesterolaemia 
(79.2% of patients with subendocardial LGE had a history of hypercholesterolaemia vs. 120 
48.3% of LGE negative patients, p=0.002), and a positive smoking history (79.2% of 
subendocardial  LGE  vs.  41.7%  LGE  negative  patients  had  ever  smoked,  p=0.001). 
Diabetes  was  present  in  a  significantly  greater  proportion  of  patients  with 
subendocardial LGE compared to LGE negative patients (54.2% vs. 30.2, Chi-squared 
p=0.028).  The  presence  of  subendocardial  LGE  was  not  associated  with  significant 
differences in gender, dialysis modality or duration, or a difference in blood pressure 
compared to those patients who were LGE negative.  
 
3.4.4  Laboratory correlates of subendocardial late gadolinium enhancement 
There  were  no  significant  differences  in  haemoglobin,  dialysis  adequacy  in 
haemodialysis  patients,  calcium,  phosphate  or  albumin  between  patients  with 
subendocardial LGE and LGE negative patients (Table 3.6). Although LDL cholesterol 
was non-significantly lower in these patients (2.2 vs. 2.9 mmol/L, p=0.054), a higher 
proportion of these patients were treated with statin therapy that LGE negative patients 
(60.9%% vs. 38.7%, p= 0.055). Serum parathyroid hormone was significantly higher in 
these patients compared to LGE negative patients (median 32.5 vs. 12.5 pg/mL, p = 
0.003). Unexpectedly in the small number of patients on peritoneal dialysis (n=5) with 
subendocardial  LGE  dialysis  adequacy,  as  indicated  by  total  weekly  creatinine 
clearance,  was  greater  in  patients  with  subendocardial  LGE  (112.1  vs.  81.0 
L/week/1.73m
2, p=0.009). This was primarily accounted for by greater residual renal 
function in these patients (64.7 vs. 31.1 L/week/1.73m
2, p=0.010). The converse was 
true  in  patients  on  haemodialysis  with  patients  with  subendocardial  LGE  having 
numerically  poorer  dialysis  adequacy,  as  indicated  by  higher  urea  reduction  ratio 
compared to LGE negative patients (66.5 vs. 70.8%, p=0.084). 
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3.4.5  Description  and  functional  implications  of  diffuse  late  gadolinium 
enhancement  
The second pattern, diffuse LGE, was less intense, without subendocardial dominance 
(Figures 3.8-3.10). Diffuse LGE was seen in 25 patients (17.2%). While this pattern was 
still  ‘patchy’  and  was  therefore  regional,  this  appears  to  represent  regional  areas  of 
diffuse fibrosis within the left ventricle. These two patterns were not mutually exclusive 
and  one  patient,  with  severe  LVH,  diabetes,  and  coronary  artery  disease  had  both 
patterns of LGE. By contrast to subendocardial LGE, patients with diffuse LGE had no 
or minimal impairment of systolic function, compared to those without LGE (Table 
3.4).  However,  diffuse  LGE  was  associated  with  significantly  greater  LV  mass 
compared to patients without LGE (105.7 vs. 100.9 g m
-2, p=0.003), and whilst the 
presence of LGE was also associated with a greater LV dilatation indicated by increased 
end  diastolic  volume  (156.9  vs.  129.2  ml,  p=0.023),  this  did  not  appear  to  have  a 
negative impact on systolic function, with no overall reduction in ejection fraction (67.0 
vs. 68.8%, p=0.389). There were no significant differences between measures of LV 
dilatation  between  patients  with  diffuse  LGE  and  LGE  negative  patients  when 
ventricular dimensions were normalised to body surface area. Unlike subendocardial 
LGE, the correlation between the mass of diffuse LGE and LV dimensions or function 
was  less  clear  with  no  significant  correlation  between  mass  of  myocardial  tissue 
indicated by diffuse LGE and any ventricular dimension. Additionally, no wall motion 
abnormalities were observed in any ventricular segments affected by diffuse LGE. 
 
3.4.6  Clinical correlates of diffuse late gadolinium enhancement 
There was no association between the presence of diffuse LGE and the presence of 
cardiovascular risk factors such as blood pressure, smoking history, gender or history of 
previous  IHD,  nor  was  this  associated  dialysis  modality  (Table  3.5).  Patients  with 122 
diffuse  LGE  had  been  receiving  treatment  with  renal  replacement  therapy  for  a 
significantly  longer  duration  than  LGE  negative  patients  (median  time  36.0  vs.  7.0 
months, p=0.036). 
 
3.4.7  Laboratory correlates of diffuse late gadolinium enhancement 
There were no significant differences in haemoglobin, dialysis adequacy or albumin 
between patients with diffuse LGE and LGE negative patients (Table 3.6). Systemic 
inflammation, as indicated by high sensitivity C-reactive protein was numerically higher 
in these patients (9.3 vs. 4.5 mg mL
-1, p=0.087). Despite proportionally lower numbers 
of  these  patients  being  treated  with  statin  therapy  (29.2  vs.  38.7  of  LGE  negative 
patients, p=0.387), patients with diffuse LGE had significantly lower total cholesterol 
than LGE negative patients (4.2 vs. 5.0 mmol L
-1, p=0.013) and LDL cholesterol (2.2 
vs.  2.9  mmol  L
-1,  p=0.033).  Additionally  these  patients  had  greater  biochemical 
evidence  of  hyperparathyroidism  than  LGE  negative  patients  (median  PTH  30.5  vs. 
12.5  pg  mL
-1,  p=0.029).  Conversely,  the  overall  calcium-phosphate  product  was 
significantly lower in patients with diffuse LGE (3.6 vs. 4.2 mmol L
-1, p=0.044). 123 
     
Figure 3.5 
Contrast enhanced images of the left ventricle in a patient with ESRD with no evidence 
of LGE. A short axis view (left) and a horizontal long axis view are shown (right). The 
myocardium  has  been  successfully  nulled  (black)  and  in  this  patient  ventricular 
dimensions and function are normal 
    
Figure 3.6 
Contrast enhanced images of the left ventricle in a patient with ESRD with evidence of 
subendocardial LGE indicating a large old inferior myocardial infarction (arrowed). A 
short axis view (left) and a horizontal long axis view are shown (right) 
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Figure 3.7 
Patient  with  an  inferior  myocardial  infarction  indicated  by  subendocardial  LGE 
(arrowed  left  panel)  and  a  corresponding  basal  inferior  wall  motion  abnormality 
demonstrated by a dyskinetic basal inferior segment arrowed in end diastole (centre 
panel) and end systole (right panel) 
 
    
Figure 3.8 
Horizontal long axis (left) and short axis (right) view of the heart of a patient with 
severe  left  ventricular  hypertrophy  and  septal  diffuse  LGE  (arrowed).  Coronary 
angiography in this patient was normal with large unobstructed coronary arteries 125 
    
Figure 3.9  Vertical long axis (left) and short axis (right) view of the left ventricle in a 
further patient with severe left ventricular hypertrophy and septal and lateral wall diffuse LGE 
(arrowed). Coronary angiography in this patient was normal with large unobstructed coronary 
arteries and additionally the patient performed  11:30 minutes of  a  Bruce protocol exercise 
tolerance test with no ECG changes 
    
Figure 3.10  Short axis (left) Horizontal long axis (left) and view of a patient with moderate 
left ventricular hypertrophy and a lesser degree of septal diffuse LGE (arrowed). There is a 
minor degree of movement artefact on the left image. The patient was 30 years old with no 
angina and performed 12 minutes of a Bruce protocol exercise tolerance test with no ECG 
changes 126 
3.4.8  Objective computerised analysis of identification and classification of late 
gadolinium enhancement 
Owing to the subjective nature of classification of pattern of gadolinium enhancement, 
objective measurement was made to compare signal intensity (or pixel intensity on the 
analysed  images),  of  the  region  of  interest  of  LGE  compared  to  that  of  nulled 
myocardium. The mean signal intensity of nulled myocardium was 6.4 units compared 
to a mean value 25.5 for all LGE positive tissue (p<0.001, Table 3.5). Subendocardial 
LGE had significantly higher mean signal intensity than that of diffuse LGE (32.6 vs. 
18.1, p<0.001) demonstrating the distinct presence of diffuse LGE separate from any 
artefact in the acquisition of images, as well as potentially indicating the different tissue 
properties of subendocardial and diffuse LGE (Figure 3.11).   
 
3.4.9  Relationship  between  results  of  contrast  enhanced  studies  and  coronary 
angiography 
In total, 64 patients underwent coronary angiography (Table 3.6). Overall 39.1% had 
normal  coronary  arteries,  with  28.1%  having  mild/moderate  coronary  artery  disease 
(CAD) and 32.8% having severe CAD. A significantly greater proportion of patients 
with subendocardial LGE had severe CAD compared to LGE negative patients (82.4 vs. 
12.9%, p<0.001) and additionally had a significantly atheromatous disease burden score 
than either patients with diffuse LGE or LGE negative patients (Mann-Whitney-U test, 
p<0.001 for comparison with either group). By contrast, the majority of patients with 
diffuse  LGE  had  either  normal  coronary  arteries  or  mild/moderate  CAD  with  only 
18.8% of these patients having severe CAD. 127 
 
 
 
Figure 3.11 Box plot showing mean pixel intensity for subtypes of LGE pattern. Each 
box shows the median, quartiles, and extreme values within the LGE category  128 
Variable  All patients  Gadolinium negative  Gadolinium positive  Subendocardial Gadolinium  Diffuse Gadolinium 
Number (%)  145  96 (66.2)  49 (33.8)  24 (16.6)  25 (17.2) 
LVH (%)  80 (55.2)  46 (47.9)  34 (69.4) *  14 (58.3)  20 (80.0) † 
LV dilatation (%)  24 (16.6)  12 (12.5)  12 (24.5)   10 (41.7) †  2 (8.0) 
LVSD (%)  25 (17.2)  8 (8.3)  17 (34.7) ‡  13 (54.2) ‡  4 (16.0) 
EF (%) (SD)  66.1 (11.8)  68.8 (8.5)  60.7 (15.1) ‡  54.1 (14.9) ‡  67.0 (12.7) 
LV mass (g)  168.3 (60.5)  157. 7 (60.6)  189.0 (55.4) †  177.3 (53.9)  200.2 (55.5) †  
LV mass/BSA(g m
-2)  91.4 (28.6)  100.9 (27.1)  86.6 (28.2) †  95.4 (28.5)  105.7 (25.5) †  
ESV(ml)  51.3 (35.4)  41.6 (25.4)  70.4 (43.9) ‡  87.8 (47.7) ‡  53.6 (32.8) 
ESV/BSA (ml m
-2)  27.7(18.3)  22.9 (13.3)  37.2 (22.8) ‡  47.1 (24.4) ‡  28.4 (17.1) 
EDV (ml)  142.4 (58.0)  129.2 (53.9)  168.2 (57.5) ‡  180 (61.5) ‡  156.9 (52.2) *  
EDV/BSA(ml m
-2)  77.2 (28.6)  71.3 (27.1)  89.1 (28.2) ‡  96.2 (30.1) ‡  82.8 (25.5) 
Mass of LGE (g)  -  -  8.2 (5.4)  9.3 (6.4)  7.2 (4.3) 
Myocardial Signal Intensity    6.4 (1.8)  25.5 (14.5) ‡  32.6 (16.7) ‡  18.1 (5.8) ‡ 
Table 3.4  Left ventricular dimensions displayed by subtype of LGE. Data are expressed as number with percent of specific subtype of 
late gadolinium enhancement (LGE) in parenthesis; all data are mean and standard deviation in parentheses  or number and percentage are 
shown as appropriate. Percentages shown are as a proportion of that subtype of LGE. Tests of significance compared to patients with 
negative LGE: *- p<0.05, †p<0.01, ‡p<0.001 129 
 
Variable  All patients  Gadolinium negative  Gadolinium positive  Subendocardial Gadolinium  Diffuse Gadolinium 
Number (%)  145  96 (66.2)  49 (33.8)  24 (16.6)  25 (17.2) 
Age (years)  51.9 (11.1)  51.1 (11.6)  53.4 (10.1)  54.4 (9.7)  52.4 (10.6) 
Sex (% male)  88 (60.7)  56 (58.3)  32 (65.3)  16 (66.7)  16 (64.0) 
Haemodialysis (%)  75 (51.7)  45 (46.9)  30 (61.2)  13 (54.2)  17 (68.0) 
Duration of RRT  8.0 (52.5)  7 (22.0)  25 (100.5)  12.0 (97.0)  36.0 (98.5) * 
History of IHD (%)  27 (18.6)  8 (8.3)  19 (38.8) ‡  16 (66.7) ‡  3 (12.0) 
History of MI (%)  16 (11.0)  2 (2.1)  14 (28.6) ‡  14 (58.3) ‡  0 (0) 
Diabetes (%)  46 (31.7)  29 (30.2)  17 (34.7)  13 (54.2) *  4 (16.0) 
Hypercholesterolaemia (%)  72 (49.7)  42 (43.8)  30 (61.2)*  19 (79.2) †  11 (44.0) 
Positive smoking history (%)  69 (47.6)  40 (41.7)  29 (59.2)*  19 (79.2) †  11 (44.0) 
SBP (mmHg)  138.9 (25.3)  137.3 (22.9)  141.9 (29.5)  144.6 (26.8)  139.2 (32.2) 
DBP (mmHg)  82.4 (13.4)  82.5 (12.1)  82.3 (15.7)  85.7 (14.7)  79.0 (16.2) 
Table 3.5 Clinical characteristics of patients as grouped by presence and subtype of LGE. Numbers displayed are absolute number with 
percentage of group of LGE subtype or as mean and standard deviation as appropriate except for RRT time which is displayed as median 
and inter quartile range. Tests of significance are Chi-squared or t-test/Mann-Whitney-U as appropriate with significance indicated as * - 
p<0.05, † - p<0.01, ‡ - p<0.001 compared to LGE negative group 130 
 
Variable  All patients  Gadolinium negative  Gadolinium positive  Subendocardial Gadolinium  Diffuse Gadolinium 
Number (%)  145  96 (66.2)  49 (33.8)  24 (16.6)  25 (17.2) 
Haemoglobin (g dL
-1)  11.6 (1.7)  11.6 (1.8)  11.3 (1.4)  11.5 (1.6 )  11.8 (1.6) 
Cholesterol (mmol L
-1)  4.8 (1.2)  5.0 (1.2)  4.3 (0.9) *  4.5 (1.1)  4.2 (0.7) * 
Triglycerides (mmol L
-1)  2.3 (1.4  2.3 (1.2)  2.4 (1.9)  2.7 (2.6)  2.1 (1.0) 
VLDL (mmol L
-1)  1.1 (0.6)  1.1 (0.5)  1.1 (0.8)  1.2 (1.1)  1.0  (0.5) 
LDL (mmol L
-1)  2.7 (1.1)  2.9 (1.0)  2.2 (1.0) †  2.2 (1.2)   2.2 (0.9) *  
HDL(mmol L
-1)  1.1 (0.4)  1.1 (0.4)  1.0 (0.5)  1.0 (0.4)  1.0 (0.5) 
CRP (mg L
-1)  4.8 (10.7)  4.5 (8.2)  9.2 (29.0)  7.8 (31.5)  9.3 (28.5) 
PTH (pg mL
-1)  16.7 (35.0)  12.5 (27.0)  31.0 (51.6) †  32.5 (57.6) †  30.5 (53.8) * 
Corrected Calcium (mmol L
-1)  2.4 (0.2)  2.4 (0.2)  2.3 (0.2)  2.3 (0.1)  2.3 (0.2) 
Phosphate (mmol L
-1)  1.7 (0.5)  1.8 (0.5)  1.7 (0.5)  1.8 (0.5)  1.6 (0.4) 
Ca-P product  4.1 (1.2)  4.2 (1.2)  3.9 (1.3)  4.3 (1.5)  3.6 (1.0) * 
Albumin (g L
-1)  39.2 (4.5)  39.1 (4.4)  39.5 (4.8)  39.9 (5.4)  40.1 (4.1) 
URR (%)  70.5 (7.5)  70.8 (7.5)  70.0 (7.7)  66.5 (8.4)  73.0 (5.6) 
CrCl (L/week/1.73m
2)  85.5 (25.1)  81.0 (21.7)  97.8 (30.4)  112.1 (28.4) †  83.6 (27.6) 
Table 3.6 Laboratory characteristics of patients grouped by presence and subtype of LGE. Numbers displayed are absolute number with 
percentage of LGE group subtype or as mean and standard deviation as appropriate. CRP and PTH are displayed as median and inter 
quartile range. URR is for HD patients. Weekly creatinine clearance is for patients on peritoneal dialysis. Tests of significance are Chi-
squared or t-test/Mann-Whitney-U as appropriate with significance indicated as * - p<0.05, † - p<0.01, ‡ - p<0.001 compared to LGE 
negative group 131 
 
 
Variable 
All 
patients 
LGE 
negative 
Subendocardial 
LGE 
Diffuse LGE 
Number (%)  64  31 (48.4)  17 (26.6)  16 (25.0) 
Normal angiogram (%)  25 (39.1)  18 (58.1)  0 (0)  7 (43.8) 
Mild/moderate CAD (%)  18 (28.1)  9 (29.0)  3 (17.6)  6 (37.5) 
Severe CAD (%)  21 (32.8)  4 (12.9)  14 (82.4) ‡  3 (18.8) 
Atheroma score  65 (164.3)  48 (100.0)   195 (155.5) ‡  36.5 (134.0) 
   
Table 3.7 
Coronary angiography results by presence and subtype of LGE. Numbers displayed are 
absolute  number  with  percentage  of  LGE  group  subtype.  Median  and  inter  quartile 
range are shown for atheroma score. Tests of significance are Chi-squared or Mann-
Whitney-U as appropriate with significance indicated as ‡ - p<0.001 compared to LGE 
negative group 
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3.5  DISCUSSION 
 
3.5.1  Uraemic cardiomyopathy defined by CMR 
Left ventricular abnormalities, previously described echocardiographically as ‘uraemic 
cardiomyopathy’ have been demonstrated to convey important prognostic implications 
in patients with ESRD. Epidemiological studies of patients with ESRD suggest that at 
inception  of  renal  replacement  therapy  the  majority  of  patients  display  some 
abnormality  in  left  ventricular  dimensions,  geometry  or  function.  This  study  was 
designed  to  reassess  the  prevalence  of  LV  disorders  using  CMR,  and  furthermore 
explore the relationship between LV abnormalities and myocardial fibrosis indicated by 
late gadolinium enhancement. 
 
Firstly, as expected patients with ESRD had significantly higher left ventricular mass 
compared to controls. Using published reference ranges for LV dimensions with CMR, 
41.3%  of  this  cohort  of  uraemic  patients  had  normal  LV  dimensions,  higher  than 
reported echocardiographically. Whether this lower prevalence of LV disorders is due to 
a ‘healthier’ cohort of patients, as these patients were fit enough to be considered for 
renal  transplantation,  better  treatment  of  hypertension  and  hence  left  ventricular 
hypertrophy, or due to  genuine differences between measurements made with CMR 
versus echocardiography requires further study of direct comparison between CMR and 
echocardiography. Only 16.2% of patients in the uraemic cohort displayed evidence of 
left ventricular systolic dysfunction, which is in keeping with reported prevalence in 
echocardiographic studies of patients with ESRD as well as those few pilot studies that 
exist with CMR(75;113;189). Blinded analysis demonstrated that CMR measures of LV 
dimensions are more reproducible than has been reported with echocardiography(194). 133 
 
This indicates that CMR may allow substantial reduction in numbers for interventional 
studies where LV mass or ejection fraction is a clinical end point(195). 
 
At the time of performing this study contrast enhanced CMR using gadolinium based 
contrast agents had become an established clinical tool in the management of patients 
with  heart  failure,  cardiomyopathies  and  coronary  artery  disease.  However,  this 
represents the first published study using this technique in patients with ESRD. Other 
centres have performed smaller pilot studies, reported in abstract form, whose results 
appear  similar  to  our  own.  The  published  literature  has  categorised  uraemic 
cardiomyopathy defined by echocardiography into three subtypes – LVH, ventricular 
dilatation or systolic dysfunction (or a combination of these patterns) with each pattern 
associated  with  cumulatively  worse  survival(75;76).  By  contrast,  the  results  of  this 
study  based  on  CMR  findings,  suggest  that  there  are  only  two  types  of  uremic 
cardiomyopathy.  The  first  is  due  to  underlying  ischaemic  heart  disease  where  LV 
dilatation and systolic dysfunction are due primarily to previous myocardial infarction 
revealed by CMR. The second form, diffuse LGE found in patients with more severe 
LVH,  is  more  specific  to  uraemia  is  consistent  with  fibrosis  in  the  hypertrophied 
ventricle. 
 
Gd-DTPA-BMA is an extracellular contrast agent that diffuses into the interstitial space 
between  cells  and  exhibits  its  effect  by  shortening  the  T1  relaxation  of  tissue  in  a 
magnetic field. There is greater space for Gd-DTPA-BMA accumulation both in areas 
of myocardial fibrosis and oedema. In areas of ischaemia or infarction, gadolinium leaks 
into  the  surrounding  fibrotic  or  oedematous,  tissue  resulting  in  late  gadolinium 
enhancement on CMR imaging(174). However, the presence of LGE is not specific and 
further subjective assessment of the pattern of LGE is required. LGE has also been 134 
 
described in patients with myocarditis, dilated cardiomyopathy and other inflammatory 
cardiomyopathies(182-184).  Importantly,  LGE  has been shown to represent collagen 
deposition in hypertrophic cardiomyopathy(177).  
 
3.5.2  Clinical implications of subendocardial LGE 
Subendocardial LGE, consistent with that described in myocardial infarction, follows a 
primarily subendocardial distribution. This reflects the perfusion of the subendocardium 
by end-arteries. Therefore, a high prevalence of myocardial infarction in this cohort of 
patients  has  been  demonstrated  indicated  by  subendocardial  LGE.  Patients  with 
subendocardial  LGE  had  greater  evidence  of  LV  systolic  dysfunction,  clearly 
highlighting  the  importance  of  underlying  ischaemic  heart  disease  as  the  cause  for 
ventricular  impairment  in  these  patients.  While  this  was  associated  with  a  previous 
history of ischaemic heart disease, eight patients (4.7% of the whole cohort or one third 
or all patients with CMR evidence of infarction indicated by subendocardial LGE) had 
CMR evidence of myocardial infarction, despite no preceding history, in keeping with 
studies  suggesting  that  ESRD  patients  are  more  likely  to  have  silent  myocardial 
ischaemia(53). Subendocardial LGE was associated with many ‘classical’ risk factors 
for  ischaemic  heart  disease,  present  in  the  general  population  such  as  diabetes  and 
positive smoking history. Although a significantly higher number of these patients were 
labelled  as  hypercholesterolaemic,  this  may  be  due  to  the  factor  that  a  higher 
numerically proportion of patients were on statin therapy than LGE negative patients 
(60.9 vs. 38.7%, p=0.055). This however did not in turn lead to a significantly lowered 
total or LDL cholesterol compared to LGE negative patients, and consequently one may 
speculate that patients with subendocardial LGE may have had higher pre-treatment 
serum cholesterol than LGE negative patients.  
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The  only  risk  factors  specific  to  uraemia  associated  with  subendocardial  LGE  were 
raised serum PTH levels and greater dialysis adequacy in patients on peritoneal dialysis. 
This second finding was unexpected and is unlikely to be of clinical significance given 
the extremely small numbers of peritoneal dialysis patients with subendocardial LGE. 
This finding may be explained by higher numbers of diabetic patients on peritoneal 
dialysis. These patients, at greatest cardiovascular risk are also likely to be commenced 
on renal replacement therapy at a higher residual GFR due to excessive symptoms of 
uraemia. Higher dialysis adequacy has not been shown to be associated with improved 
outcomes  in  peritoneal  dialysis  patients(196).  By  contrast,  the  presence  of 
hyperparathyroidism  contributes  to  accelerated  cardiovascular  disease  in  uraemia  by 
two mechanisms. Firstly, it is likely that high levels of PTH are associated with arterial 
calcification, which in turn may be associated with atherosclerosis (particularly intimal 
calcification)(197).  Of  interest,  in  the  current  study,  this  was  not  associated  with 
significant abnormalities in serum calcium, phosphate or calcium-phosphate product. 
Additionally,  it  has  been  shown  that  parathyroid  hormone  as
  a  permissive  factor 
promoting  cardiac  fibroblast  activation
  and  intercardiomyocytic  fibrosis  therefore 
promote LVH(139). This is likely to be important in the pathogenesis of diffuse LGE, 
which will be discussed later in this section. 
 
The data on coronary angiography explore further the relationship between results of 
contrast  enhanced  CMR,  LGE  and  cardiomyopathy.  First,  in  the  absence  of  LGE 
patients were relatively unlikely to have significant coronary artery disease requiring 
intervention. Only 12.9% of these patients had severe coronary artery disease. As this 
technique  represents  a  static  scan,  a  negative  CMR  for  LGE  does  not  exclude  the 
presence of critical coronary disease, but makes it less likely. Conversely, no patients 
with subendocardial LGE had a normal angiogram and the majority of these patients 136 
 
had critical coronary stenosis, where coronary intervention with angioplasty or bypass 
surgery may be appropriate. Similarly, these patients have a significantly higher total 
atheroma burden than either LGE negative patients or those with diffuse LGE. 
 
The discovery of this high prevalence of myocardial infarction in ESRD patients is 
important given the poor long-term survival of these patients post-infarction and general 
trend towards under treatment in this patient group(53). Thus, the diagnosis of sub-
clinical myocardial infarction with CMR is likely to have prognostic and therapeutic 
implications  and  may  be  an  indication  for  further  assessment  with  angiography, 
particularly if the patient is being considered for renal transplantation. Furthermore, in 
patients  with  coronary  artery  disease  requiring  intervention,  CMR  can  assess 
myocardial  viability  prior  to  revascularisation,  allowing  optimal  identification  of 
patients likely to benefit from coronary intervention(175).  
 
3.5.3  Other studies displaying myocardial ischaemia with subendocardial LGE at 
CMR 
Recent  studies  using  similar  CMR  protocols  to  detect  the  presence  of  myocardial 
infarction, represented by the presence of subendocardial LGE, have focused on various 
goals such as early detection of myocardial infarction, detection of silent infarction, 
accurately  characterising  the  location  of  infarcted  tissue  and  most  promisingly 
prediction  of  myocardial  viability  post  revascularisation  in  patients  with  critical 
coronary artery lesions: 
•  Kim  et  al  used  CMR  to  identify  reversible  myocardial  dysfunction  can  be 
identified by contrast-enhanced MRI before coronary revascularisation (either 
surgical or by percutaneous intervention). Their results suggest that in areas of 
abnormal ventricular contraction, improvement in contractility can be predicted 137 
 
by the percentage of that myocardial segment that is composed of tissue indicted 
by  LGE.  For  instance,  contractility  increased  in  256  of  329  segments  (78 
percent) with no LGE before revascularisation, but in only 1 of 58 segments 
with LGE occupying more than 75 percent of tissue. The percentage of the left 
ventricle that was not enhanced before revascularisation was strongly related to 
the degree of improvement in the ejection fraction after revascularisation(175) 
•  In a study of patients with dilated cardiomyopathy of unknown aetiology CMR 
differentiated between patients with ischaemic cardiomyopathy and idiopathic 
dilated  cardiomyopathy.  This  has  important  implications  for  both  secondary 
prevention in ischaemic heart disease and genetic screening for patients with 
idiopathic  dilated  cardiomyopathy  which  may  have  an  underlying  genetic 
basis(182) 
 
3.5.4  Clinical implications of diffuse LGE  
The second pattern of gadolinium enhancement demonstrated was a pattern of diffuse, 
less  intense,  LGE.  This  was  an  unexpected  finding.  This  diffuse  gadolinium 
enhancement is less striking than that seen in, for example, myocardial infarction or 
hypertrophic cardiomyopathy. However, it was reproducible and not due to artefact in 
the imaging process, and was associated with features of uraemic cardiomyopathy, most 
notably LVH. Coronary angiography revealed that that many patients with diffuse LGE 
had either no or minimal coronary artery disease. This was perhaps unexpected but 
suggests that diffuse LGE is not due to large vessel coronary artery disease. This does 
not  exclude  that  it  may  be  due  to  low  grade  ischaemia  leading  to  fibrosis  or  to 
permissive factors in uraemia as discussed previously.   
 138 
 
Diffuse gadolinium enhancement implies an additional pathological process, other than 
large vessel myocardial infarction. It may reflect diminished capillary blood supply with 
associated fibrosis, which is a prominent histopathological finding in the uraemic heart, 
or low-grade ischaemia. It may be that small vessel disease is also present in patients in 
the absence of epicardial atherosclerosis. Alternatively, this pattern of enhancement may 
most likely represent fibrosis throughout the hypertrophic ventricle, being evident in 
severe hypertrophy. Overall, the presence of gadolinium enhancement may not be due 
to  a  single  process.  To  address  whether  uraemia  or  ventricular  hypertrophy  is  a 
dominant  factor  in  its  pathogenesis,  a  larger  study  of  gadolinium  enhancement  in 
patients with LVH due to hypertension and normal renal function is required.  
 
The clinical and laboratory correlates of diffuse LGE to an extent support the notion that 
LVH  represents  a  form  of  cardiomyopathy  more  specific  to  uraemia  than  systolic 
dysfunction, which is primarily due to underlying ischaemic heart disease. Diffuse LGE 
was in particular associated with a significantly greater duration of renal replacement 
therapy than LGE negative patients. There were no associations with conventional risk 
factors  for  coronary  artery  disease  such  as  smoking  history,  age,  diabetes,  blood 
pressure or hypercholesterolaemia. Indeed, despite lower proportions of patients with 
diffuse  LGE  being  on  statin  therapy  (29.2%),  these  patients  had  significantly  lower 
serum total and LDL-cholesterol than LGE negative patients as well as higher (although 
non-significantly) C-Reactive protein. This suggests that these patients are at greater 
risk of the malnutrition-inflammation complex syndrome, which has been postulated in 
patients  on  dialysis  therapy(160).  Further  support  for  this  concept  is  illustrated  by 
significantly lower serum phosphate levels in these patients which may suggest poor 
nutritional  intake.  Conversely  lower  phosphate  levels  are  usually  a  marker  of  good 139 
 
dialysis and have been previously associated with better outcome, therefore this result 
may be paradoxical(137). 
 
3.5.5  Other studies displaying diffuse LGE with contrast enhanced CMR 
Although no directly comparable reports of use of CMR in patients with ESRD exist, a 
number of authors have performed similar studies in other patient groups: 
•  Recent data have emerged suggesting that areas of scarring similar to diffuse 
LGE are present in patients with adaptive LVH secondary to aortic stenosis. 
Although the terminology used by the authors for the description of the pattern 
of LGE is different in the study of aortic stenosis the images are remarkably 
similar(198) 
•  Our own group have demonstrated areas of diffuse LGE in the interventricular 
septum  in  patients  with  right  ventricular  pressure  overload  due  to  primary 
pulmonary hypertension(199)  
•  Patchy foci of midwall LGE have been described in patients with idiopathic 
dilated cardiomyopathy. In this study the authors speculate that these foci of 
midwall  LGE  probably  reflect  focal  segmental  fibrosis  found  at  autopsy  in 
patients with dilated cardiomyopathy(182) 
•  A form of diffuse LGE has been described in patients with systemic amyloidosis 
and associated infiltrative cardiomyopathy(185) 
•  LGE  has  also  been  reported  in  two  storage  diseases  with  myocardial 
involvement,  namely  glycogenosis  and  Anderson-Fabry  disease(200;201).  In 
Anderson-Fabry  disease  diffuse  LGE  was  mainly  localised  to  the  basal 
inferolateral LV wall and was not involving the subendocardium 
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3.5.6  Other studies assessing myocardial tissue composition in ESRD 
A number of studies have reported tissue abnormalities in patients with ESRD: 
•  Aoki et al performed endomyocardial biopsies in patients with no evidence of 
coronary  artery  disease  and  cardiac  dysfunction  and  found  evidence  of 
myocardial fibrosis(202) 
•  Post  mortem  studies  have  shown  evidence  of  tissue  fibrosis  in  patients  with 
ESRD(85) 
•  Animal models have demonstrated similar findings and explored factors which 
may promote tissue fibrosis in renal failure(203) 
•  Using CMR spectroscopy it has been demonstrated that myocardial metabolism 
is altered in patients with ESRD. This abnormality is accentuated by diabetes 
and may be ameliorated by renal transplantation(204). Whether these metabolic 
abnormalities are related to myocardial fibrosis is unknown 
 
3.5.7  Limitations 
This study has some weaknesses. The patients studied were being considered for renal 
transplantation, who are fitter than the majority of patients with ESRD, and hence found 
a lower prevalence of systolic dysfunction than might be expected. To fully appreciate 
the burden of cardiovascular disease in patients with ESRD, it would be necessary to 
study the entire dialysis population. Therefore, selection bias cannot be excluded, and a 
higher prevalence of LVSD may be expected (but also an even higher prevalence of 
IHD)  in  an  unselected  cohort  of  dialysis  patients.  Coronary  angiography  (and 
endomyocardial biopsy) in all patients would provide additional information regarding 
the relationship between LGE and coronary artery disease, but is invasive, and therefore 
not  without  risk.  This  was  not  deemed  ethically  justifiable  by  the  consultants 
responsible for the patients’ overall care. Hence correlation between angiographic and 141 
 
CMR  findings  should  be  interpreted  with  caution.  In  analysis  of  LGE,  using  signal 
intensity, greater distinction between nulled myocardium and areas of LGE (using a 
signal intensity of LGE >2 standard deviations higher the mean intensity of an area of 
reference  myocardium),  would  give  greater  distinction  in  image  analysis,  but  may 
exclude definite areas of LGE. Future use of computer software to automatically detect 
areas of LGE will optimise detection of enhancement.  
 
3.5.8  Conclusions 
In  this  study,  systolic  dysfunction  and  ventricular  dilatation  are  not  present  in  the 
absence of late gadolinium enhancement and it is only patients with focal gadolinium 
enhancement that have significant ventricular dilatation and systolic dysfunction. This 
suggests  that  LVH  is  the  only  cardiomyopathy  truly  associated  with  uraemia  (and 
presumably is a consequence of hypertension and other factors associated with renal 
failure) whilst systolic dysfunction is not due to uraemia, but to underlying ischemic 
heart disease. Therefore CMR represents an advance for cardiovascular investigation to 
guide invasive assessment, particularly in asymptomatic patients, undergoing evaluation 
for  renal  transplantation.  The  implication  is  that  patients  with  systolic  dysfunction 
require  investigation  of  coronary  heart  disease.  The  prognostic  implications  of  both 
subendocardial and diffuse LGE require further study.  
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Chapter 4 
 
 
A comparative study of echocardiography and electrocardiography with cardiac 
magnetic resonance imaging 143 
 
4.1  INTRODUCTION 
Left ventricular function, dimensions and geometry have conventionally been assessed 
using  echocardiography.  As  previously  discussed,  this  technique  is  convenient  and 
reproducible and conveys important prognostic and diagnostic information for patients 
with  ESRD.  However  M-mode  echocardiography,  a  one-dimensional  technique, 
overestimates  left  ventricular  mass  in  this  population  compared  to  CMR(189).  The 
disparities  between  the  two  methods  have  also  been  demonstrated  in  other  patient 
populations.  The  geometrical  assumptions  used  by  M-mode  echocardiography  have 
primarily been validated in normal hearts or in small studies compared to post mortem 
specimens(205;206).  Echocardiography  is  operator  dependent  and  is  limited  by  the 
acoustic window which depends on cardiac geometry, body habitus and co-morbidity 
such as respiratory disease or obesity. No attempt has been made to derive a correction 
factor to optimise M-mode echocardiographic measures of left ventricular mass in this 
population.  
 
The electrocardiogram (ECG) is readily available, easy and inexpensive to acquire and 
is  widely  used  in  both  research  and  clinical  practise  to  diagnose  left  ventricular 
hypertrophy (LVH). Like echocardiography, ECG measures of LVH have prognostic 
value in patients with ESRD(207). However, the criteria used to classify LVH were 
derived  from  echocardiographic  measures  of  left  ventricular  mass  which  may  have 
limitations, particularly in groups where there is a high prevalence of LVH.  These 
studies were designed to:  
•  Compare echocardiographic measures of left ventricular dimensions in patients 
in patients with ESRD with CMR 
•  Use CMR to optimise echocardiographic formula to derive left ventricular mass 144 
 
•  Evaluate  the  Sokolow-Lyon  voltage,  Cornell  sex-specific  voltage,  Sokolow-
Lyon product and Cornell product criteria against left ventricular mass index   as 
measured by CMR in a cohort of patients with ESRD 
•  Use  CMR  to  derive  optimised  ECG  partition  values  for  LVH  in  the  ESRD 
population 
 
4.2  METHODS 
 
4.2.1  CMR and echocardiography 
All patients were studied with CMR technique and echocardiography performed on the 
same day described in detail in Chapter 2 (2.3.2). As some of the disparity between 
echocardiographic and CMR measures of LV dimensions may be due to changes in 
hydration status related to the dialysis cycle, only patients with ESRD established on 
dialysis therapy on with both echocardiographic and CMR data were studied.  
 
4.2.2  Echocardiogram- analysis 
Left ventricular (LV) dimensions were determined from two-dimensional guided M-
mode  images,  using  American  Society  of  Echocardiography  leading  edge 
recommendations. The  mean of three measurements was taken. As the most widely 
used method the Penn (Devereux-Reichek) was used for the majority of analyses of LV 
mass. The utility of the following alternative formulae for calculation of left ventricular 
mass was also assessed(205;206;208;209): 
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where LVID - left ventricular internal diameter, IVST - interventricular septal thickness 
and PWT - posterior wall thickness. LVH was defined by conventional criteria (LVMI 
≥131 or 110 g/m
2 in men and women, respectively). Systolic function was assessed by 
measuring LV ejection fraction (LVEF), calculated from end-systolic and end-diastolic 
volumes determined from the mean of three measurements in different cardiac cycles 
using modified biplane disc summation (Simpson’s rule).  
 
4.2.3  Electrocardiogram 
This was performed prior to echocardiography. ECG criteria were analysed in a blinded 
fashion. The following ECG criteria were tested: Sokolow-Lyon voltage(210), Cornell 
sex-specific voltage(211), Cornell product, and Sokolow-Lyon product(212). LVH was 
defined as a Sokolow-Lyon voltage amplitude of (SV1+RV5 or RV6)≥35 mV, a Cornell 
voltage  of  (RaVL+SV3)≥28  mV  for  men  and  ≥20  mV  for  women,  and  a  Cornell 
product  of  [(RaVL+SV3)*QRS  duration]  ≥2440  mV  ms.  There  is  no  recognised 
partition value for the Sokolow-Lyon product [(SV1+RV5 or RV6)*QRS duration]. 
 
4.2.4  Statistical methods 
Correlations between cardiac dimensions by the various methods were assessed with 
Pearson and Spearman correlation co-efficient as appropriate, with comparisons made 
using Bland-Altman plots. Receiver operator characteristic (ROC) curves were plotted 
Penn:  =  1.04 x [(IVST + PWT + LVID)
3 – LVID
3] -13.6 
ASE:  =  0.80 x [(IVST + PWT + LVID)
3 – LVID
3] + 0.6 
Troy  =  1.05 x [(IVST + PWT + LVID)
3 – LVID
3] -13.6 
Teichholz:  =  1.04 x {[7/(2.4 + IVST + PWT + LVID)] x (IVST + PWT + LVID)
3 – 
[7/(2.4 + LVID)] x (LVID)
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to  assess  diagnostic  utility  of  tests  for  categorical  variables.  All  analyses  were 
performed using the SPSS 13.0 statistical software package (SPSS Inc., Chicago, IL., 
USA),  except  Bland-Altman  plots  and  ROC  curves  which  were  performed  with  the 
MedCalc software package (MedCalc 8.1, MedCalc Software, Belgium). Derivation of 
revised  echocardiographic  formula  was  performed  with  OriginPro  7.0  software 
(OriginLab Corporation, Northampton, MA, USA). 
 
4.3  RESULTS OF ECHOCARDIOGRAPHIC STUDIES 
 
4.3.1  Patient demographics 
Echocardiography combined with CMR were available on 128 patients, of whom 28 
were  excluded  as  not  established  on  long  term  dialysis  therapy  (25  advanced  renal 
failure not yet started dialysis, 3 failing renal transplant). Patient demographics for the 
100 patients studied at the time of scan are shown in Table 4.1. 15 (15.0%) patients had 
insufficient M-mode echocardiographic images to calculate LVM and 30 (30.0%) had 
inadequate images for calculation of LVEF by Simpson’s bi-plane method. 
 
4.3.2  Echocardiographic  compared  to  CMR  descriptions  of  uraemic 
cardiomyopathy 
Subdividing the cohort by conventional definitions of uraemic cardiomyopathy using 
the  Penn  formula  to  calculate  LVM  with  echocardiography;  16.5%  had  normal  left 
ventricular  dimensions  and  function,  81.2%  had  LVH,  34.9%  had  left  ventricular 
dilatation and 18.7% had left ventricular systolic dysfunction. This compares to CMR 
measures  for  the  entire  cohort  of  patients  on  dialysis  therapy  of  54.0%  with  LVH, 
18.0% LV dilatation and 13.0% systolic dysfunction. 39.0% of patients had normal LV 
dimensions by CMR. For both imaging modalities these patterns were not mutually 147 
 
exclusive and by echocardiography, 50.6% had isolated LVH, with 15.3% of patients 
having combined LVH and LV dilatation and 7.1% of patients having combined LVH, 
dilatation  and  LVSD.  By  CMR,  39.0%  had  isolated  LVH,  9.0%  had  combined  LV 
dilatation and LVH, and 6.0% having combined LVH, dilation and LVSD (Figures 4.1-
4.2). LVM was greater in patients on haemodialysis compared to peritoneal dialysis 
(LVMI by CMR 102.9 vs. 78.7g m
-2, p<0.001). 
 
4.3.3  Echocardiographic measures of left ventricular geometry 
Using the criteria described in Chapter 2 to describe ventricular remodelling, 45.2% had 
normal ventricular geometry and 54.8% had eccentric remodelling.  Of the patients with 
LVH,  44.9%  had  concentric  LVH  and  55.1%  had  eccentric  LVH.  There  were  no 
significant  differences  in  remodelling  patterns  in  between  patients  on  haemodialysis 
compared to peritoneal dialysis (44.2% of haemodialysis patients had normal geometry 
compared to 46.9% of peritoneal dialysis, Chi-squared p=0.813), nor between patients 
with a past history of ischaemic heart disease (41.2% of patients with IHD had normal 
geometry compared to 46.3% with no history of IHD, Chi-squared p=0.706). Patients 
with  eccentric  remodelling  had  a  significantly  greater  degree  of  left  ventricular 
dilatation than those with normal or concentrically remodelled ventricles (117.3 vs. 89.7 
ml m
-2, p=0.001; Figure 4.3). 
 
4.3.4  Comparison  of  CMR  with  echocardiography  for  calculation  of  left 
ventricular mass and dimensions 
Results and correlation between the echocardiographic dimensions using the Simpson’s 
bi-plane method and Penn formula for LV mass and CMR studies are shown in Table 
4.2 The correlations between CMR and echocardiographic measures of LV mass and 
LVMI measures using the Penn, ASE, Troy and Teichholz formulae are shown in Table 148 
 
4.3  and  Figure  4.4.  A  Bland-Altman  plot  (Figures  4.5  and  4.6)  comparing  the  two 
methods indicates that using echocardiographic formula the Penn formula overestimates 
LVM  by  a  mean  of  141.9g  and  the  ASE  formula  overestimates  a  mean  of  89.9g  
compared to CMR. Echocardiography overestimates LVMI by 77.6g m
-2 and 49.4g m
-2 
with  the  Penn  and  ASE  formulae  respectively  compared  to  CMR.  The  Teichholz 
formula overestimated LV mass by and LVMI by 15.5g and 9.4g m
-2. There was no 
significant difference in over estimation of LV mass when patients were compared by 
pattern  of  ventricular  remodelling  (overestimation  for  eccentric  remodelling  and 
hypertrophy 140.6 vs. normal geometry and concentric LVH 143.6 g, p=0.87). Using 
the  Simpson’s  bi-plane  method  to  calculate  end  diastolic  and  end  systolic  volumes, 
echocardiography underestimates end diastolic volume by a mean of 46.9ml and end 
systolic volume by 7.2ml compared to CMR (Figures 4.7 and 4.8). 149 
 
 
   
Number  100 
Male (%)  65  (65.0) 
Age (years)  52.3  (11.0) 
Height (m)  168.5  (10.2) 
Weight (kg)  74.7  (16.7) 
SBP (mmHg)  138.8  (26.1) 
DBP (mmHg)  81.7  (18.3) 
Haemodialysis (%)  59  (59) 
1
0 Renal Disease (%)   
  Diabetes  22  (22.0) 
  APKD  9  (9.0) 
  GN  25  (25.0) 
  CPN  10  (10.0) 
  Renovascular  5  (5.0) 
  Unknown/Other  29  (29.0) 
RRT time (months)  9  (59.3) 
Previous IHD (%)  21  (21.0) 
 
Table 4.1 
Background  demographics  for  patients  studied  with  CMR  and  echocardiography. 
Results  are  show  as  mean  with  standard  deviation  in  parenthesis  or  number  with 
percentage in parenthesis as appropriate except for RRT time which is displayed as 
median and inter quartile range  
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Figure 4.1  Prevalence of left ventricular abnormalities as detected by CMR 
 
Figure 4.2   
Prevalence of left ventricular abnormalities as detected by echocardiography 151 
 
 
Figure 4.3   
Proportion of patients with left ventricular dilatation as classed by echocardiographic 
pattern of remodelling 152 
 
 
Figure 4.4   
Scatter plots of echocardiographic measures versus CMR measures of LV mass for 
various M-mode echocardiographic formulae to calculate LV mass 153 
 
 
  Echocardiography  CMR  R  p 
EF (%)  58.4  (7.4)  67.6  (10.5)  0.51  <0.001 
EDV (mL)  105.7  (34.9)  142.8  (59.1)  0.86  <0.001 
ESV (mL)  45.0  (20.0)  48.5  (31.4)  0.82  <0.001 
EDV/BSA (mLm
-2)  57.8  (17.0)  77.1  (28.9)  0.86  <0.001 
ESV/BSA (mLm
-2)  24.6  (10.3)  26.1  (16.1)  0.82  <0.001 
Mass (g)  315.2  (130.1)  173.1  (65.2)  0.84  <0.001 
Mass/BSA (g m
-2)  171.5  (63.7)  93.2  (30.8)  0.81  <0.001 
 
Table 4.2  Comparison  of  echocardiographic  and  CMR  measures  of  left  ventricular 
dimensions. Values displayed are mean with standard deviation in parentheses. Correlation 
between variables (R) is by Spearman co-efficient  
 
Method  Mean LV mass (g)  R  p  Mean LVMI (g m
-2)  R  p 
ASE  263.6  (104.1)  0.84  <0.001  143.5  (50.8)  0.81  <0.001 
Penn  315.2  (130.1)  0.84  <0.001  171.5  (63.7)  0.81  <0.001 
Troy  332.0  (131.4)  0.84  <0.001  180.7  (64.1)  0.81  <0.001 
Teichholz  190.1  (58.2)  0.82  <0.001  104.0  (28.7)  0.76  <0.001 
 
Table 4.3   
Comparison of M-mode methods of calculating left ventricular mass. Values displayed 
are  mean  with  standard  deviation  in  parentheses.  Correlation  is  by  Spearman  co-
efficient (R) compared to CMR measures of LV mass 154 
 
 
Figure 4.5 
 
Figures 4.5 and 4.6. Bland-Altman plots of Echocardiographic LV mass minus CMR 
LV mass against mean of echocardiographic and CMR LV mass for the Penn (Figure 
4.5) and Teichholz formulae (Figure 4.6)  155 
 
 
Figure 4.7  Scatter plots of echocardiographic measures versus CMR measures of 
LV volume for end diastolic and end systolic volume. End diastolic and end systolic 
volume are calculated by Simpson’s bi-plane method 
 
Figures 4.8    
Bland-Altman plot of CMR LV mass minus Echocardiographic LV mass minus against 
mean of echocardiographic and CMR LV for end diastolic volume 156 
 
4.3.5  Derivation of revised echocardiographic formula for use in ESRD patients 
The highest correlation between CMR and echocardiographic MV mass is using the 
cubed based formulae (Penn, ASE, Troy). As the best fit for a relationship between 
cubed  based  formulae  is  linear  (Figure  4.4),  a  linear  fit  equation  can  be  derived  to 
estimate LV mass calculated from CMR, using M-mode echocardiographic recordings 
continuing with cubic assumptions of ventricular geometry. Derivation is shown from 
Figure  4.9  and  subsequently  the  final  formula  is  plotted  against  CMR  LV  mass  in 
Figure 4.10. 
 
Therefore:  CMR LVM (Y) = A + B x X 
 
If the LV is assumed to be cubic then : 
X = (LVID + PWT + IVST)
3 – (LVID)
3 
 
Then deriving from linear fitting of this graph:   A = 31.3  B = 0.45 
 
A potentially re-derived cubed formula for use in ESRD would therefore be: 
 
CMR LV Mass = 31.3 + 0.45 {(LVID + PWT + IVST)
3 – (LVID)
3} 157 
 
 
Figure 4.9  
LV mass by CMR plotted against the LV dimensions cubed to calculate volume of LV 
myocardial tissue with 95% confidence intervals shown 
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Figure 4.10 
Calculated LV Mass using formula LVM= 31.3 + 0.45 {(LVID + PWT + IVST)
3 – 
(LVID)
3} derived above plotted against  CMR LV mass with 95% confidence intervals 
shown  159 
 
4.4  RESULTS OF ELECTROCARDIOGRAPHIC STUDIES  
 
4.4.1  Patient demographics 
Electrocardiogram  (ECG)  combined  with  CMR  data  were  available  on  139  patients 
(61.9%) male), of whom 30 (21.5%) were not yet established on long term dialysis 
therapy (28 advanced renal failure not yet started dialysis, 2 failing renal transplant), 61 
(43.9%) on haemodialysis and 48 (34.5%) on peritoneal dialysis. 92.1% of patients had 
a previous history of hypertension and 16.5% had a past history of ischaemic heart 
disease. 
 
4.4.2  Prevalence of left ventricular hypertrophy by CMR  
The  mean  CMR  LVMI  for  the  cohort  was  91.6  g  m
-2  (S.D.  29.4).  LVMI  was 
significantly higher in males than females (101.3 g m
-2 vs. 76.3 g m
-2, p<0.001). Based 
on published normal ranges of LV mass, significantly higher numbers of males had 
LVH as defined by CMR compared to females 64.0% of males and 45.3% (Chi-squared 
p=0.031). Significantly higher numbers of patients on haemodialysis (72.1%) had LVH 
compared to those on peritoneal dialysis (41.7%) or those yet to start dialysis therapy 
(50.0%), p=0.003. 
 
4.4.3  Prevalence of left ventricular hypertrophy by ECG 
Using  the  Cornell  criteria  for  LVH  20.1%  of  patients  had  LVH,  with  23.7%  by 
Sokolow-Lyon criteria and 15.8% by Cornell product. To examine need for revised 
partitions values for LVH in ESRD patients, the cohort were divided by the presence of 
LVH on CMR (Table 4.4) with gender specific QRS voltages and QRS voltage-duration 
products  according  to  LVH  status  calculated.  Patients  with  CMR  LVH  had  greater 
Sokolow-Lyon voltage, Sokolow-Lyon product, Cornell and Cornell product than those 160 
 
without LVH (p<0.001 for all criteria). As voltage criteria for LVH are gender specific, 
criteria were compared between males and females, with significantly greater Sokolow-
Lyon product in males with LVH than females with LVH (p=0.022). In patients without 
LVH  males  had  significantly  greater  Cornell  product  (p=0.046),  Sokolow  voltage 
(p=0.023) and Sokolow-Lyon product (p=0.013) than females.  
 
4.4.4  Optimisation of ECG criteria for left ventricular hypertrophy  
The sensitivity and specificity of the four criteria were tested using established partition 
values: Sokolow-Lyon ≥35 mV; Cornell gender specific, male ≥28 mV, female ≥20 mV 
and Cornell product ≥2440 mV ms. There is no current Sokolow-Lyon product value 
defined as a cut point for diagnosing LVH and Sokolow-Lyon product ≥2940 mV ms 
was  used.  This  was  also  tested  in  males  and  females  to  determine  revised  gender 
specific  partition  values  for  the  various  criteria.  Using  currently  defined  criteria  for 
Sokolow-Lyon  product  had  the  highest  overall  sensitivity  (37.9%).  Sokolow-Lyon 
voltage and Sokolow-Lyon product were more sensitive in males while Cornell voltage 
and  Cornell  product  were  more  sensitive  in  females  (Table  4.5).  Receiver  operator 
characteristic (ROC) curves (Figures 4.11-4.12) were constructed to test sensitivity and 
specificity of the four criteria and derive new ECG partition values for the diagnosis of 
LVH compared to CMR. Area under a ROC curve was similar for all criteria in the 
whole cohort. When compared by gender, area under the ROC curve was greater in 
females for all criteria, with the maximum area under the curve of 0.828 for Cornell 
voltage in female subjects (Table 4.6). To optimise clinical applicability of partition 
values, the respective sensitivities of the four criteria were calculated at a specificity of 
95% (Table 4.7). 161 
 
 
 
LVH on CMR  No LVH on CMR 
ECG criteria  Male  Female  Male  Female 
Cornell (mV)  18.8 (8.1)  21.5 (8.1)  15.3 (6.5)  12.45 (5.1) 
Cornell product (mV.ms)  1974 (828)  1828 (854)  1403.2 (644)*  1097.5(500) 
Sokolow (mV)  32.0 (13.6)  26.4 (8.3)  23.7 (6.9)*  19.4 (7.4) 
Sokolow product (mV ms)  3089* (1386)  2382 (777)  2164.90(684)*  1698.4 (719) 
 
Table 4.4 
Mean values for QRS voltages and QRS voltage-duration products displayed by gender 
and  CMR  LVH  status.  Standard  deviations  are  in  parenthesis.  *  -  p<0.05,  male 
compared to female 
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  Sensitivity   Specificity 
All patients     
Cornell voltage  30.3 %  93.3 % 
Cornell product  24.1 %  95.0 % 
Sokolow-Lyon voltage  36.9 %  93.3 % 
Sokolow Lyon product  37.9 %  90.0 % 
  Sensitivity  Specificity 
  % (95% CI) 
Positive predictive value  Negative predictive value 
Male         
Cornell voltage  16.4 (7.8- 28.8)  93.5 (78.5- 99.0)  81.8  38.6 
Cornell product  20.0 (10.4- 33.0)  93.5 (78.5- 99.0)  84.6  39.7 
Sokolow-Lyon voltage  34.5 (22.2- 48.6)  93.5 (78.5- 99.0)  90.5  44.6 
Sokolow Lyon product  43.6 (30.3- 57.7)  83.9 (66.3- 94.5)  82.8  45.6 
Female         
Cornell voltage  50.0 (29.1- 70.9)  93.1 (77.2- 99.0)  85.7  69.2 
Cornell product  33.3 (15.7- 55.3)  96.6 (82.2- 99.4)  88.9  63.6 
Sokolow-Lyon voltage  20.8 (7.2- 42.2)  100.0 (87.9- 100.0)  100.0  60.4 
Sokolow Lyon product  20.8 (7.2- 42.2)  96.6 (82.2- 99.4)  83.4  59.5 
Table 4.5  Sensitivities and specificities of the established ECG criteria for LVH compared to CMR with gender specific sensitivities 
and specificities 163 
 
 
 
   
Figure  4.11  Receiver  operator  characteristic  curves  for  Cornell  voltage  and  Cornell 
product for diagnosis of LVH by CMR 
 
   
 
 
Figure  4.12  Receiver  operator  characteristic  curves  for  Sokolow-Lyon  voltage  and 
Sokolow-Lyon product for diagnosis of LVH by CMR 
 
 164 
 
  Area under ROC curve  Sensitivity  Specificity 
  (95% CI) 
p  Best cut point 
% (95% CI) 
Positive predictive 
value 
Negative predictive 
value 
All patients               
Cornell Voltage  0.714 (0.631- 0.787)  < 0.0001  14  74.7 ( 63.6- 83.8)  63.3 (49.9- 75.4)  72.8  65.5 
Cornell product  0.722 (0.639- 0.794)  < 0.0001  1224  75.9 ( 65.0- 84.9)  63.3 (49.9- 75.4)  73.1  66.7 
Sokolow-Lyon voltage  0.715 (0.632- 0.788)  < 0.0001  28  50.6 ( 39.1- 62.1)  85.0 (73.4- 92.9)  81.6  56.7 
Sokolow Lyon product  0.734 (0.653- 0.805)  < 0.0001  2184  69.6 ( 58.2- 79.5)  75.0 ( 62.1- 85.3)  78.5  65.2 
Male               
Cornell Voltage  0.631 (0.520- 0.732)  0.0318  14  70.9 (57.1- 82.4)  51.6 (33.1- 69.8)  72.3  49.9 
Cornell product  0.645 (0.534- 0.745)  0.0160  1350  69.1 (55.2- 80.8)  58.1 (39.1- 75.4)  74.5  51.4 
Sokolow-Lyon voltage  0.696 (0.588- 0.791)  0.0005  26  61.8 (47.7- 74.6)  71.0 (52.0- 85.7)  79.1  51.1 
Sokolow Lyon product  0.703 (0.595- 0.797)  0.0003  2184  70.9 (57.1- 82.4)  64.5 (45.4- 80.8)  78.0  55.5 
Female               
Cornell Voltage  0.828 (0.700- 0.918)  < 0.0001  14  83.3 (62.6- 95.2)  75.9 (56.5- 89.7)  74.1  84.6 
Cornell product  0.826 (0.697- 0.916)  < 0.0001  1152  87.5 (67.6- 97.2)  69.0 (49.2- 84.7)  70.0  86.9 
Sokolow-Lyon voltage  0.731 (0.591- 0.843)  0.0011  28  45.8 (25.6- 67.2)  93.1 (77.2- 99.0)  84.6  67.5 
Sokolow Lyon product  0.756 (0.618-  0.863)  0.0002  2160  66.7 (44.7- 84.3)  86.2 (68.3- 96.0)  80.0  75.7 
Table 4.6  Area under receiver operator curves for ECG diagnostic criteria for LVH, with best cut point, sensitivities, specificities, 
positive and negative predictive values defined for the cohort and subdivided by gender 165 
 
 
  Sensitivity %  Male Sensitivity %  Female Sensitivity %  Male partition value  Female partition value 
Cornell voltage  22.8  14.5  37.5  >29  >25 
Cornell product  25.3  18.2  41.7  > 2668  >2132 
Sokolow-Lyon voltage  31.6  34.5  25.0  > 36  > 30 
Sokolow-Lyon product  29.1  30.9  25.0  > 3588  > 2760 
 
Table 4.7 Sensitivities of the four ECG criteria and the male/female partition values at 95% specificity166 
 
4.5     DISCUSSION 
 
4.5.1   Results of echocardiographic studies 
As discussed previously, left ventricular disorders, namely LVH, LV dilatation and LVSD, 
so called ‘uraemic cardiomyopathy’, have survival implications for patients with ESRD. 
Previous studies in both ESRD and other populations have suggested that echocardiography 
overestimates LV mass compared to CMR. However in ESRD this finding was based on a 
small pilot study, using a 1.0 Tesla scanner and a fast low angle shot (FLASH) imaging 
sequence(189).  The  current  study  was  performed  using  a  1.5  Tesla  scanner  using  a 
trueFISP sequence, allowing better contrast between the ventricular myocardium and blood 
pool. Echocardiography is well established, portable and widely available and therefore 
will likely remain a vital clinical tool but has drawbacks, including operator dependence 
and  difficulty  in  obtaining  satisfactory  acoustic  windows.  The  major  limitation  of 
echocardiography is the geometric assumptions required to calculate LV mass and function. 
As ventricular dimensions are measured in the minor axis and then volumes obtained by 
cubing these values, any error in these initial errors is cubed. Moreover, these techniques 
assume the left ventricle to be cubic and while these methods have been validated in normal 
hearts,  patients  with  ESRD  have  a  high  prevalence  of  LV  abnormalities,  particularly 
eccentric remodelling(213). As LVH in ESRD is due to a combination of pressure and 
volume overload, both concentric and eccentric remodelling ensues. The high prevalence of 
eccentric  remodelling  in  this  study  (54.8%)  essentially  invalidates  these  formulae  to 
calculate LV mass in this population.   
 
Previous  studies  have  suggested  that  in  incident  ESRD  patients,  the  echocardiographic 
prevalence of LVH is 50-80%, with left ventricular dilatation in 20-40% and LVSD present 167 
 
in 16% of patients(75). Echocardiographic prevalence of LV disorders from the current 
study is similar to these historical data. However, the CMR data suggests that this may 
represent  an  overestimation  of  the  prevalence  of  these  disorders,  due  to  inherent 
inaccuracies in the use of echocardiography in the ESRD patient population. Overall, by 
CMR, 39.0% of patients had normal left ventricular dimensions and whilst LVH was the 
most common abnormality, the prevalence was lower than by echocardiographic studies at 
54%. The majority of these cases had isolated LVH, rather than a combination of LVH with 
LV dilatation and LVSD. This suggests that as LV chamber dimension is dependent on 
hydration status which varies during the interdialytic period in patients on haemodialysis 
(or is chronically overloaded in patients on peritoneal dialysis), any error in calculation of 
LV  mass  due  to  changes  in  chamber  dimension  is  greatly  magnified,  when 
echocardiography is used. Some changes in LV mass do occur though the dialysis cycle 
due  to  changes  in  the  water  content  of  the  interstitial  tissues  of  the  heart  in  volume 
overload, but these have been shown by CMR to be of the order of 10g(166).  
 
4.5.2   Echocardiographic studies used to derive measures of left ventricular mass 
The  first  calculations  used  to  estimate  LV  mass  from  M-mode  echocardiography  were 
described  in  1972  by  Troy  et  al,  based  on  the  assumption  that  the  LV  is  cubic(209). 
Subsequent attempts have been made to refine these: 
•  The Penn convention equation was derived in later from a modified regression 
equation,  based  on  echocardiographic  studies,  validated  from  subsequent  post 
mortem studies in 34 patients. Although this study was pivotal, the patient group 
was  somewhat  heterogeneous,  with  ten  patients  with  normal  hearts,  two  had 
congestive cardiac failure, previous myocardial infarction was present in twelve 
patients and a variety of underlying conditions, both cardiac and non cardiac, were 168 
 
the cause of death. The time between echocardiography and death was variable 
ranging from 1-120 days(205) 
•  A new adjusted formulae (the ASE convention) was derived and validated by the 
same group of authors on a further 52 individuals. This refined formula is widely 
used, but as the authors acknowledge LV shape was relatively normal in almost 
all patients in this study and therefore the authors recommend that their formulae 
must be restricted to patients without gross distortion of LV chamber shape(206) 
•  The  Teichholz  formula  was  developed  at  approximately  the  same  time  as  the 
cubed formulae and has been shown to be effective in correcting systematic errors 
in LV volumes calculated by the cube function but has not been adopted widely 
for use in clinical studies, perhaps due to its complexity(208) 
 
4.5.3   CMR as a gold standard for calculation of left ventricular dimensions 
These  studies  to  both  compare  and  improve  echocardiography  and  electrocardiography 
methods is dependent on the fundamental premise that CMR does truly represent a ‘gold 
standard’  for  measurement  of  LV  dimensions,  i.e.  a  reproducible,  accurate  method, 
independent of geometric assumptions and ideally validated with post mortem specimens.  
 
A  number  of  studies  have  shown  CMR  to  be  reproducible  with  low  inter-  and  intra-
observer variability, both in normal volunteers as well as in patients with left ventricular 
hypertrophy, heart failure(194), and dilated cardiomyopathy(214). Post mortem validation 
comparing  in  vivo  CMR images  with  post  mortem  specimens has  not  been  performed, 
although  animal  studies  and  ex  vivo  imaging  studies  in  humans  show  close  agreement 
between CMR measured ventricular mass and true LV mass(215;216).  
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4.5.4   Feasibility  of  deriving  novel  regression  formula  for  calculation  of  left 
ventricular mass in end stage renal disease 
Derivation of a revised echocardiographic formula for estimation of LV mass in ESRD is 
an attractive concept, and the formula derived displayed good correlation with CMR LV 
mass. However this formula requires prospective validation in a separate cohort of ESRD 
patients. Other potential limitations of this formula exist. Critically, it is still derived from 
the  cube  method.  This  is  subject  to  the  same  assumptions  and  limitations  regarding 
ventricular  geometry  as  other  cube  formula.  As  these  measures  were  developed, 
conventionally  the  papillary  muscles  are  included  in  drawing  endocardial  borders  to 
perform CMR analysis of LV mass(169). With echocardiography, the papillary muscles are 
avoided for M-mode measurements and excluded from the endocardial border for bi-plane 
measurements. This would appear to be a crucial issue but perhaps as both methods have 
evolved essentially separately and been validated against post mortem specimens, animal 
models and latex models, this issue is underplayed in the literature. 
 
Despite there being a high prevalence of eccentric remodelling in this study, the pattern of 
ventricular remodelling did not influence the degree of overestimation of LV mass (and 
associated underestimation of end diastolic volume) by echocardiography. The finding that 
end diastolic volume was under-estimated while LV mass was overestimated are consistent, 
but  different  methods  were  used  (M-mode  and  Simpson’s  bi-plane)  to  calculate  these 
parameters.  These combined findings suggest that fundamentally the disparities between 
CMR  and  echocardiographic  measures  are  due  to  difficulty  in  accurately  defining 
endocardial  borders  and  subsequent  errors  being  magnified  by  calculations  to  calculate 
dimensions. These errors are accentuated in the ESRD population due to high prevalence of 
both hypertrophied and dilated ventricles.  170 
 
 
4.5.5   Studies comparing echocardiographic and CMR measures of left ventricular 
mass in other populations 
A number of studies have compared CMR with M-mode echocardiographic measures of 
LV  mass.  The  correlation  between  CMR  and  echocardiography  and  the  degree  of  any 
systematic  discrepancy  between  the  methods  have  to  an  extent  been  dependent  on  the 
population studied.  
•  In  a  study  of  212  healthy  army  recruits  echocardiography  (ASE  formula) 
consistently underestimated LV mass compared to CMR by a mean of 14.3g(217) 
•  Echocardiography (Penn formula) overestimated LV mass in 39 patients with LVH 
due to aortic stenosis scheduled for aortic valve replacement by a mean of 37g(218) 
•  In  one  study  of  hypertensive  patients  using  echocardiography  and  CMR, 
echocardiography  overestimated  LV  mass  by  41g(219)  whilst  in  another  small 
study (n=20) of patients with LVH echocardiography overestimated LV mass by 
27.6g(220) 
 
Overall these studies, in keeping with the current study and others in ESRD, suggest that in 
patient  groups  with  a  high  prevalence  of  LVH  (and  therefore  distorted  LV  geometry) 
echocardiography  tends  to  overestimate  LV  mass,  but  the  opposite  is  true  when  large 
population with normal hearts are studied.  
 
4.5.6   Alternative  echocardiographic  techniques  to  assess  left  ventricular  mass 
compared to CMR 
Although less widely used to estimate LV mass than the M-mode method, two-dimensional 
(2D)  echocardiography  is  thought  to  be  more  accurate  and  reproducible  than  M-mode 171 
 
methods. However one study using these methods in patients with hypertension suggests 
that this technique still suffers from intra-observer variability as well as wide limits of 
agreement compared to CMR(221). Using intravenous contrast combined with harmonic 
Doppler imaging has been shown to improve the accuracy of LV mass measurements with 
echocardiography but using this method the convenience of echocardiography as a clinical 
tool is diminished(222). Finally three-dimensional echocardiography measures of LV mass 
appear to show close correlation with CMR measures, although few comparative studies 
exist to date(223). Three-dimensional echocardiography is currently constrained by limited 
availability compared to conventional echocardiography. 
 
4.5.7   Reduction  in  numbers  required  to  power  studies  using  CMR  compared  to 
echocardiography 
As CMR is highly reproducible, it offers the potential advantage of reducing the number of 
patients  required  in  clinical  trials  to  show  the  benefit  of  a  therapeutic  intervention  on 
cardiac dimensions. Using the data generated from these studies a clinical trial aimed at 
regression of LV mass index of 10g m
-2 with 80% power would require 76 patients at 5% 
significance if performed with CMR but 328 patients with echocardiography(224).  
 
4.5.8   Discussion of ECG studies 
Using  current  ECG  criteria,  in  this population  with  a  high  prevalence  of  LVH,  all  the 
current criteria in use have a high sensitivity for diagnosing LVH compared to when used 
in the general population (Table 4.5). However, the performance of the various criteria 
varied by gender with the Cornell voltage and Cornell product being superior in females, 
with the Sokolow-Lyon voltage and product being more sensitive indicators of LVH in the 
males.  This  anomaly  in  performance  when  compared  by  gender  is  similar  to  previous 172 
 
studies of ECG versus CMR for diagnosis of LVH in the general population. Similarly, 
when area under a ROC curve was used to compare the criteria (Table 4.6), it is apparent 
that, whilst overall performances of the criteria are similar, the Cornell criteria provide 
considerably superior diagnostic measures in females. Although use of the QT interval to 
calculate  Cornell  and  Sokolow-Lyon  product  would  be  expected  to  further  improve 
sensitivity  and  specificity,  in  reality  this  was  not  the  case,  perhaps  due  to  differing 
sensitivities  of  these  criteria  in  this  patient  group  due  to  baseline  prevalence  of  LV 
disorders, but also as QT dispersion in this population is highly variable. 
 
4.5.9   Feasibility of redefinition of partition values for left ventricular hypertrophy in 
end stage renal disease 
Due the high prevalence of LVH in ESRD, the diagnostic utility of the ECG for diagnosing 
LVH is much higher in the general population and therefore this study confirms it is a 
useful screening test in this group of patients, particularly in light of its low cost and ready 
availability. Other authors have used CMR to optimise partition values in patients with 
hypertension  and  LVH(225).  The  high  prevalence  of  LVH  theoretically permits  further 
increases in the sensitivity of the ECG for diagnosis of LVH by lowering the partition 
values. Although, as expected specificity is lost, it may be that the ECG could be used as a 
screening tool using this method to identify patients for clinical trials. Whilst gender was 
taken into account in analyses to identify optimise partition values for diagnosis of LVH, 
there appears to be very little difference in gender specific optimised cut points (Table 4.7). 
If  however  values  are  selected to  maintain  95%  specificity,  it  can  be  seen that  female 
partition  values  for  all  four  criteria  are  lower  than  male.  Even  at  95%  sensitivity,  the 
diagnostic  utility  of  the  ECG  for  diagnosing  LVH  is  higher  than  in  the  non  ESRD 
population. 173 
 
 
4.5.10  Limitations of ECG for diagnosis of LVH in ESRD 
The majority of the patients in this study had a history of hypertension in common with the 
broader  ESRD  population.  Although  patients  with  previous  myocardial  infarction  were 
included,  this  study  did  not  take  into  account  the  influence  of  previous  infarction  and 
subsequent myocardial remodelling on the ECG. The chief influence on LV mass is likely 
to be blood pressure but valvular heart disease (particularly due to calcific aortic stenosis) is 
a  significant  promoter  of  LVH(226).  No  attempt  to  delineate  between  valvular  and 
hypertensive LVH was made and it may be that these features are associated with different 
remodelling  processes  and  direct  diagnostic  use in  ESRD  patients  with  purely  valvular 
remodelling is not appropriate.  Similarly, although LVH has prognostic implications, both 
for patients with ESRD as well as the general population(227), the presence of secondary 
repolarisation abnormalities or ‘LVH with strain’ has much greater influence on subsequent 
cardiac outcome in patients with ESRD(207).  Whilst long term study  of this cohort of 
patients can identify if this effect persists in this group, it is difficult to derive a simple 
algorithm or cut point for diagnosis of LVH that takes into account the presence of these 
repolarisation abnormalities. Finally, as QT dispersion in this group of patients is variable 
and dependent on time point in the dialysis cycle(228), these revised partition values can 
only be applied at the same point that these patients were studied. As a heterogeneous 
group (haemodialysis, peritoneal dialysis and advanced chronic renal failure) this may not 
be appropriate.  
 
4.5.11  ECG as inclusion point for studies 
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study used ECG 
criteria for LVH to identify patients at higher cardiovascular risk who were subsequently 174 
 
randomised to therapy with atenolol or losartan based antihypertensive therapy(12). As well 
as demonstrating a reduction in cardiovascular morbidity with losartan, this study was also 
able to demonstrate electrocardiographic regression of LVH with both interventions but to a 
greater extent with losartan. Use of the ECG as an inclusion or end point for studies is 
attractive due to its low cost and availability, but is unlikely to be a successful strategy in 
ESRD,  due  to  the  large  numbers  of  patients  required  to  use  this  strategy.  Moreover  it 
remains unclear to  what  extent  LVH  can  genuinely  be  regressed  in this population,  as 
opposed to artefactual improvements in LV mass primarily due to better volume control, 
such as that seen post renal transplantation, leading to reduced overestimation of LV mass 
with echocardiography. 
 
4.5.12  Conclusions on ECG studies 
Using current criteria for ECG diagnosis of LVH, it is possible to identify patients with 
elevated LV mass index. Therefore, when calibrated against the gold standard of CMR, 
ECG remains a useful tool in identifying patients with LVH. Further refinement of these 
partition values is possible, but has to be interpreted in the context of reduced specificity.  
Using  CMR  to  optimise  more  readily  available  investigations  such  as  ECG  and 
echocardiography may represent one way of utilising an expensive and highly specialised 
cardiovascular investigation.  
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Chapter 5 
 
 
A study of the determinants of uraemic cardiomyopathy 176 
 
5.1   INTRODUCTION 
As discussed in the introduction, previous reports suggest that the presence of uraemic 
cardiomyopathy is associated with poor long term outcome in patients with ESRD. LVH, 
LV dilatation and LVSD cumulatively confer a worse prognosis. Risk factors previously 
associated  with  the  presence  of  LVH  include  hypertension(229),  anaemia(124;230), 
hyperparathyroidism(231) and arterial stiffness(232) whilst the presence of ischaemic heart 
disease is the predominant risk factor for LVSD(233).  Studies performed in chapter 3 
confirm  that  the  presence  of  conventional  cardiovascular  risk  factors  such  as  diabetes, 
cigarette smoking and a past history of ischaemic heart disease are strongly associated with 
CMR  findings  in  keeping  with  previous  myocardial  infarction  and  therefore  likely  to 
correlate with the presence of LVSD. All previous studies describing the determinants of 
uraemic cardiomyopathy have been performed using echocardiography.  
 
It is not clear if the same factors are responsible for the evolution of LVH (or other forms of 
uraemic  cardiomyopathy),  when  defined  by  the  more  accurate  method  of  CMR.  For 
example, anaemia has previously been associated with LVH, but it is possible that anaemia 
is secondary to haemodilution in ESRD in fluid overloaded patients and in turn this leads to 
hypertension(113). By using a volume independent measure of LV mass, the following 
studies will attempt to assess how much of these relationships are artefactual interactions 
between systematic overestimation of LV mass in volume overloaded patients and whether 
these relationships are confirmed with CMR. These studies were performed to assess the 
clinical determinants of LVH assessed both by CMR and echocardiography in ESRD. 
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5.2  METHODS 
 
5.2.1 CMR and echocardiography 
Patients were studied with CMR and echocardiography on the same day (described in detail 
in Section 2.3.2). Only patients with ESRD established on dialysis therapy on with both 
echocardiographic and CMR data were studied. CMR and echocardiograms were analysed 
as previously described. 
 
5.2.2   Dialysis data and blood sampling 
Pre- and post-haemodialysis blood pressures were recorded from the dialysis data recorded 
on the electronic patient record. The mean of readings from the three  dialysis sessions 
preceding the CMR scan were used. Haemoglobin, albumin, corrected calcium, phosphate 
and urea reduction ratio were collected from the mean of values from the three months 
preceding the scan. All these results were collected as routine part of monitoring for audit 
and clinical care of patients on haemodialysis. The value for the three months preceding the 
scan was used for parathyroid hormone levels, which are checked less often.  In patients on 
peritoneal  dialysis  blood  pressure  readings  were  the  mean  of  the  three  clinic  blood 
pressures preceding the scan. The blood results as before were averaged for these three 
clinic visits, with weekly urinary, peritoneal and total creatinine clearances assessed from 
the recording during the three months prior to the scan. 
 
5.2.3   Statistical methods 
To assess the determinants of cardiac dimensions correlations were sought between these 
and continuous clinical variables by the various methods were assessed with Pearson and 
Spearman  correlation  co-efficient  as  appropriate.  Independent  determinants  of  cardiac 178 
 
dimensions were assessed using a linear regression model. All analyses were performed 
using the SPSS 13.0 statistical software package (SPSS Inc., Chicago, IL., USA) 
 
5.3    RESULTS  
 
5.3.1   Patient demographics 
Only patients established on dialysis therapy were studied. The cohort consisted of 148 
patients of whom 93 (62.8%) were male. 88 (59.5%) patients were on haemodialysis with 
60 (40.5%) on peritoneal dialysis. Baseline clinical and laboratory data for haemodialysis 
and peritoneal dialysis patients are shown in Table 5.1. Cardiac dimensions are in Table 5.1 
are  as  measured  by  CMR.  Tests  of  significance  are  t-test  or  Mann-Whitney-U  as 
appropriate.  
 
5.3.2   Determinants of left ventricular mass in ESRD using CMR 
Overall  cardiac  dimensions  (LVM,  end  diastolic  and  end  systolic  volume)  were 
significantly  elevated in HD patients compared to those on PD (Table 5.1). Significant 
correlations  were  displayed  between  haemoglobin  (Pearson’s  R=  -0.23,  p=0.006), 
parathyroid  hormone  (Spearman’s  R=  0.24,  p=0.006)  and  serum  phosphate  levels 
(Spearman’s R= 0.17, p=0.044) and LVMI. In patients on haemodialysis both pre-dialysis 
(Pearson’s  R-  systolic  blood  pressure=  0.66,  p<0.001,  diastolic  blood  pressure=  0.59, 
p<0.001)  and  post-dialysis  blood  pressure  (Pearson’s  R-  systolic  blood  pressure=  0.76, 
p<0.001,  diastolic  blood  pressure=  0.60,  p<0.001)  correlated  strongly  with  LVMI. 
Similarly  in  PD  patients  LVMI  was  significantly  correlated  with  clinic  blood  pressure 
(Pearson’s  R-  systolic  blood  pressure=  0.55,  p<0.001,  diastolic  blood  pressure=  0.32, 
p=0.023). The overall correlation between blood pressure and LVMI is show in Figure 5.1. 179 
 
Although  in  HD  patients  there  was  a  significant  negative  correlation  between  dialysis 
adequacy as measured by urea reduction ratio and LVMI (Pearson’s R= -0.33, p=0.004), no 
significant  relationship  existed  between  dialysis  adequacy  measured  by  total  weekly 
creatinine clearance and LVMI in patients on PD. 
 
Table 5.2 shows the results of multivariate linear regression analysis on the determinants of 
LVMI in patients. In these analyses, post-dialysis blood pressure measures were used in 
HD  patients  with  clinic  blood  pressures  used  in  PD  patients.  Due  to  their  close 
interdependence  systolic  and  diastolic  blood  pressure  were  entered  separately  into  the 
model. The table shown uses systolic blood pressure. The major, significant determinants 
of LVMI were systolic or diastolic blood pressure and cholesterol.  
 
The analysis was repeated using the same multivariate linear regression model for only HD 
patients to assess the impact of HD adequacy on LVMI. From this analysis urea reduction 
ratio was not an independent determinant of LVMI. 
 
5.3.3   Determinants of left ventricular mass in ESRD using echocardiography 
Echocardiographic data were available in 88 patients. Again LVMI (181.9 vs. 148.7 g m
-2, 
p=0.013), end diastolic volume (Simpson’s biplane end diastolic volume- 111.4 vs. 92.3 
ml, p=0.017) and end systolic volume (48.8 vs. 37.5 ml, p=0.014) were significantly greater 
in  patients  on  haemo-  compared  to  peritoneal  dialysis.  Significant  correlations  were 
demonstrated between LVMI and duration of renal replacement therapy (Spearman’s R= 
0.27,  p=0.010),  blood  pressure  (post-dialysis  blood  pressure  measures  in  HD  patients 
combined with clinic blood pressures in PD patients - Pearson’s R- systolic blood pressure= 
0.53,  p=0.001,  diastolic  blood  pressure=  0.39,  p=0.001),  parathyroid  hormone  levels 180 
 
(Spearman’s  R=  0.33,  p=0.002)  and  haemoglobin  (Pearson’s  R=  -0.24,  p=0.029).  
Additionally aortic valve gradient, not easily measured by CMR, displayed a significant 
correlation  with  LVMI  (Spearman’s  R=  0.40,  p<0.001).  Echocardiographic  aortic  jet 
velocity  and  aortic  valve  pressure  gradient  were  assessed  in  93  patients.  Severe  aortic 
stenosis was not present in the patients studied although 5 (5.4%) patients had moderate 
aortic stenosis (aortic jet velocity 3.0-4.0 m s
-1).  
 
As before, multivariate linear regression analysis was performed to assess the determinants 
of LVMI in these patients as measured by echocardiography. Only nine variables were 
entered in the model as fewer patients were available to analyse. The following variables 
were not predictive in initial exploration of the data and were not entered in the model- age, 
gender, diabetes, C - reactive protein and smoking history.  Blood pressure variables were 
treated  as  previously.  The  major,  significant  determinants  of  LVMI  were  systolic  or 
diastolic  blood  pressure,  duration  of  renal  replacement  therapy,  cholesterol,  phosphate, 
aortic valve gradient and serum corrected calcium. 181 
 
 
  Haemodialysis  Peritoneal dialysis  p value 
Number  88  (59.5)  60  (40.5)   
Male  62  (70.5)  31  (51.7)  0.02 
Age (years)  52.5  (11.0)  53.0  (10.5)  0.757 
Height (m)  170.1  (10.5)  166.2  (9.3)  0.026 
Weight (kg)  75.2  (17.5)  73.4  (14.1)  0.522 
RRT time (months)  12.5  (93.0)  5.0  (11.0)  <0.001 
1
0 Renal Disease           
  Diabetes  15  (17.0)  23  (38.3) 
  APKD  12  (13.6)  5  (8.3) 
  GN  21  (23.9)  10  (16.7) 
  CPN  11  (12.5)  4  (6.7) 
  Renovascular  3  (3.4)  4  (6.7) 
  Unknown/Other  26  (29.5)  23  (38.3) 
0.06 
Pre-d SBP (mmHg)  149.9  (24.9)  -     
Pre-d DBP (mmHg)  82.6  (13.1)  -     
Post-d SBP (mmHg)  136.0  (25.7)  -     
Post-d DBP (mmHg)  75.9  (14.2)  -     
Clinic SBP (mmHg)  -    139.7  (22.5)   
Clinic DBP (mmHg)  -    82.3  (11.5)   
Haemoglobin (g dL
-1)  11.7  (1.8)  11.5  (1.6)  0.375 
Albumin (g L
-1)  40.0  (4.2)  37.9  (4.6)  0.005 
Corrected Calcium (mmol L
-1)  2.4  (0.2)  2.4  (0.2)  0.929 
Phosphate (mmol L
-1)  1.8  (0.5)  1.7  (0.4)  0.734 
Ca-P product  4.1  (1.3)  4.2  (1.0)  0.852 
PTH (pmol L
-1)  20.0  (34.0)  17.15  (39)   
URR (%)  70.7  (8.2)  -     
CrCl (L/week/1.73m
2)  -    86.6  (25.8)  0.871 
LV mass (g)  184.2  (65.5)  153.5  (49.7)  0.003 
LV mass/BSA(g m
-2)  99.3  (31.7)  84.3  (25.8)  0.003 
Ejection fraction (%)  65.8  (11.9)  66.9  (12.2)  0.590 
ESV(ml)  57.8  (40.4)  42.6  (26.2)  0.011 
ESV/BSA (ml m
-2)  31.2  (21.3)  22.9  (13.0)  0.009 
EDV (ml)  157.6  (62.7)  123.9  (43.7)  <0.001 
EDV/BSA(ml m
-2)  85.1  (31.3)  67.5  (21.2)  <0.001 
Table 5.1 Baseline characteristics of patients. Data are number or mean with percentage or standard deviation 
in parentheses expect for RRT time and PTH where median and interquartile range are shown 182 
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Figure 5.1 
Scatter plot of systolic and diastolic blood pressures plotted against  LVMI assessed by 
CMR. Post-dialysis blood pressure measures were used in HD patients with clinic blood 
pressures used in PD patients 
LVMI-SBP R=0.60, p<0.001 
LVMI-DBP R=0.39, p<0.001 183 
 
 
 
 
Standardised 
coefficient (β) 
Significance (p)  95% CI for β 
LVMI (CMR)         
R
2= 0.62         
(Constant)  89.0  0.175  (-40.68,  218.72) 
SBP  0.54  <0.001  (0.40,  0.92) 
DBP  0.40  0.001  (0.23,  1.40) 
Cholesterol  -0.30  0.008  (-13.37,  -2.11) 
Diabetes  -2.00  0.080  (-28.25,  1.63) 
Haemoglobin  -0.18  0.129  (-7.18,  0.93)   
Albumin  0.12  0.278  (-0.67,  2.29) 
PTH  0.06  0.600  (-0.15,  0.26) 
Calcium  -0.07  0.518  (-45.18,  22.99) 
Phosphate  0.06  0.593  (-9.18,  15.94) 
RRT time  0.16  0.158  (-0.03,  0.15) 
CRP  -0.07  0.546  (-0.51,  0.27) 
 
Table 5.2  
Determinants of LVMI as measured by CMR in a multivariate linear regression model 
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Standardised 
coefficient (β) 
Significance (p)  95% CI for β 
LVMI (echo)         
R
2= 0.63         
(Constant)  -24.64  0. 813  (-232.34,  183.07) 
RRT time  0.31  <0.001  (0.18,  0.45) 
SBP  1.54  <0.001  (1.06,  2.02) 
DBP  1.93  <0.001  (0.97,  2.88) 
Cholesterol  -14.25  0.002  (-23.03,  -5.46) 
Phosphate  27.25  0.010  (6.89,  47.61) 
Calcium   -64.71  0.026  (-121.22,  -8.20) 
Aortic gradient  1.19  0.045  (0.03,  2.35) 
Albumin  2.40  0.050  (-0.002,  4.807) 
PTH  0.18  0.293  (-0.157,  .51) 
Haemoglobin  2.40  0.493  (-4.56  9.34) 
 
Table 5.3  
Determinants of LVMI as measured by echocardiography in a multivariate linear regression 
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5.4      DISCUSSION 
 
5.4.1   Overall determinants of left ventricular mass 
Multiple factors were associated with raised LVMI in this cohort of patients. When CMR 
was used as the method of measuring LVMI elevated blood pressure, hyperphosphataemia, 
hyperparathyroidism  and  anaemia  were  all  associated  with  greater  LVMI.  Improved 
dialysis adequacy was associated with lower LVMI in haemodialysis patients but not in 
peritoneal dialysis patients. Haemodialysis patients had greater LVMI compared to those on 
peritoneal dialysis. Other groups have observed this and a commonly cited mechanism for 
this is the presence of  an arterio-venous fistula for dialysis access leading to increased 
cardiac output(112). Additionally work from our group has observed that for a given rise in 
cardiac  output  (e.g.  due  to  the  arterio-venous  fistula)  patients  with  ESRD  have  an 
augmented  blood  pressure  response  which  in  turn  promotes  LVH(113).  In  any  case, 
patients on haemodialysis are exposed to greater systolic blood pressures particularly pre-
dialysis as shown in Table 5.1, in turn promoting LVH.   
 
Factors  which  correlated  with  echocardiographic  measures  of  LVH  included  blood 
pressure, time on renal replacement therapy, hyperparathyroidism, anaemia and peak aortic 
valve pressure gradient. When subjected to multivariate analysis the chief determinant of 
elevated LVMI measured by either CMR or echocardiography was blood pressure, chiefly 
systolic blood pressure. One other variable independently associated with higher LVMI 
measured by either method was hypocholesterolaemia. Male gender was the only other 
independent predictor of increased LVMI measured by CMR, but by echocardiography 
time on renal replacement therapy, hyperphosphataemia, hypocalcaemia and peak aortic 
valve pressure gradient were additional independent predictors of raised LVMI. 186 
 
 
5.4.2   Blood pressure as a determinant of LVH in ESRD 
Overall in this study hypertension was the major determinant of LVH and represents a 
potential target for treatment to reduce LVH. The nature of this study does not however 
demonstrate the natural history of evolution of LVH in earlier CKD and by the time the 
patient has established ESRD, intervention may be less likely to succeed. Previous work 
form our group has demonstrated that LVMI is elevated even in early CKD, when serum 
creatinine is normal(78). This study only analyses blood pressure trends over the preceding 
three months and whilst this may represent a continuing insult to the uraemic heart, may not 
reflect the long history of exposure to hypertension prior to commencing dialysis. Similarly 
extracellular  fluid volume, the  chief determinant of  changes  in  blood  pressure  was not 
assessed  in  this  study.  Clinical  assessment  is  notoriously  inaccurate  for  precise 
measurement of extracellular fluid volume, and bioimpedance is required to assess this 
exactly(234). Many other groups have reported the association between hypertension and 
LVH(235;236). There is some debate as to the optimum time to measure blood pressure 
particularly in haemodialysis patients where blood pressure is dependent on timing with 
respect to the dialysis cycle(237). In a similar sized cohort of patients Fagugli et al used 
bioimpedance  analysis  to  demonstrate  a  close  correlation  between  extracellular  water 
volume, blood pressure and LVMI(235).  
 
A number of studies have suggested that 24 hour ambulatory blood pressure monitoring 
(ABPM)  is  superior  for  diagnosis  and  monitoring  of  hypertension  in  dialysis  patients. 
Cannella  et  al  have  demonstrated  using  ABPM  that  many  haemodialysis  patients  with 
borderline  treated  hypertension  have  significantly  higher  systolic  and  diastolic  blood 
pressures over a 24 hour period than the pressures measured in the dialysis centre(238). 187 
 
Again blood pressure correlated strongly with LVMI in this study. Similarly, Agarwal et al 
found systolic blood pressure 24 hour ABPM to be a much stronger predictor of LVMI than 
any dialysis centre reading.(237) 
 
Multiple sources of inaccuracy exist in measurement of blood pressure in dialysis patients.  
Appropriate  measurement  of  blood  pressure  should  be  after  5  minutes  in  quiet  room 
without talking or active listening. This is difficult to achieve in the dialysis unit. Other 
non-uraemia specific sources of inaccuracy include the white coat effect, cuff size, and 
obesity or vascular disease making obtaining the brachial pulse difficult. Haemodialysis 
specific inaccuracies may be due to difficulty measuring brachial blood pressure in an arm 
with  previous  haemodialysis  access  surgery.  Immediately  post  dialysis  there  is  a  rapid 
reduction in extracellular fluid volume leading to hypotension. However, the reduction in 
serum potassium leads to vasoconstriction in skeletal muscle and subsequent hypertension. 
Therefore, for accuracy post-dialysis blood pressure should normally be measured at least 
20 minutes post dialysis, but this is frequently inconvenient for patients. 24 hour ABPM is 
likely  to  demonstrate  the  true  blood  pressure  more  accurately  but  is  time  consuming, 
expensive and additionally as dialysis patients frequently have high systolic blood pressures 
and  a  wide  pulse  pressure,  the  high  cuff  pressures  required  for  measurement  lead  to 
discomfort(239). 
 
5.4.3   Comparison  of  determinants  of  left  ventricular  mass  as  assessed  by  CMR 
compared to echocardiography 
Variables that were predictors for LVH by echocardiography, but not by CMR, included 
duration  of  renal  replacement  therapy,  hyperphosphataemia,  hypocalcaemia  and  aortic 
valve gradient. As discussed previously, severity of aortic stenosis is not readily assessed 188 
 
within the context of an uncomplicated CMR protocol and CMR sequences to measure this 
were  not  performed  in  this  study.  Perhaps  unexpectedly  duration  of  renal  replacement 
therapy was not predictive of LVH by CMR. As patients have been on dialysis for longer, 
they become more chronically volume overloaded leading to LV chamber dilatation and 
ventricular remodelling may ensue. It may be that inaccuracies in measurement of LVM 
with echocardiography are augmented in patients with a long history of renal replacement 
therapy.  As  CMR  measurements  are  less  volume  dependent  and  volume  dependent 
inaccuracy  is  minimised.    It  is  difficult  to  explain  why  hyperphosphataemia  and 
hypocalcaemia are associated with greater LVM as measured by echocardiography but not 
CMR. 
 
5.4.4   Hyperparathyroidism,  hyperphosphataemia  and  vascular  calcification  as 
determinants of LVH 
In this study serum PTH and phosphate correlated with LVMI.  Both of these factors are 
likely to increase LVMI by a direct effect on the myocardium and indirect vascular effect. 
Animal  models  of  uraemia  have  demonstrated  both  PTH  and  phosphate  to  have  a 
permissive effect on development of myocardial fibrosis therefore demonstrating a close 
interaction between these circulating factors and development of LVH(240). These animal 
studies  are  confirmed  by  a  number  of  clinical  cohort  studies(73;241).  Moreover 
hyperphosphataemia and hyperparathyroidism are key drivers in development of arterial 
calcification in patients in ESRD. Arterial calcification increases cardiac after load hence 
further  promoting  LVH(232).  One  dilemma  is  that  patients  with  the  longest  history  of 
receiving renal replacement therapy are those who have more complications of ESRD such 
as secondary hyperparathyroidism making it difficult to assess the interdependence of the 
relationships between duration of ESRD and the various complications of ESRD such as 189 
 
LVH and secondary hyperparathyroidism. Analysis of the determinants of LVH in patients 
with ESRD from the Dialysis Morbidity and Mortality Study Wave 2, a study of 2,584 new 
ESRD patients commencing dialysis therapy demonstrated that PTH was an independent 
risk factor for LVH(77). 
A number of studies have demonstrated that increased arterial calcification, measured either 
by pulse wave velocity or by electron beam CT scanning has been associated with LVH in 
ESRD patients: 
•  One study in children with stages 2-4 CKD and ESRD has demonstrated that these 
alterations in arterial calcification and LVM occur early in CKD and are dependent on 
hyperphosphataemia(241) 
•  One study has reported improvements in LVM in a case series of 12 dialysis patients 
following parathyroidectomy(242) 
•  Finally,  in  patients  with  primary  hyperparathyroidism  and  normal  renal  function 
cardiomyopathy  and  cardiac  calcification  has  been  reported  presumably  due  to  a 
direct effect of parathyroid hormone on the myocardium(243) 
 
5.4.5   Other potential determinants of LVH in ESRD 
Hypocholesterolaemia appears in this study to be directly linked to the presence of LVH. 
Although a direct mechanistic link between low serum cholesterol and increased LVMI is 
unlikely  this  can  be  interpreted  in  two  ways.  First,  patients  with  LVH  are  at  higher 
cardiovascular risk and the clinician responsible for the patient’s care may have elected to 
treat  these  patients  with  statins  leading  to  a  reduction  in  serum  cholesterol.  Second, 
although  not  demonstrated  in  this  study,  other  authors  have  demonstrated  a  weak 
correlation between hypoalbuminaemia and increased LVM(244). The same study reported 
a  close  independent  correlation  between  C  -  reactive  protein  and  LVM.  It  is  therefore 190 
 
plausible  that  low  serum  cholesterol  represents  either  malnutrition  (represented  by 
hypoalbuminaemia) or inflammation (high C - reactive protein) and in conjunction with 
LVH  may  represent  the  presence  of  the  malnutrition-atherosclerosis-inflammation 
syndrome, thereby explaining why low cholesterol offers little cardiovascular protection in 
ESRD. 
 
Although in this current study, patients on haemodialysis had greater LVMI than those on 
peritoneal dialysis, other authors have reported the reverse(245). The explanation given by 
the authors was that patients on peritoneal dialysis are more volume expanded. However, in 
that study pre-dialysis blood pressure and blood pressure in the peritoneal dialysis patients 
were similar and therefore it is possible that peritoneal dialysis patients in this study were 
exposed in total to a greater blood pressure load(245).  
 
5.4.6   Aortic stenosis as a risk for LVH in ESRD 
Aortic valve peak pressure gradient at echocardiography was identified as an independent 
determinant of LVMI. In the general population aortic stenosis classically causes pressure 
induced concentric remodelling, followed by the development of ventricular hypertrophy. 
The presence of aortic valvular calcification has been previously shown to be associated 
with higher LVMI. The severity of aortic stenosis, measured either by peak flow velocity or 
pressure  gradient  has  been  demonstrated  to  correlate  with  LVMI(226).  Therefore 
prevention of valvular calcification may be a therapeutic target for reduction of LVH. Once 
established,  aortic  stenosis  has  been  demonstrated  to  progress  rapidly  in  patients  with 
ESRD, thereby increasing the necessity for early valve replacement(246). 
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5.4.7   Anaemia as a risk factor for LVH in ESRD- fact or fiction? 
In this study, as well as others from our group, anaemia correlated with greater LVMI, 
whether  measured  with  echocardiography  or  CMR.  When  subjected  to  multivariate 
analysis, however this was not an independent predictor of LVMI. In the anephric patient 
anaemia, volume  status,  blood  pressure  and  haemodilution  are  closely  related  and it  is 
difficult  to  tease  out  whether  the  relationship  between  low  haemoglobin  and  increased 
LVMI is a direct effect or indirectly due the action of hypervolaemia on both haemodilution 
and increased blood pressure. A number of studies have demonstrated either a correlation 
between the presence of anaemia and the presence of LVH or showing anaemia to be a risk 
factor for progression of LVH. Most of these progression studies are in patients established 
on dialysis therapy: 
•  In a study of 48 dialysis patients, prior to availability of recombinant erythropoietin 
for treatment of renal anaemia, an increase in LVMI increased significantly in parallel 
with the decrease in haemoglobin(247) 
•  In 175 patients initiated on dialysis therapy, followed up with echocardiograms at an 
18 month interval, anaemia and systolic blood pressure were independent risk factors 
for LVH(75) 
•  In 246 dialysis patients with echocardiography performed at a 12 month interval, even 
after  adjusting  for  baseline  LVMI,  haemoglobin  level  and  systolic  blood  pressure 
remain independently important predictors of left ventricular growth (124) 
•  By contrast, in the era of established treatment with erythropoietin from the Dialysis 
Morbidity  and  Mortality  Study  Wave  2,  a  studying  of  2,584  new  ESRD  patients 
commencing  dialysis  therapy,  anaemia  was  not  identified  as  an  independent  risk 
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However  despite  the  correlation  between  the  presence  of  anaemia  and  LVH  and  the 
comparable comparison between persisting low haemoglobin levels and increasing LVMI, 
evidence from randomised controlled trials using various forms of erythropoietin does not 
support  a  treatment  strategy  of  full  correction  of  anaemia  in  patients  with  either  early 
chronic kidney disease or ESRD: 
•  Roger et al showed that treatment with erythropoietin alpha to maintain haemoglobin 
at  12-13g/dL  did  not  affect  progression  of  LVH  compared  to  maintaining 
haemoglobin at 11-12g/dL (female) or 11-13g/dL (male) in patients with stage 3-4 
chronic kidney disease(127) 
•  Besarbab et al demonstrated in randomised controlled trial of 1233 haemodialysis 
patients with clinical evidence of congestive heart failure or ischaemic heart disease, 
the use of increasing doses of erythropoietin to achieve and maintain a haematocrit of 
42 percent, was associated with excess mortality compared to maintain a haematocrit 
of 30 percent(126) 
•  More  recently,  in  the  Correction  of  Haemoglobin  and  Outcomes  in  Renal 
Insufficiency (CHOIR) trial, the use of a target haemoglobin level of 13.5 g/dL (as 
compared with 11.3 g/dL) was associated with increased risk of cardiac events and no 
incremental  improvement  in  the  quality  of  life  in  patients  with  GFR  15-
50ml/min(128),  whilst  the  Cardiovascular  Risk  Reduction  by  Early  Anaemia 
Treatment with Epoetin Beta (CREATE) study showed no significant difference in 
LVM in patients randomised to a haemoglobin of 10.5-11.5 g /dL compared to a 
normal haemoglobin of 13.0-15.0 g/dL in patients with GFR of 15-35.0 ml/min(125) 
 
Therefore  whilst  there  is  no  doubt  that  historically  anaemia  and  LVH  have  been 
interrelated,  it  is  now  unclear  in  the  era  of  treatment  of  with  erythropoietin,  what  the 193 
 
optimum target haemoglobin should be, either to prevent LVH or improve quality of life, 
whilst minimising risks from non-physiological overcorrection.   
 
5.4.8   Reinventing the wheel -treatment strategies to reduce LVH in ESRD 
Based  on  this  work,  focus  should  once  again  be  redirected  at  treating  blood  pressure, 
chiefly  systolic  blood  pressure,  to  prevent  development  and  progression  of  LVH. 
Regression of LVH is likely to be more difficult once the patient has established ESRD and 
focus should be directed at aggressive antihypertensive treatment earlier in the course of 
chronic kidney disease, as part of standard management of patients with progressive renal 
disease and hypertension.   
 
Once established on dialysis therapy the options for treatment of hypertension primarily are 
maintenance of euvolaemia (‘dry weight’), antihypertensive medication or a combination of 
these  strategies.  A  number  of  studies  have  addressed  these  issues  using  changes  in 
echocardiographic LVMI as an end point. One confounding factor is that any intervention 
that  reduces  extracellular  fluid  will  reduce  ventricular  dilatation  and  consequently  the 
degree of artefactual overestimation of LVMI. Therefore while this strategy is likely to be 
beneficial due to its effect on blood pressure, the positive outcome reported on LVMI may 
partly be due to optimisation on intra-ventricular fluid volume. A number of examples of 
such studies illustrate this point: 
•  One  uncontrolled  Turkish  study  of  19  haemodialysis  has  demonstrated  excellent 
blood pressure control with rigorous salt control and fluid restriction. LVMI reduced 
by a mean of 43g m
-2 over a 6 month period. Although this is an excellent outcome 
for these patients, this reduction in LVMI is so dramatic that it is more likely that 
some of this improvement is artefactual(248)  194 
 
•  A  number  have  studies  have  demonstrated  improvements  in  LVMI  following 
conversion to nocturnal haemodialysis, allowing slower ultrafiltration over a greater 
dialysis period. Chan et al showed that nocturnal haemodialysis allowed reduction in 
the need for antihypertensive therapy, improved blood pressure and a reduction in 
LVMI  over  a  follow  up  period  of  1  year  in  28  patients  switched  to  nocturnal 
haemodialysis compared to their counterparts on conventional haemodialysis(20)  
•  Changing  patients  from  thrice  weekly  to  short  daily  on-line  haemodiafiltration  as 
dialysis modality has been demonstrated to significantly reduce LVMI in one small 
study (eight patients). Interestingly this study used CMR to measure LVMI and found 
similar magnitudes of reduction as the echocardiographic studies quoted above. This 
intriguing finding needs explored in larger controlled studies. Whether this dialysis 
modality confers additional benefits via actions on uraemic toxins is unknown(249) 
•  Similar findings have been reported in peritoneal patients on both blood pressure and 
LVMI  in  an  open-label  randomised  controlled  trial  using  icodextrin  compared  to 
conventional glucose peritoneal dialysis for the night time dwell. Again it is likely 
that the main beneficial effect on LVMI was mediated via improved volume status 
and blood pressure(250) 
 
Limited trial data exist on the use of pharmacological agents to reduce blood pressure or 
LVMI  in  ESRD.  Two  small  studies  have  demonstrated  a  benefit  of  using  angiotensin 
receptor blockers in haemodialysis patients either as monotherapy. In an non-blinded three 
treatment arm study of 33 patients, Suzuki et al reported increased regression of LVMI 
with  combined  losartan  and  enalapril  either  agent  alone  independent  of  blood 
pressure(251), whilst losartan was shown to have a beneficial effect as monotherapy on 
LVMI compared to amlodipine or enalapril in a similar study(252). 195 
 
Out with treating blood pressure and revisiting the dilemma of treatment targets in renal 
anaemia,  alternative  strategies  to  treat  LVMI  may  revolve  around  addressing  calcium 
phosphate  balance  and  secondary  hyperparathyroidism.  Sevelamer  hydrochloride  has 
already been shown to produce less coronary artery calcification (as measured by electron 
beam CT scanning) compared to calcium containing phosphate binders(143). Reduction of 
arterial (and potentially valvular) calcification may reduce cardiac after load and minimise 
LVH. This end point has not been studied using this agent. Similarly vitamin D analogues 
such  as  calcitriol  have  been  demonstrated  in  small  studies  to  reduce  progression  of 
LVH(253). The calcimimetic agent, cinacalcet, currently used for treatment of secondary 
and  tertiary  hyperparathyroidism  may  yet  prove  to  have  beneficial  outcomes  on  either 
arterial  calcification  or  LVH.  Whilst  CMR  is  not  able  to  directly  demonstrate  calcium 
deposition,  techniques  developed  for  assessing  arterial  stiffness  may  prove  useful  end 
points for  such  studies and may  yet  provide  surrogate  equivalent measures  of  vascular 
function, at the same time as providing definitive LV assessment. 196 
 
 
 
Chapter 6 
 
 
Survival of patients undergoing cardiovascular screening for renal transplantation 
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6.1  INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death after renal transplantation as 
well as the leading cause of death of patients  on the renal transplant  waiting list(254). 
Various  guidelines  have  been  developed  to  assess  peri-operative  risk  in  the  general 
population(255) as well as for renal transplant assessment(192;256).  Further studies using 
a variety of clinical scoring criteria or screening tests have been performed in an attempt to 
identify  patients  at  increased  risk  of  early  post  transplant  death(257).  Many  of  the 
guidelines used in the general population use conventional cardiovascular risk factors to 
classify those patients at increased peri-operative risk. However some of these risk factors, 
such as diabetes, hypertension, ECG abnormalities (or even renal dysfunction itself) are 
either ubiquitous or have a much higher prevalence in the ESRD population. Other risk 
factors  such  as  hypercholesterolaemia  have  different  relationship  with  outcome  in  the 
ESRD population. No study to date has used CMR to generate long term follow up data in 
the  ESRD/renal  transplant  candidate  population,  including  those  patient  undergoing 
assessment who are not transplant listed, and there are still relatively few outcome studies 
for any conditions using CMR.   
 
Identifying patients at high risk is beneficial for a number of reasons. Firstly, some patients 
will be at such high peri-operative risk or have such a short anticipated survival that renal 
transplantation is unlikely to offer any improvement in the quality or longevity of life for 
that patient. As cadaveric organs are in short supply, it is unlikely to be an appropriate use 
of  a  valuable  resource  to  allocate  kidneys  to  such  patients.  Other  patients  may  be  at 
increased risk of dying, but their risk may potentially be lowered, either by medical therapy 
or surgical intervention. In these cases where evidence may not exist for intervention these 
patients may be identified as suitable for clinical trials of interventions to reduce risk. Some 198 
 
patients who are at lower cardiovascular risk may not benefit from screening, although in 
these  cases  results  may  be  reassuring  and  provide  a  baseline  assessment  as  patients 
frequently face an uncertain wait for a cadaveric kidney. For this reason, the screening tests 
should ideally be non invasive and carry a minimal risk of harm. At the time of study, CMR 
was ideally placed to offer such a test. 
 
The  aims  of  these  studies  were  to  assess  the  utility  of  CMR  in  identifying  the  renal 
transplant candidate at high risk of premature death. Specific hypotheses to be addressed 
included:  
•  Does the presence of uraemic cardiomyopathy, as defined by cardiac dimensions at 
CMR predict outcome? 
•  Would the presence of LGE on CMR scanning predict poorer patient prognosis? 
•  Can  CMR  provide  additional  information  above  standard  clinical  information  to 
inform likely patient outcomes? 
 
6.2  METHODS 
 
6.2.1  Patient demographics 
Patients were recruited from the renal transplant assessment clinic at the Western Infirmary 
as described in Chapter 2. To achieve greater statistical power a larger cohort was created 
by  addition  of  patients  assessed  for  transplantation  during  the  period  February  2002  – 
March  2006,  including  patients  studied  as  part  of  a  previous  British  Heart  Foundation 
Fellowship to Dr Nicola Johnston, as well as the current studies.  199 
 
6.2.2  Cardiovascular assessment 
All  patients  studied  underwent  CMR  to  assess  cardiac  dimensions  and  function  as 
described previously. Contrast-enhanced CMR was performed in the majority of patients 
scanned  with  reasons  for  not  administering  Gd-DTPA-DMA  as  before  (precipitating 
decline  in  renal  function,  patient  choice,  scan  duration  and  poor  venous  access).    A 
proportion  of  patients  underwent other  tests  including clinical history  and  examination, 
electrocardiography, exercise tolerance testing and angiography as clinically appropriate. 
Methods described in Chapter 2 were used for these tests. All tests were performed within 
the Department of Cardiology at the Western Infirmary, Glasgow. 
 
6.2.3  Coronary angiography 
A  subset  of  patients  underwent  coronary  angiography  as  part  of  assessment  for  renal 
transplant  listing.  Criteria  used  to  select  patients  for  angiography  were  as  described  in 
Chapter 3.2.3 with angiography performed within three months (before or after) of CMR. 
Decision to perform angiography was by an independent cardiologist blinded to the results 
of  these  studies.  Angiograms  were  classified  for  severity  of  coronary  artery  disease  as 
previously described. 
 
6.2.4  Follow up 
Follow up data was collected from date of the CMR scan to 9
th November 2006 using 
electronic  patient  records  from  the  Western  Infirmary,  Glasgow  and  Glasgow  Royal 
Infirmary Renal Units. With this cohort, death was the only end point used. All patient 
deaths  were  included in  the  patient  survival analysis.  From  these data  the  influence  of 
various parameters on patient survival were determined.  
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6.2.5  Statistical methods 
Measures of cardiac function were compared between patients who died during the follow 
up  period,  with  t-test  and  Chi-squared/Fisher’s  exact  test  used  to  compare  groups. 
Unadjusted survival analysis was performed using the Kaplan–Meier method. Statistical 
significance was determined by the log-rank test. The data were then analysed by Cox 
survival  analysis  to  assess  the  influence  of  multiple  variables  on  outcome.  Variables 
identified as possibly influential on outcome by univariate analysis were then entered into a 
forward  stepwise  regression  model.  All  analyses  were  performed  using  the  SPSS  13.0 
statistical software package (SPSS Inc., Chicago, IL., USA). 
 
6.3  RESULTS 
 
6.3.1  Patient demographics and survival 
Baseline patient demographics are shown in Table 6.1. A total of 300 patients were studied 
(84 with advanced  renal failure not on dialysis  therapy, two patients with failing  renal 
transplants  157  patients  on  haemodialysis  and  57  on  peritoneal  dialysis).  The  median 
follow period was 32.5 months. There were 60 patient deaths during the follow up period. 
Survivors were significantly younger than those who died during the follow up period. A 
significantly  higher  proportion  of  patients  with  a  past  history  of  diabetes  mellitus, 
ischaemic  heart  disease  (Figure  6.1),  cerebrovascular  disease  and  peripheral  vascular 
disease  died.  Gender,  dialysis  modality  at  the  time  of  scanning,  duration  of  renal 
replacement therapy, smoking history and blood pressure at the time of scanning were not 
associated with patient mortality. 
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6.3.2  Laboratory data and patient outcome 
Certain  laboratory  parameters  were  associated  with  better  patient  outcome  (Table  6.2). 
Patients  who  died  during  the  follow  up  period  were  more  likely  to  be  anaemic  than 
survivors and additionally were more likely to be malnourished with lower serum albumin. 
Evidence of greater systemic inflammation indicated by higher C- reactive protein was non-
significantly  higher  in  patients  who  died  during  the  follow  up  period.  There  were  no 
differences  in  corrected  calcium,  phosphate,  calcium  phosphate  product  or  cholesterol 
levels between patients alive and dead at the end of the follow up period. 
 
6.3.3  Transplant list status, renal transplant listing and outcome 
78  (26.0%)  patients  were  not  transplant  listed  following  independent  assessment.  222 
patients (74.0%) were transplant listed. 80 (26.7%) patients went on to receive  a renal 
transplant of  which  five  diabetic  patients  received  combined  cadaveric  kidney-pancreas 
transplants.  Patients who were not transplant listed were significantly likely to be older, 
more likely to be diabetic or have a history of peripheral vascular disease. There were a non 
significantly lower proportion of patients with ischaemic heart disease in the transplant 
listed group. The outcome of the patients divided by transplant outcome is shown in Figure 
6.2. There were only seven post transplant deaths during the follow up period with a 1 year 
post transplant patient survival of 95.3%. As the post transplant numbers are relatively 
small  with  a  short  post  transplant  follow  up  data  were  not  censored  at  the  point  of 
transplantation and post transplant outcomes were not studied in detail.  
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  Alive  Dead  p value 
Number  240   (80.0)  60   (80.0)   
Male  154   (64.2)  37   (61.7)  0.719 
Age (years)  50.3  (10.8)  56.5  (9.6)  <0.001 
SBP (mmHg)  136.2  (24.5)  140.1  (24.0)  0.283 
DBP (mmHg)  81.3  (12.8)  80.1  (12.0)  0.525 
1
0 Renal Disease       
  Diabetes  49  (20.4)  17  (28.3) 
  APKD  30  (12.5)  6  (10.0) 
  GN  47  (19.6)  8  (13.3) 
  CPN  25  (10.4)  2  (3.3) 
  Renovascular  12  (5.0)  4  (6.7) 
  Unknown/Other  77  (32.1)  23  (38.3) 
0.294 
RRT time (months)  12.0  (39.0)  20.0  (41.0)  0.139 
Smoker       
  Never  126  (52.5)  27  (45.0) 
  Current  62  (25.8)  21  (35.0) 
  Ex  52  (21.7)  12  (20.0) 
0.359 
Diabetes  52  (21.7)  21  (35.0)  0.031 
Previous IHD  36  (15.0)  20  (33.3)  0.001 
TIA/CVA  13  (5.4)  9  (15.0)  0.011 
PVD  10  (4.2)  7  (11.7)  0.025 
Table 6.1   
Baseline demographic data for patients alive and dead at the end of the follow up period. Data are 
number with percentage in parentheses or mean with standard deviation in parentheses except for 
RRT time where median and intra-quartile are shown. Tests of significance are t-test and Chi-
square except for renal replacement therapy time where Mann-Whitney is used 203 
 
 
  Alive  Dead  p value 
Haemoglobin  11.6  (1.8)  11.0  (1.4)  0.017 
Albumin  39.7  (4.5)  36.0  (5.1)  0.001 
Corrected calcium  2.36  (0.2)  2.38  (0.2)  0.654 
Phosphate  1.75  (0.5)  1.75  (0.6)  0.988 
Ca-P product  4.1  (1.1)  4.3  (1.5)  0.402 
PTH  20.0  (31.3)  20.0  (37.5)  0.876 
Cholesterol  5.4  (1.8)  5.1  (1.4)  0.262 
CRP  7.0  (11.0)  16.0  (34.0)  0.074 
 
Table 6.2 
Laboratory parameters for patients alive and dead at the end of the follow up period. Data 
are mean with standard deviation in parentheses except for parathyroid hormone and C - 
reactive protein where median and intra-quartile are shown. Tests of significance are t-test 
except for parathyroid hormone and C - reactive protein where Mann-Whitney is used 204 
 
 
 
Not transplant 
listed 
Transplant 
listed but not 
transplanted 
Transplanted  p value 
Number  78  (26.0)  142  (47.3)  80  (26.7)   
Male  49  (62.8)  84  (59.2)  58  (72.5)  0.137 
Age (years)  54.3  (11.3)  52.3  (10.0)  47.5  (11.1)  <0.001 
1
0 Renal Disease           
  Diabetes  24  (30.8)  26  (18.3)  16  (20.0) 
  APKD  5  (6.4)  24  (16.9)  7  (8.8) 
  GN  13  (16.7)  26  (18.3)  16  (20.0) 
  CPN  6  (7.7)  14  (9.9)  7  (8.8) 
  Renovascular  4  (5.1)  7  (4.9)  5  (6.3) 
  Unknown/Other  26  (33.3)  45  (31.7)  29  (36.3) 
0.412 
RRT time (months)  12.0  (40.0)  10.0  (43.0)  24.0  (39.0)  0.739 
Diabetes  30  (38.5)  26  (18.3)  17  (21.3)  0.003 
Smoker           
  Never  38  (48.7)  81  (57.0)  34  (42.5) 
  Current  25  (32.1)  33  (23.2)  25  (31.3) 
  Ex  15  (19.2)  28  (19.7)  21  (26.3) 
0.250 
Previous IHD  20  (25.6)  25  (17.6)  11  (13.8)  0.144 
TIA/CVA  10  (12.8)  8  (5.6)  4  (5.0)  0.095 
PVD  12  (15.4)  3  (2.1)  2  (2.5)   
Table 6.3  Baseline demographic data for patients subdivided by the transplant status at the 
end of the follow up period. Data are number with percentage in parentheses or mean with standard 
deviation in parentheses except for RRT time where median and intra-quartile are shown. Tests of 
significance are  Chi-square  except  for  age  and renal  replacement therapy  time  where  one  way 
analysis of variance is used 205 
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Figure 6.1 (above) and 6.2 (below) Kaplan-Meier survival curves of patients stratified by 
the presence of ischaemic heart disease and transplant status respectively 
  
p=0.001 
p<0.001 
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6.3.4  Uraemic cardiomyopathy as assessed by CMR and outcome 
In the entire cohort of patients there were no significant differences in cardiac dimensions 
or  ejection  fraction  between  patients  who  died  and  survivors  (Table  6.4).  There  was 
however a trend towards poorer survival in patients with systolic dysfunction compared to 
those  with  isolated  LVH  (Figure  6.3).  In  those  patients  undergoing  contrast  enhanced 
CMR,  a  significantly  greater  number  of  patients  who  died  displayed  evidence  of 
myocardial  fibrosis  indicated  by  LGE,  in  particular  subendocardial  LGE  demonstrating 
previous myocardial infarction (Figure 6.4).  
 
6.3.5  Resting and exercise electrocardiogram and outcome 
263  patients  had  a  resting  12-lead  ECG  taken  at  the  time  of  assessment  available  for 
analysis. Of these 143 (54.4%) were normal.  82 (31.2%) showed LVH by Sokolow-Lyon 
criteria. A total of 79 (30.0%) showing ischaemic changes (either ST abnormalities or the 
presence  of  Q-waves)  of  which  39  (14.8%)  showed  LVH  with  additional  ischaemic 
changes (‘LVH plus strain’). Patients who died during the follow up period demonstrated a 
significantly greater prevalence of presence of ischaemic changes on the ECG (Figure 6.5). 
The presences of LVH or LVH plus strain in isolation were not associated with poorer 
survival (Table 6.5).  
 
212 (70.7%) patients were able to attempt a Bruce protocol exercise tolerance test (Table 
6.5).  Survival  was  significantly  poorer  in  those  patients  unable  to  exercise.  Of  those 
patients  who  could  exercise,  the  presence  of  electrocardiographic  changes  at  exercise 
testing was not predictive of long term outcome. However, exercise time was a predictor of 
outcome, with lower median exercise times for patients who died during follow up and with 
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those patients unable to exercise for 6 minutes (as an arbitrary but clinically pragmatic cut 
point) having a greater mortality (Figure 6.6).  
 
6.3.6  Coronary angiography and outcome 
96  (32.0%)  patients  underwent  coronary  angiography  as  selected  by  an  independent 
cardiologist.  Overall  survival  in  patients  who  underwent  angiography  was  no  different 
compared to those who did not have this investigation performed (p=0.633). A  greater 
burden of coronary artery disease at angiography was associated with poorer outcome, with 
those patients with a total atheromatous plaque burden greater than 74 (equating to one 
coronary  artery  stenosis  >74%  or  an  accumulation  of  lesser  plaque  disease)  having 
significantly poorer survival (Figure 6.7). 208 
 
 
  Alive  Dead  p value 
  240  (80.0)  60  (20.0)   
LV ejection fraction (%)  66.5  (11.7)  65.0  (13.5)  0.378 
LV mass (g)  175.1  (64.9)  184.3  (64.4)  0.328 
End diastolic volume (ml)  141.2  (58.8)  142.0  (62.7)  0.930 
End systolic volume (ml)  50.4  (37.9)  54.4  (44.7)  0.479 
LV mass/BSA (g m
-2)  94.7  (31.8)  100.0  (31.2)  0.259 
End diastolic volume/BSA (ml m
-2)
  75.7  (29.4)  77.1  (32.7)  0.765 
End systolic volume/BSA(ml m
-2)  27.3  (20.6)  29.0  (23.6)  0.605 
LGE given  168  (82.8)  35  (17.2)  0.804 
LGE positive  45  (26.8)  16  (45.7)  0.026 
Subendocardial LGE  23  (13.7)  11  (31.4)  0.008 
Diffuse LGE  21  (12.5)  5  (14.3)  0.540 
 
Table 6.4   
Left ventricular dimensions in patients who died and those who were still alive at the end of 
the follow up period. Data are expressed as mean with standard deviation in parentheses for 
cardiac dimensions and number with percentage in for LGE results. Tests of significance 
are t-test and Chi-square/Fisher’s exact test as appropriate 209 
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Figure 6.3 (above) and 6.4 (below) Kaplan-Meier survival curves of patients stratified by 
the presence of left ventricular abnormalities and presence and subtype of LGE respectively
    
p=0.216 
p=0.024 
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6.3.7  Independent predictors of survival in all patients 
In the Cox multivariate model based on factors identified during the earlier analyses; age, 
previous  ischaemic  heart  disease,  receiving  a  renal  transplant  and  ability  to  attempt an 
exercise tolerance test were identified as independent predictors of mortality (Table 6.6). 
As there may be an inherent degree of bias in patient selection to receive a renal transplant 
(e.g. patients on the transplant list were younger than those not listed), the analysis was 
performed again leaving this factor out of the model. The results were no different with 
age,  previous  ischaemic  heart  disease,  and  ability  to  attempt  an  exercise  tolerance  test 
identified as independent predictors of mortality in this model. When a similar model was 
used in patients who underwent contrast enhanced CMR, the presence of LGE was not a 
predictor of patient survival independent of other variables (Table 6.7). When only patients 
studied  with  contrast  enhanced  CMR  age  were  analysed,  age,  diabetes,  and  ability  to 
attempt an exercise tolerance test were independent predictors of mortality. 
 
6.3.8  Independent predictors of patients listed for renal transplantation 
As identifying patients at high risk of mortality on the renal transplant waiting list or early 
post renal transplantation may optimise both patient selection and post transplant outcomes, 
a similar Cox multivariate model was performed on the cohort of patients on the renal 
transplant list (Table 6.8).  In these patients predictors of mortality were age, history of 
ischaemic heart disease and female gender. When a similar model was used in patients on 
the transplant list who underwent contrast enhanced CMR, the presence of LGE was not a 
predictor of patient survival independent of other variables. 211 
 
 
  Alive  Dead  p value 
Normal ECG  120  (56.6)  23  (45.1)  0.139 
LVH  66  (31.1)  16  (31.4)  0.973 
LVH plus strain  30  (14.2)  9  (17.6)  0.528 
ST changes  50  (23.6)  19  (37.3)  0.046 
Q waves  16  (7.5)  7  (13.7)  0.161 
Any ischaemic changes  57  (26.9)  22  (43.1)  0.023 
Performed exercise tolerance test  178  (74.2)  31  (51.7)  0.001 
ECG changes  30  (16.6)  7  (22.6)  0.416 
Median exercise time (minutes)  7.0  (3.25)  5.0  (4.0)  <0.001 
 
Table 6.5   
Electrocardiographic data for patients who died and those who were still alive at the end of 
the follow up period.  Data are number with percentage in parentheses except for exercise 
time  where  median  and  intra-quartile  are  shown.  Tests  of  significance  are  Chi-square 
except for exercise time where Mann-Whitney-U is used 212 
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Figure 6.5 (above) and 6.6 (below) 
Kaplan-Meier survival curves of patients stratified by the presence of an ischaemic ECG 
and ability to perform an exercise tolerance test 
 
p=0.014 
p<0.001 
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Figure 6.7 
Kaplan-Meier survival curves of patients stratified by coronary angiography status 
p=0.011 
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Table 6.6 
Results of the Cox regression survival analysis for all patients 
  Patient survival 
  Univariate analysis  Multivariate analysis 
Variable  HR  (95.0% CI )  p  HR  (95.0% CI)  p 
Age  1.064  (1.025,  1.104)  0.001  1.063  (1.025,  1.102)  0.001 
IHD  2.786  (1.333,  5.824)  0.006  2.828  (1.488,  5.374)  0.002 
Transplanted  0.339  (0.145,  0.790)  0.012  0.361  (0.157,  0.830)  0.016 
Able to attempt ETT  0.550  (0.278,  1.087)  0.085  0.510  (0.273,  0.954)  0.035 
Haemoglobin  0.882  (0.751,  1.035)  0.123         
Diabetes  1.800  (0.834,  3.882)  0.134         
SBP  0.989  (0.975,  1.004)  0.158         
Gender (ref female)   0.629  (0.308,  1.282)  0.201         
Ischaemic ECG  1.566  (0.769,  3.189)  0.217         
RRT time (months)  0.995  (0.987,  1.004)  0.263         
LVMI  1.006  (0.994,  1.017)  0.354         
Ejection fraction  1.012  (0.987,  1.037)  0.365         
Ever smoked  1.321  (0.667,  2.616)  0.425         215 
 
 
Table 6.7 
Results  of  the  Cox  regression  survival  analysis  for  patients  who  underwent  contrast 
enhanced CMR 
  Patient survival 
  Univariate analysis  Multivariate analysis 
Variable  HR  (95.0% CI )  p  HR  (95.0% CI)  p 
Diabetes  3.386  (1.162  9.866  0.025  2.777  (1.095,  7.044)  0.032 
Age  1.051  (0.993,  1.112)  0.083  1.057  (1.004,  1.113)  0.036 
Ischaemic ECG  2.095  (0.784,  5.594)  0.140  2.486  (1.063,  5.814)  0.036 
SBP  0.982  (0.961,  1.004)  0.108         
Transplanted  0.406  (0.117,  1.403)  0.154         
Gender (ref female)  0.447  (0.147,  1.361)  0.156         
Able to attempt ETT  0.534  (0.199,  1.435)  0.214         
Ever smoked  1.741  (0.680,  4.460)  0.248         
Presence of LGE  1.744  (0.554,  5.497)  0.342         
Ejection fraction  1.024  (0.971,  1.080)  0.373         
IHD  1.870  (0.428,  8.168)  0.405         
RRT time  0.997  (0.987,  1.007)  0.509         
LVMI  1.007  (0.985,  1.029)  0.541         
Haemoglobin  0.981  (0.779,  1.237)  0.874         216 
 
 
Table 6.8 
Results of the Cox regression survival analysis for patients on the renal transplant list 
  Patient survival 
  Univariate analysis  Multivariate analysis 
Variable  HR  (95.0% CI )  p  HR          (95.0% CI)  p 
Age  1.114  (1.055,  1.177)  0.000  1.111  (1.056,  1.168)  <0.001 
IHD  5.597  (1.953,  16.036)  0.001  6.154  (2.616,  14.476)  <0.001 
Gender (ref female)  0.273  (0.102,  0.729)  0.010  0.301  (0.131,  0.692)  0.005 
Transplanted  0.314  (0.107,  0.922)  0.035         
Haemoglobin  0.836  (0.668,  1.046)  0.117         
Diabetes  2.605  (0.751,  9.030)  0.131         
Able to attempt ETT  0.513  (0.204,  1.286)  0.154         
Ejection fraction  0.975  (0.934,  1.018)  0.245         
Ever smoked  1.659  (0.667,  4.127)  0.277         
Ischaemic ECG  1.426  (0.470,  4.321)  0.531         
RRT time  0.998  (0.985,  1.010)  0.701         
LVMI  0.997  (0.978,  1.018)  0.804         
SBP  0.998  (0.976,  1.021)  0.869         217 
 
6.4  DISCUSSION 
 
6.4.1  Predictors of survival in a cohort of patients screened for renal transplantation 
In this cohort of all patients undergoing cardiovascular screening as part of assessment for 
renal  transplantation,  the  independent  predictors  of  patient  survival  were  younger  age, 
absence of ischaemic heart disease, receipt of a renal transplant and ability to attempt an 
exercise  tolerance  test.  Similarly  in  patients  on  the transplant  list,  age,  ischaemic  heart 
disease and female gender were predictors of mortality. The original hypothesis that factors 
consistent with uraemic cardiomyopathy would be associated with adverse outcome was 
not  confirmed  as  patients  who  died  had  neither  significantly  greater  LVMI  nor  lower 
LVEF.  However,  with  contrast  enhanced  CMR,  the  presence  of  LGE,  in  particular 
subendocardial LGE, indicating myocardial fibrosis, was associated with adverse outcome. 
Cardiovascular risk factors either associated with, or indicating the presence of ischaemic 
heart disease, such as ischaemic changes on the ECG or diabetes were also associated with 
mortality.  
 
Although the presence of LGE at contrast enhanced CMR conferred a worse prognosis, this 
finding was not independent of other variables. It is not clear if the lack of independent 
prognostic information provided by CMR is due to lack of statistical power, with fewer 
patients studied with this method or due to the close association between the findings at 
contrast  enhanced  CMR  and  cardiovascular  risk  factors  leading  to  a  lack  of  any 
independent association. Nonetheless, the follow up data support the notion that CMR may 
identify those patients at greater risk of premature death. Other studies have looked at the 
prognostic value of LGE in different patient groups at high cardiovascular risk: 218 
 
•  In  a  CMR  study  of  101  patients  with  idiopathic  dilated  cardiomyopathy  the 
presence of midwall myocardial fibrosis indicated by LGE was demonstrated by 
multivariate  analysis  to  be  the  sole  significant  predictor  of  death  or 
hospitalisation(190) 
•  A  study  of  195  patients  with  classical  ischaemic  heart  disease  but  with  not 
documented previous myocardial infarction the presence of LGE provided further 
prognostic  value  for major  adverse  cardiac  events  and  cardiac  mortality  beyond 
common clinical, angiographic, and functional predictors(258) 
 
Both these studies have shown that in other patient groups at high risk of cardiovascular 
disease  LGE  identifies  patients  at  elevated  risk  of  major  adverse  cardiac  events, 
hospitalisation or death. As patients with ESRD are at least as high risk as these patient 
groups  it  seems  plausible  that  contrast  enhanced  CMR  may  provide  further  useful 
information  of  long  term  outcome  in  patients  which  may  yet  inform  either  transplant 
workup, or the decision to proceed to invasive investigations.   
 
6.4.2  The  resting  and  exercise  ECG  and  outcome  in  potential  renal  transplant 
candidates 
Although many of these findings demonstrating the relationship with cardiovascular risk 
factors  and  outcome  in  patients  screened  for  renal  transplantation  have  been  reported 
previously(207;259); the finding that objective assessment of functional capacity with the  
Bruce  protocol  exercise  tolerance  test  predicts  outcome  is  novel.  This  simple,  widely 
available test has been used to risk stratify patients with suspected or confirmed ischaemic 
heart disease for many years. Conventional logic suggests that this test is unlikely to be 
useful  in  cohorts  of  patients  with  renal  failure  due  the  high  prevalence  of  ECG 219 
 
abnormalities  and  the  lower  functional  capacity  due  to  issues  such  as  fluid  status, 
arthropathy associated with renal bone disease and peripheral vascular disease. As a tool for 
indicating which patients have underlying severe coronary artery disease, the exercise ECG 
is  unlikely  to  be  a  useful  tool  and  perhaps  paradoxically  the  resting  ECG  has  been 
demonstrated to a better predictor of the presence of coronary artery disease(49). However, 
this study has shown that the exercise test is an excellent test to assess functional capacity, 
irrespective  of  the  presence  of  ECG  changes.  Furthermore  the  American  College  of 
Cardiology/American  Heart  Association  (ACC/AHA)  guidelines  for  perioperative 
cardiovascular  evaluation  for  noncardiac  surgery  suggest  that  functional  assessment  in 
metabolic equivalent (MET) levels should form part of evaluation for surgery(255). Stage 1 
of the exercise test is equivalent to 4.8 MET and therefore is a reassuring finding prior to 
non/semi-urgent surgery such as renal transplantation. 
 
6.4.3  Guidelines  for  screening  for  cardiovascular  disease  in  potential  renal 
transplant recipients 
Various guidelines for screening for cardiovascular disease in potential renal transplant 
recipients have been generated under the auspices of organisations such as the American 
Society of Transplantation and the European Renal Association(192;256). Interestingly, at 
the time of writing the previous draft guidelines from the British Transplant Society have 
been withdrawn for revision and the draft Australian guidelines (Caring for Australians 
with Renal Impairment) have been withdrawn and not replaced. Further British guidelines 
may appear from the Renal Association at some point. It is recognised that cardiovascular 
disease  is  the  leading  cause  of  death  after  renal  transplantation.  However  in  Western 
populations  cardiovascular  disease  is  often  the  leading  cause  of  death  in  the  general 
population as well as in the dialysis population. Therefore, the focus should be on reducing 220 
 
the risk of post transplant cardiovascular disease, and in particular perioperative and early 
post transplant death. Hence the reasons for screening potential renal transplant recipients 
for  cardiovascular  disease  are  threefold.  First,  identifying  transplant  candidates  with 
ischaemic  heart  disease  allows  patients  and  clinicians  to  better  understand  the  risk  of 
transplantation. Second, it would be hoped that pre-transplant revascularisation that may 
reduce the risk of transplantation.  Finally intensive risk factor modification may lead to 
better patient and graft outcomes(37). 
 
The most detailed guidelines from the American Society of Transplantation suggest the 
following strategy. First, assess ischaemic heart disease risk factors: a prior history of IHD, 
men ≥45 or women ≥55 years, (IHD in a first degree relative, current cigarette smoking, 
diabetes,  hypertension,  hypercholesterolaemic  and  left  ventricular  hypertrophy).  Next 
aggressive  risk  factor  modification  should  be  pursued.  Patients  at  high  risk,  diabetic 
nephropathy, prior history of IHD, or ≥2 risk factors, should have a cardiac stress test and 
those with a positive cardiac stress test should undergo coronary angiography for possible 
revascularisation  prior  to  transplantation(192).  The  current  European  Renal  Association 
guidelines are less detailed but suggest that as cardiovascular disease is the main cause of 
mortality  after  transplantation  careful  evaluation  is  mandatory  to  detect  and  treat 
symptomatic coronary disease, valve disease, cardiomyopathy and pericardial disease(256). 
The  ACC/AHA  guidelines  for  perioperative  cardiovascular  evaluation  for  noncardiac 
surgery are broadly similar suggesting that the risk of the surgical procedure, risk factor 
assessment, functional capacity and non invasive testing should guide patient selection for 
coronary angiography(255).   
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The dilemma exists in patients with ESRD that the evidence for cardiovascular risk factor 
reduction  with  statins  or  with  blood  pressure  management  is  not  present.  Many  of  the 
cardiac risk factors have accumulated over a long period of renal insufficiency and are 
potentially  irreversible  (such  as  LVH,  family  history  and  diabetes).  Most  of  these 
recommendations  for  assessment  are  based  on  observational  studies  either  with 
radionuclide myocardial perfusion imaging or stress echocardiography rather than on any 
specific intervention.  
 
Reviewing the studies of perfusion imaging, a meta analysis by Rabbat et al of the 12 
studies  using  myocardial  perfusion  scanning  in  potential  renal  transplant  recipients 
concluded  that  both  reversible  and  fixed  perfusion  defects  were  associated  with  a 
significantly increased risk of cardiac death and myocardial infarction(260). As there was 
no difference between fixed and reversible defects, it is difficult to know whether these 
studies  identify  patients  who  would  have  benefited  from  coronary  revascularisation. 
However,  a  negative  scan  is  reassuring.  Similarly,  in  a  comparative  study  between 
myocardial  scintigraphy  (SPECT),  dobutamine  stress  echocardiography,  and  coronary 
angiography in 126 renal transplant candidates showed a sensitivity and negative predictive 
value of <75% for the presence of coronary disease suggesting that whilst these scans may 
well carry prognostic information they are of limited value at guiding the need for coronary 
angiography(261). 
 
6.4.4  Coronary angiography, ischaemic heart disease and renal transplantation 
In  the  current  study,  survival  was  not  significantly  different  between  those  patients 
undergoing angiography and those who did not. However patients with a greater burden of 
coronary atheroma, fared significantly worse over the follow up period. The implication is 222 
 
that  irrespective  of  the  original  indication  for  performing  angiography,  the  degree  of 
coronary  atherosclerosis  predicts  outcome.  In  this  cohort  of  96  patients  undergoing 
angiography,  very  few  went  on  to  have  coronary  revascularisation  (eight  undergoing 
percutaneous intervention and two undergoing coronary artery bypass grafting).The reasons 
for this are unclear but may reflect perceived high procedure risk, absence of symptoms 
leading to reluctance to perform revascularisation, or the technical challenge of performing 
revascularisation in ESRD where the vessels are typically heavily calcified. With such a 
small cohort it is not possible to analyse any impact coronary revascularisation has on 
survival. 
 
There are few studies to inform the decision to revascularise asymptomatic patients prior to 
major  surgery.  One  large  study,  the  Coronary  Artery  Revascularisation  Prophylaxis 
(CARP)  trial,  assessed  the  long-term  benefit  of  preoperative  coronary-artery 
revascularisation  among  510  patients  with  stable  coronary  artery  disease  scheduled  for 
elective vascular surgery (aneurysm repair or peripheral vascular surgery(262). At 30 days 
after  the  vascular  operation,  a  postoperative  myocardial  infarction,  defined  by  elevated 
troponin levels, occurred in 12 percent of the revascularisation group and 14 percent of the 
no-revascularisation  group  (p=0.37)  indicating  no  significant  difference  between  the 
groups, suggesting that in patients on optimal medical management, a strategy of coronary-
artery revascularisation before elective vascular surgery among patients with stable cardiac 
symptoms  cannot  be  recommended.  These  patients  did  not  have  significant  renal 
impairment with only one patient in each group requiring post operative dialysis therapy.  
 
In patients with ESRD assessed for transplantation undergoing coronary revascularisation, 
only  one  study  exists  of  26  asymptomatic  diabetic  patients  who  were  found  to  have 223 
 
stenoses  of  greater  than  75%(263).  Patients  randomised  to  revascularisation  (either 
percutaneous  intervention  or  bypass  grafting)  prior  to  transplantation  had  fewer  post 
transplant  cardiovascular  disease  events  than  patients  managed  with  medical  therapy. 
However this study could be criticised as patients in the medical treatment arm received 
short acting nifedipine, which has been suggested to cause an increase in ischaemic heart 
disease events, where current optimal medical management would include a beta-blocker. 
The small sample size makes it possible that the observed differences were due to chance 
and additionally as this study was only performed in diabetics it is not clear whether the 
findings can be extrapolated to non diabetic patients.  
 
A more practical strategy may be to use perioperative beta blockade which has been shown 
in retrospective analysis of larger United States patient databases to be associated with 
lower risk of perioperative death in patients at high (but not low) cardiac risk(264). This 
strategy has not been trialled in ESRD, but would appear to be a more pragmatic approach 
than  undertaking  a  programme  of  coronary  revascularisation,  particularly  where  the 
evidence from the general population does not support such a course of action. 
 
6.4.5  Renal transplantation and survival compared to dialysis as treatment for end 
stage renal disease 
Until fairly recently it was difficult to be certain whether renal transplantation offered a 
survival advantage compared to long term dialysis therapy. Inevitably selection bias exists 
between patients on the transplant list who tend to be  younger, fitter  and have less co 
morbidity, and those patients who are not transplant listed.   Wolfe et al studied outcome in 
228,552 patients on dialysis using data from the United States Renal Data System 1991-
1996. Only 46,164 patients were on the transplant list, of whom, 23,275 received a first 224 
 
cadaveric renal transplant(265). Patients on the transplant list were younger and healthier 
than those who were not, but long-term mortality rate was 48 to 82 percent lower among 
transplant recipients than patients on the waiting list with relatively larger benefits among 
patients who were 20 to 39 years old, white patients, and younger patients with diabetes. 
Similar benefits were shown in a much smaller cohort of patients comparing wait listed 
patients to transplanted patients in Ontario, Canada(266). However it still remains unclear 
whether  patients  at  greatly  increased  cardiovascular  risk,  at  much  higher  perioperative 
mortality would still benefit from renal transplantation, which becomes a greater dilemma 
when one considers that the demand for cadaveric kidneys greatly outstrips supply.  
 
Oniscu et al studied patients listed for transplantation in Scotland and have suggested that 
even in elderly patients (>60 years old) transplantation offers significant survival advantage 
as  a  treatment  for  ESRD  than  dialysis(267).  Again  in  this  study,  patients  who  were 
transplanted  had  significantly  less  co  morbidity.  In  another  United  States  Renal  Data 
System analysis, Meier-Kriesche et al observed that rates of cardiovascular disease peaked 
in the first three months post operatively and thereafter continued to fall, whilst in wait 
listed patients the risk of cardiovascular events continued to rise inexorably, and hence the 
authors  proposed  that  transplantation  halts  the  progression  of  cardiovascular  disease  in 
ESRD(268). An attractive but implausible interpretation of this study would be to suggest 
that patients at the very highest risk of cardiovascular disease should be offered cadaveric 
kidneys as a priority, as long as they are prepared to accept the increased perioperative risk 
of death. One dilemma in patients with greater risk of cardiovascular disease is that they 
may require further cardiac investigations, which dependent on healthcare resources, may 
be time consuming. This may result on further time spent on the renal transplant waiting 
list (or delay access to the waiting list). The long term consequences of this may result in 225 
 
poorer graft outcome post transplantation as it is well documented that increased waiting 
time on dialysis is a powerful predictor of poorer graft survival(269). 
 
6.4.5  Limitations  of  the  current  study  of  outcome  in  patients  undergoing 
cardiovascular screening for renal transplantation 
As  a  single  centre  study,  this  analysis  is  too  small  to  truly  assess  the  impact  of 
transplantation  on  patient  survival.  The  very  low  revascularisation  rate  has  made  it 
impossible to contribute further to debate on impact of this intervention in potential renal 
transplant recipients. Furthermore, as not all patients had the same investigations, including 
angiography, it may be difficult to draw any more conclusions of the impact of these test 
results on outcome. The reason for this was primarily that it was felt to be unethical to 
submit  all  patients  to  invasive  investigations  as  part  of  a  study  and  so  invasive 
investigations and interventions were only performed by a clinician blinded to the notion 
that long term patient outcomes were being studied. Finally as an end point, death was used 
in  survival  analysis  rather  than  major  adverse  cardiac  events  such  as  hospitalisation, 
myocardial infarction (fatal and non-fatal), cardiac failure and cardiac death. The reason for 
this was that as patients were frequently followed up at another hospital, the investigator 
was unable to be certain regarding the cause of hospitalisation or diagnosis of a major 
adverse  cardiac  event.  Defining  myocardial infarction  or cardiac  failure  are  difficult  in 
ESRD due to the high prevalence of ECG abnormalities, frequent rises in biomarkers of 
myocardial  necrosis  such  as  troponin  in  the  absence  of  coronary  artery  occlusion  and 
development  of  pulmonary  oedema  due  to  hypervolaemia  rather  that  primary  cardiac 
dysfunction.  
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6.4.6  Conclusions  and  further  studies  required  in  the  role  of  cardiovascular 
assessment for renal transplantation 
There is a high mortality amongst patients screened as potential renal transplant recipients 
with 20% of patients dying over a median follow up period of 32.5 months. Patients who 
received a renal transplant had a better survival than those who did not, with the major 
predictors of death being the presence of, or risk factors for ischaemic heart disease. CMR 
with  contrast  indicated  patients  at  greater  risk  of  death,  but  not  independent  of  other 
variables. Based on the results of these data, an appropriate strategy would be to attempt to 
reduce the risk of ischaemic heart disease a long time prior to the development of ESRD 
and the need for renal transplantation. Further study of reduction of perioperative risk in 
patients  undergoing  renal  transplantation  is  required,  examining  whether  coronary 
revascularisation  has  any  benefits  in  this  cohort  of  patients  as  well  as  investigation  of 
optimal medical therapy for the potential renal transplant recipient.  227 
 
 
 
Chapter 7 
 
 
A study of the diagnostic utility of brain natriuretic peptide in end stage renal disease 228 
 
7.1   INTRODUCTION 
Brain natriuretic peptide (BNP) is a hormone synthesised and secreted primarily by the 
ventricles  of  the  heart(270).  Natriuretic  peptides,  specifically  brain  natriuretic  peptide 
(BNP) are released from the heart in response to chamber distension and thus are increased 
in the presence of volume expansion and cardiac overload. Their physiological role is to 
cause  vasodilatation  and  promote  natriuresis  to  maintain  volume  homeostasis(271). 
Increasingly serum levels of BNP are used to both diagnose and manage cardiovascular 
disorders(272).  However,  the  diagnostic  role  of  serum  BNP  levels  in  patients  with 
advanced  renal  dysfunction  remains  to  be  defined.  Patients  with  ESRD  have  a  high 
prevalence of left ventricular disorders, specifically LVH, which may reduce the diagnostic 
utility of BNP. In addition, ventricular stretch may be determined by intravascular volume 
status rather than by cardiac dysfunction.    
 
Nonetheless, since the prognosis of patients with end stage renal failure and co-existing 
heart failure is so poor, the availability of a further marker of cardiac “distress” may in 
future become a useful diagnostic tool and in due course may become a primary goal for 
titration  and  tailoring  of  therapy.  Whilst  population  studies  demonstrate  that  BNP  is  a 
useful test for targeted screening for LVSD in the general population(272), in the ESRD 
population  echocardiographic  studies  have  suggested  that  BNP  correlates  with  LV 
dimensions,  but  appears  to  be  more  closely  related  to  LV  mass  than  cardiac 
dysfunction(273).  Similarly,  BNP  may  be  a  predictor  of  long  term  survival  in  these 
patients(274),  but  there  are  limited  ‘real  world’  studies  of  patients  with  ESRD  and 
superimposed ischaemic heart disease and/or congestive heart failure.  
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The following studies were performed in order to determine the diagnostic accuracy of 
serum BNP in patients with ESRD for both the presence of LVH and LVSD. Additionally 
the relationship between serum BNP and long term survival was examined. 
 
7.2  METHODS 
 
7.2.1  CMR technique and analysis 
All patients were studied with the CMR technique described in detail in Chapter 2 (2.3.2).  
 
7.2.2  Measurement of serum brain natriuretic peptide levels 
Prior to CMR scanning 30ml of venous blood was drawn. 5ml of blood was added to a 
potassium-EDTA tube and centrifuged for 10 minutes at 3000 revolutions per minute prior 
to freezing at -20
0C. Samples were analysed in batches in the neuroendocrine laboratory 
(Dr Ian Morton, University of Glasgow). Serum BNP was measured using by a one step 
radioimmunoassay (ShionoRIA, Shinogi, Japan).   
 
7.2.3  Statistical methods 
Differences between groups of patients were analysed by Chi-squared or Fisher’s exact test 
(as appropriate)  for categorical data  and paired  t-test and Mann–Whitney–U testing for 
parametric or nonparametric data. One way analysis of variance (ANOVA) was used for 
comparisons between more than two groups. As BNP demonstrated a skewed distribution 
log-transformation  was  performed. Correlations between  cardiac dimensions, volume of 
myocardial fibrosis and BNP were assessed with Pearson and Spearman correlation co-
efficient  as  appropriate.  Receiver  operator  characteristic  (ROC)  curves  were  plotted  to 
assess diagnostic utility of serum BNP. BNP levels between patients who died or had a 230 
 
vascular event during the follow up period were divided into tertiles and subjected to an 
unadjusted survival analysis by the Kaplan–Meier method. All analyses were performed 
using the SPSS 13.0 statistical software package (SPSS Inc., Chicago, IL., USA), except 
ROC curves which were performed with the MedCalc software package (MedCalc 8.1, 
MedCalc Software, Belgium).  
 
7.3  RESULTS 
 
7.3.1  Dialysis modality and serum BNP levels 
Blood sampling and CMR scanning was performed on 114 patients (60 haemodialysis, 37 
peritoneal dialysis and 17 pre-dialysis patients).  Serum log10BNP was significantly lower 
in pre-dialysis patients than in patients on haemodialysis (log10BNP in pre-dialysis patients 
1.70 vs. 2.28 in HD patients, p=0.004) but not peritoneal dialysis (1.70 vs. 1.77 in CAPD 
patients, p=0.717). Although the elevation in BNP levels in HD may reflect differences in 
LV dimensions (mean  LVMI- HD 101.3g m
-2, PD 80.4 g m
-2, pre-dialysis 80.1 g m
-2, 
p=0.005), to minimise any potential effect of renal excretory function on serum BNP levels, 
only results for patients established on renal replacement therapy were analysed. 
 
7.3.2  Baseline demographics and serum BNP levels 
Baseline  demographics,  LV  dimensions  and  BNP  levels  are  shown  in  Table  7.1. 
Significantly more male patients studied were on haemodialysis compared to peritoneal 
dialysis. Correspondingly patients on HD were significantly taller. A significantly greater 
proportion of patients with diabetes were on PD. Patients on PD had been receiving renal 
replacement  therapy  for  a  shorter  duration.  LV  dimensions  were  significantly  larger  in 
patients on HD (LVMI 101.3 vs. 80.4 g m
-2, p=0.001; end diastolic volume/BSA 85.0 vs. 231 
 
66.6 p=0.003). Serum BNP and log10BNP levels were greater in patients on HD (mean 
log10BNP was 2.28 in HD patients vs. 1.77 in PD patients, p<0.001). 
 
7.3.3   Relationship between left ventricular dimensions and serum BNP levels 
Serum  log10  BNP positively  correlated  with  LVMI,  end  diastolic  volume/BSA  and  end 
systolic volume/BSA.  Serum BNP negatively correlated with LVEF. Similar degrees of 
correlation  were  demonstrated  in  both  patients  receiving  haemodialysis  and  peritoneal 
dialysis (Table 7.2). 
 
7.3.4  Serum  BNP  levels  in  patients  with  left  ventricular  hypertrophy  and/or  left 
ventricular systolic dysfunction 
Patients with LVH had significantly higher BNP levels than those without LVH (patients 
with LVH mean Log10BNP was 2.32 vs. 1.75 in patients without LVH, p<0.001) as did 
patients with LVSD (mean Log10BNP was 2.67 in patients with LVSD vs. 1.99 in patients 
without LVSD, p=0.001; Figure 7.1). The utility of BNP levels as a diagnostic test for LVH 
or LVSD was tested using area under receiver operator characteristic (ROC) curves. The 
area under the curve (AUC) for the diagnosis of LVH for the whole cohort population using 
BNP  was  0.74  and  0.78  for  a  diagnosis  of  LVSD  (Figure  7.2).  Table  7.3  gives  the 
sensitivity,  specificity,  and  positive  and  negative  predictive  values  for  a  BNP 
concentrations determined by optimum cut-point of the ROC for diagnoses of LVH and 
LVSD  in  the  whole  cohort,  as  well  as  patients  subdivided  by  dialysis  modality.  The 
sensitivity of BNP as a test for LVH was 50.0% and specificity was 85.4% and for LVSD 
the sensitivity and specificity were 69.2% and 83.3% respectively. 
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7.3.5  Relationship between BNP and presence of late gadolinium enhancement 
From  this  cohort, 92  patients  underwent  contrast  enhanced  CMR  with  intravenous  Gd-
DTPA-BMA underwent as described in Chapter 2. 30 (32.6%) patients had evidence of 
myocardial  fibrosis  indicated  by  LGE,  of  which  18  (19.6%)  had  subendocardial  LGE 
representing  old  myocardial  infarction  and  12  (13.0%)  had  diffuse  LGE.  Patients  with 
evidence of myocardial fibrosis indicated by LGE had higher serum BNP levels than LGE 
negative patients (LGE positive mean log10BNP 2.38 vs. 1.94 in LGE negative patients, 
p=0.003). Comparing subtypes of LGE, patients with subendocardial LGE had significantly 
higher BNP levels than LGE negative patients (subendocardial LGE log10BNP mean 2.54 
vs. 1.94 in LGE negative patients, p<0.001). There were no significant differences in BNP 
between patients with the two subtypes of LGE (subendocardial LGE mean log10BNP 2.54 
vs. 2.14 in diffuse LGE patients, p=0.158), nor were there significant differences between 
patients with diffuse LGE and LGE negative patients (Figure 7.3). 
 
Overall there was  a significant correlation between serum  BNP levels  and the mass of 
myocardial  fibrotic  tissue  indicated  by  LGE  (R=0.38,  p=0.041).  Patients  with 
subendocardial LGE demonstrated a significant correlation between serum BNP and mass 
of tissue indicated by LGE (R=0.50, p=0.034) shown in Figure 7.4, whilst in patients with 
diffuse LGE there was not a significant correlation between BNP and mass of myocardial 
fibrotic tissue (R=0.15, p=0.640). 233 
 
  Haemodialysis  Peritoneal Dialysis  p value 
Number (%)  60    37     
Age  51.4  (11.3)  53.7  (11.0)  0.322 
Male (%)  46  (76.7)  19  (51.4)  0.010 
Height (m)  170.9  (9.4)  166.2  (9.7  0.024 
Weight (kg)  75.1  (16.9)  74.3  (13.8  0.817 
RRT time (months)  26.4  (84.4)  6.2  (11.1)  <0.001 
Past history of IHD (%)  11  (18.3)  7  (18.9)  0.942 
Diabetes (%)  9  (15.0)  (16)  (43.2)  0.002 
Smoker (%)           
  Never  32  (53.3)  17  (45.9)   
  Current  18  (30.0)  13  (35.1)  0.226 
    Ex  10  (16.7)  7  (15.8)   
SBP (mmHg)  136.9  (27.3)  140.6  (22.8)  0.511 
DBP (mmHg)  81.8  (14.9)  82.5  (12.0)  0.814 
Ejection fraction (%)  66.6  (9.5)  66.5  (13.0)  0.978 
LV mass index (g m
-2)  101.3  (32.5)  80.4  (20.6)  0.001 
End diastolic volume/BSA (ml m
-2)  85.0  (31.0)  66.6  (20.6)  0.003 
End systolic volume/BSA (ml m
-2)  29.6  (18.4)  22.7  (13.1)  0.052 
BNP  191.0  (750)  54.0  (91)  <0.001 
Log10 BNP  2.28  (0.70)  1.77  (0.53)  <0.001 
Table 7.1   
Background demographics for dialysis patients. Results are show as mean with standard 
deviation in parenthesis or number with percentage in parenthesis as appropriate except for 
RRT  time  and  BNP  which  are  displayed  as  median  and  inter  quartile  range.  Tests  of 
significance are t-test and Chi-squared between groups, except for RRT time and BNP 
where Mann-Whitney-U was used 234 
 
  All patients  Haemodialysis  Peritoneal dialysis 
  Spearman’s R
  p  Spearman’s R
  p  Spearman’s R
  p 
Ejection fraction  -0.33  0.001  -0.33  0.011  -0.45  0.005 
LV mass  0.51  <0.001  0.47  <0.001  0.40  0.015 
End diastolic volume  0.51  <0.001  0.47  <0.001  0.40  0.013 
End systolic volume  0.52  <0.001  0.48  <0.001  0.54  0.001 
LV mass index  0.61  <0.001  0.58  <0.001  0.48  0.004 
End diastolic volume/BSA  0.58  <0.001  0.56  <0.001  0.43  0.011 
End systolic volume/BSA  0.56  <0.001  0.52  <0.001  0.58  <0.001 
 
Table 7.2 
Correlation co-efficients between ventricular dimensions and serum BNP 235 
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Figure 7.1  Box plots for Log10BNP in patients with and without LVH defined by CMR 
evidence (above) and LVSD (below) 
p<0.001
p=0.001236 
 
 
 
Figure 7.2  Receiver  operator  characteristic  curves  BNP  for  the  diagnosis  of  LVH 
(above) and LVSD (below)  237 
 
  Best cut-off  AUC for ROC curve  p  Sensitivity  Specificity  PPV  NPV 
  pmol/L  (95% CI)    % (95% CI)     
All patients               
LVH  196  0.74   (0.64-0.83)  <0.001  50.0 (36.3-63.7)  85.4 (70.8-94.4)  82.4  55.6 
LVSD  397  0.78   (0.68-0.86)  <0.001  69.2 (38.6-90.7)  83.3 (73.6-90.6)  39.1  94.6 
Haemodialysis               
LVH  196  0.73   (0.60-0.84)  <0.001  61.5 (44.6-76.6)  76.2 (52.8-91.7)  82.8  51.6 
LVSD  1082  0.82   (0.70-0.91)  0.002  71.4 (29.3-95.5)  90.6 (79.3-96.8)  50.0  96.0 
Peritoneal dialysis               
LVH  54  0.71   (0.54-0.85)  0.017  70.6 (44.1-89.6)  75.0 (50.9-91.2)  70.6  75.0 
LVSD  114  0.87   (0.72-0.96)  <0.001  83.3 (36.1-97.2)  87.1 (70.1-96.3)  55.6  96.4 
 
Table 7.3 
Areas under receiver-operator-characteristic curves for the use of BNP for the diagnosis of LVH and LVSD in the whole cohort, 
patients receiving haemodialysis and patients receiving peritoneal dialysis. Percent and 95% confidence intervals are shown for 
the threshold of best cut-point values. The best cut-point values are defined as those which maximise both sensitivity and 
specificity 238 
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Figure 7.3 
Box plots for Log10BNP in patients defined by subtype of LGE demonstrated by CMR  
p<0.001239 
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Figure 7.4   
Log transformed serum BNP level plotted against mass of subendocardial myocardial 
fibrosis indicated by LGE  
 
R=0.50 
p=0.034 240 
 
7.3.6  Prognostic value of brain natriuretic peptide 
During the follow up period eleven patients died. The median follow up period was 838 
days (inter quartile range 385). There were no significant differences in BNP between 
survivors and patients who died during the follow up period (survivors mean log10BNP 
2.09 vs. 1.98 patients who died, p=0.626). The influences of the measures of BNP on 
survival are shown as Kaplan-Meier survival curves in Figures 7.5.  
 
During the follow up period there were an additional seven non-fatal cardiovascular 
events  (five  patients  had  a  myocardial  infarction;  one  patient  underwent  coronary 
revascularisation and one patient had a cerebrovascular event). Again there were no 
significant differences in serum BNP between than survivors who remained event-free 
and  patients  who  had  a  non-fatal  cardiovascular  event  (event-free  patients  mean 
log10BNP 2.06 vs. 2.46 in patients who had a cardiovascular event, p=0.074). 
 
Combining death with non-fatal cardiovascular events as a combined cardiovascular end 
point (total of 18 events), there were no significant differences in serum BNP between 
than survivors who remained event-free and patients who had a non-fatal cardiovascular 
event (mean log10BNP 2.06 vs. 2.17 in patients who died, p=0.562).  241 
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Figure 7.5 
Kaplan-Meier survival curves for all cause mortality with patients stratified by serum 
BNP tertile 
 
 
 
 
 
 
p=0.180 242 
 
7.4  DISCUSSION 
 
7.4.1  Serum  BNP  in  cardiovascular  disorders  in  the  general  population  and 
ESRD 
BNP was originally isolated from porcine brain, and is produced in small amounts by 
the glomerular epithelial cells(275). The past decade has seen a developing role for the 
use of natriuretic peptides (both BNP and atrial natriuretic peptide- ANP) to screen for 
left ventricular dysfunction in the general population(272;276). Additionally, it is likely 
that using serum BNP levels will become a routine tool to assess response to therapeutic 
interventions in patients with chronic heart failure (CHF)(277). To date the situation is 
less  clear  in  patients  with  ESRD.  The  prognostic  implications  of  left  ventricular 
disorders  in  patients  with  ESRD  are  well  established  with  LVH,  left  ventricular 
dilatation and LVSD being associated with worse survival(76;77). There is a pressing 
need  for  new  diagnostic  and  prognostic  tools  to  identify  patients  with  ESRD  at 
increased risk of premature cardiovascular events, specifically those with structural and 
functional  abnormalities  of  the  left  ventricle,  to  facilitate  appropriate  and  timely 
therapeutic  intervention.  However,  in  dialysis  patients  there  is  difficulty  in  defining 
ventricular chambers volumes which are dependant on hydration status and vary in the 
intra-dialytic period. Furthermore, the levels of circulating natriuretic peptides depend 
on renal function, due to renal metabolism and excretion(278). Thus natriuretic peptide 
levels may be increased by volume overload due to intravascular volume and reduced 
renal clearance in the absence of any cardiac dysfunction(279). The high incidence of 
ventricular disorders in the dialysis, compared to the general population, may further 
alter the diagnostic potential of BNP as a screening test. 
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7.4.2  Basic pathophysiology of mechanisms of production, action and excretion of 
brain natriuretic peptide 
BNP is a 32 amino acid polypeptide (molecular weight 3.5 kDa), with a plasma half life 
of  approximately  22  minutes  in  healthy  individuals(280).  It  is  secreted  mainly  by 
cardiac ventricles and, to a small extent, by renal glomerular cells. Cardiac secretion is 
in  response  to  ventricular  volume  expansion,  pressure  overload  and  increased  wall 
tension. Thus, plasma BNP levels reflect the level of left ventricular overload and, in 
patients with CHF, BNP levels correlate with LV filling pressures, NYHA class and are 
inversely related to left ventricular ejection fraction, or exercise performance(281). BNP 
is synthesised as high molecular weight preproBNP in the ventricular myocardium, and 
enzymatically  cleaved  to  proBNP  in  response  to  myocyte  stretching.  It  is  thereafter 
released  as  hormonally  active  BNP  and  inactive  N-terminal-proBNP  (NT-
proBNP)(282).  
 
Serum levels of both BNP and NT-proBNP are elevated in patients with CHF and tend 
to change in parallel. However, due to differences in molecular size and metabolism 
there  is  variation  between  the  utility  of  BNP  and  NT-proBNP  in  the  diagnosis  of 
ventricular dysfunction or hydration status, specifically in patients with renal failure.  
BNP  is  eliminated  from  plasma  primarily  by  neutral  endopeptidase  receptors  and 
degraded. Although these enzymes are found in the kidney, glomerular filtration has 
only a minor role in elimination of BNP. NT-proBNP is a larger molecule (molecular 
weight 8.5kDa) and is  not cleared significantly by the clearance receptor or neutral 
endopeptidases(283). It has been speculated that clearance of NT-proBNP is principally 
by  renal  excretion.  These  confounding  factors  may  explain  the  direct  correlation 
between renal function and serum NT-proBNP levels and therefore the limited utility of 
serum NT-proBNP in patients with CKD(284).  244 
 
The physiological actions of BNP, and other natriuretic peptides, oppose the effects of 
over-activity  of  the  renin  angiotensin-aldosterone  system,  the  sympathetic  nervous 
system  and  endothelin-1.  In  the  kidney,  BNP  inhibits  sodium  resorption,  promoting 
natriuresis and increases glomerular filtration rate. The natriuretic peptides also relax 
vascular smooth muscle, causing both arterial and venous dilation, thereby reducing 
blood pressure and ventricular preload(271).  
 
Even in normal individuals there is considerable inter-individual variability in plasma 
BNP levels. This may contribute to susceptibility to volume overload and hypertension. 
From the Framingham dataset it appears that heritable factors may have a substantial 
role in determining plasma BNP levels, with a region suggestive of genetic linkage on 
chromosome 12p13(285). This finding provides insight into the mechanisms present in 
patients with normal ventricular dimensions and no obvious cause for a raised BNP. 
Moreover, due to its short half-life BNP production is dependent on continuing gene 
expression and translation.  
 
Several studies have investigated the impact of CKD on serum levels and metabolism of 
BNP. This issue is particularly vexed by the increasing prevalence of LVH in patients 
with progressive renal disease(78). Myocyte hypertrophy causes increased serum BNP 
even in the presence of normal renal function(286). As BNP can be found in relatively 
normal to high levels in the urine of patients with CKD, it can be assumed that BNP is 
cleared  sufficiently  by  the  endopeptidase  system  to  ensure  that  it  maintains  some 
diagnostic utility in the presence of renal impairment(287).  
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7.4.3  Results of study of diagnostic properties of serum brain natriuretic peptide 
in end stage renal disease 
In this cohort of patients BNP correlated more closely with LVMI than any parameter 
indicating  LV stretching (LV end diastolic or end systolic volume) or LV function, 
although there were also significant correlations between these factors and serum BNP 
levels.  However,  using  ROC  analysis  serum  BNP  appeared  to  be  a  worthwhile 
diagnostic tool in the diagnosis of either LVH or LVSD.  In particular BNP had a high 
negative predictive value (94.6%) for excluding the diagnosis of LVSD. Conversely, 
when used as a diagnostic tool for LVH, the reverse was true, with serum BNP having a 
high positive predictive value for LVH but a much lower negative predictive value. 
Either way, when compared to LV dimensions it would appear that BNP may be a 
useful indicator of patients with LV abnormalities requiring further assessment of LV 
function (with either echocardiography or CMR). In patients who underwent contrast 
enhanced CMR, perhaps unsurprisingly; higher BNP levels appeared to indicate patients 
with  previous  myocardial  infarction,  in  keeping  with  the  findings  of  Chapter  4 
suggesting that LVSD in uraemia is almost inevitably linked to underlying coronary 
artery disease. In the small number of patients with myocardial infarction, BNP directly 
correlated  with  the  mass  of  infarcted  tissue.  Whether  this  indicates  that  BNP  is 
produced primarily by infarcted tissue or as a secondary response to the presence of 
infarction is unclear from this study. Laboratory studies of cultured cardiac fibroblasts 
suggest  that  BNP  is  likely  to  be  produced  in  response  to,  and  to  counteract  the 
production of myocardial fibrosis(288). 
 
 BNP was higher in patients on haemodialysis than peritoneal dialysis. Whilst this is 
likely to be related to greater LV mass, some studies have suggested that the presence of 246 
 
an arteriovenous fistula as vascular access for haemodialysis may additionally lead to 
raised natriuretic peptide levels by increasing cardiac output(112). 
 
7.4.4  Diagnostic properties of brain natriuretic peptide in the general population 
One of the most promising uses of serum BNP is in the assessment of left ventricular 
dysfunction. Population based studies have shown that it may be an effective tool for 
screening for asymptomatic left ventricular dysfunction. By identifying patients with 
asymptomatic  left  ventricular  dysfunction  it  is  likely  that  evolution  to  clinical  heart 
failure  will  be  prevented  by  instigating  evidence  based  therapy  with  angiotensin 
converting enzyme (ACE) inhibitors and beta-blockers. Examples of studies using BNP 
to screen or diagnose echocardiographic LVSD or clinical heart failure are listed: 
•  In  one  population  based  study  the  presence  of  a  raised  BNP  concentration 
(greater than 5.2 pmol/L) gave an overall sensitivity of 77% and specificity of 
87% (92% and 72%, respectively, in participants aged 55 years or older) for the 
presence of echocardiographic LVSD. However, this population based study has 
either  not  reported  renal  dysfunction  in  the  main  analysis  and  subsequently 
found renal failure to be associated with the presence of a raised serum BNP (or 
NT-BNP) despite normal echocardiographic findings(272;289). 
•  In patients with of acute dyspnoea presenting to hospital, the large “Breathing 
Not Properly” study found a raised BNP to be better than any clinical variable at 
predicting a final diagnosis of heart failure One of the most useful points to 
emerge from this study is that in this setting BNP appears to be an extremely 
useful tool for ruling out heart failure with a negative predictive value of 90% 
for a BNP threshold of 28.9 pmol/L with a sensitivity of 90% for a diagnosis of 
heart failure(290). It should be noted that patients with severe renal failure (GFR 
<15ml/min/1.73m
2 or dialysis dependent) were excluded from this study 247 
 
•  In the BNP for Acute Shortness of Breath Evaluation (BASEL) study, a BNP 
based  strategy  for  the  initial  assessment  and  management  of  patients  with 
dyspnea  can  prevent  hospitalisation,  the  need  for  intensive  care  and  reduce 
length of hospital stay in patients presenting with acute dyspnoea. Furthermore, 
these improvements ensure that treatment of these patients is carried out in a 
cost effective manner(291) 
 
The obvious difference between these population based studies and the cohort of ESRD 
patients is that the diagnostic cut points for either LVSD or LVH is much greater in 
ESRD than in the general population (196 pmol/L for LVH and 397pmol/L for LVSD). 
This is in keeping with findings of a previous study from our group and is likely to 
reflect both the reduced clearance of BNP in ESRD and the greater prevalence of LVH 
in patients with ESRD. From these and other studies, it is apparent that serum BNP is a 
promising diagnostic tool for the diagnosis of left ventricular dysfunction in the general 
population, either used as a targeted screening measure in asymptomatic patients, as part 
of  the  diagnostic  workup  of  patients  presenting  with  acute  dyspnoea  or  to  monitor 
response to therapy. The current study suggests that BNP may be a useful tool in the 
ESRD  population,  although  our  previous  findings  suggest  than  the  same  diagnostic 
utility does not hold true across a spectrum of CKD(292). 
 
7.4.5  Diagnostic properties of BNP in end stage renal disease 
The high prevalence of LVH and LVSD in ESRD (compared to the general population) 
poses an additional problem that may limit the diagnostic screening potential of BNP, 
notwithstanding the additional problems of defining appropriate serum BNP levels in 
ESRD.  Nevertheless,  there  have  been  some  other  promising  studies  that  assess  the 
diagnostic potential of BNP in dialysis patients: 248 
 
•  In  an  echocardiographic  study  combining  both  haemodialysis  and  peritoneal 
dialysis patients, a close correlation was found  between serum  BNP and  LV 
mass.  BNP  had  a  high  sensitivity  (88%)  for  the  diagnosis  of  LVH,  with  a 
positive predictive value of 87%. In the same study BNP was a less impressive 
marker for LVSD with a sensitivity of 94% but a specificity of only 22%(273) 
•  It  has  been  reported  that  BNP  levels  are  lower  in  PD  patients  than  in  HD 
patients(293). Whether this is due to reduced cardiac stress in PD patients, as 
suggested by the  authors, or due to  a reduction in BNP related to improved 
residual renal function in PD patients is not addressed by this small study 
•  Although BNP levels are generally higher in ESRD patients with LVSD, the 
relationship between BNP and LV ejection fraction does not appear to be as 
strong as its correlation with LV mass(273). In studies assessing the relationship 
between BNP and the presence of atherosclerotic coronary disease, it appears 
that HD patients with CAD have higher levels of serum BNP that those with 
normal coronary arteries(294). This supports the notion of a close association 
between LVSD and coronary artery disease in ESRD as demonstrated in Chapter 
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Many of these studies specifically excluded patients with a history of CHF, exposing 
limitations  on  these  investigations  into  the  relationship  between  serum  BNP  and 
severity  of  LVSD  as  the  patients  with  most  severe  cardiac  dysfunction  have  been 
excluded. This current study suggests that, while BNP shows potential as a marker of 
LVH and has been proposed to be a further therapeutic target to assess regression of 
LVH, it is unlikely that serum BNP will be able to replace echocardiography (or CMR) 
in  the  diagnosis  of  LVSD.  Further  study  is  required  of  a  larger  number  of  dialysis 249 
 
patients to define BNP levels consistent with normal LV dimensions, LVH and LVSD 
taking into account hydration status, to improve the diagnostic utility of BNP. 
 
7.4.6  Prognostic role of serum brain natriuretic peptide in end stage renal disease 
Serum BNP was highest in the patients who were at highest cardiac risk, based on CMR 
findings  and  previous  reports  on  the  prognostic  implications  of  uraemic 
cardiomyopathy. In this study however, BNP did not predict patients likely to die or 
have a cardiac  event during the follow up period. Possible limitations of this study 
include  the  small  cohort  of  patients,  relatively  short  follow  up  period  and  limited 
number  of  events.  On  the  basis  of  this  study  alone  BNP  does  not  provide  useful 
prognostic  information  for  the  management  of  patients  with  ESRD.  This  finding 
conflicts  with  other  similar  studies  in  this  ESRD  population.  As  well  as  providing 
diagnostic value, a number of studies have shown the prognostic value of serum BNP in 
dialysis patients:  
•  The CREED investigators have demonstrated that serum BNP appears to be an 
important  predictor  of  mortality  in  a  group  of  haemodialysis  and  peritoneal 
dialysis  patients,  independent  of  LV  mass  and  LV  function(274).  This  is  an 
important finding given the interdependence of these factors already outlined 
•  Other studies of shown that in patients on maintenance HD with no prior history 
of cardiac events, an elevated BNP is significantly associated with an increased 
risk of cardiovascular mortality. These studies however all had a relatively low 
number  of  events  (13-16  events)  and  it  of  interest  that  despite  fairly  similar 
cohort size and follow up time, their results appear to conflict with the current 
study(295;296) 
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Therefore based on these and the current study it is clear that the role of serum BNP as a 
prognostic marker for patients on renal replacement therapy, needs to be defined in 
larger studies, specifically controlling for the presence of coronary artery disease, itself 
a major determinant of both LVSD and poor cardiovascular outcomes.  
 
7.4.7  Other potential roles for brain natriuretic levels in end stage renal disease 
BNP has been touted as a potential marker to assess hydration status in the dialysis 
patient. As natriuretic peptides are secreted in response to myocardial stretch, and are 
therefore increased in patients with hypervolaemia, and BNP measurement may guide 
assessment  of  ‘dry  weight’  in  the  haemodialysis  patient.  From  a  physiological 
standpoint, atrial natriuretic peptide has been shown to increase in response to volume 
overload,  and  theoretically  would  appear  to  the  most  promising  for  assessment  of 
volume status. A number of studies have tried to compare the use serum BNP to assess 
hydration status with measurement of extracellular water content by bioimpedance or 
inferior  vena  caval  diameter(297;298).    Results  of  these  studies  have  also  been 
disappointing, with a lack of a correlation between  BNP levels and pre- and  post-
dialysis hydration status, although pre-dialysis BNP appeared to a significant predictor 
of pre dialysis over hydration indicated by extra-cellular fluid/total body water ratio 
assessed by bioimpedance(298). Again difficulty exists in interpreting these studies if 
the confounding factor of increased LVM is taken into account.  
 
As  BNP  has  been  shown  to  predict  survival  in  some  studies  in  ESRD  a  role  may 
develop for the use of BNP as a goal of treatment in interventional studies in ESRD. 
This approach has been used in patients with heart failure. One short study, using BNP 
levels to guide titration of ACE inhibitor dosage, showed a more favorable response in 
heart  rate  and  other  neurohumoral  factors  in  patients  whose  therapy  was  titrated 251 
 
specifically to reduce BNP levels(299). However, this possibility has yet to be tested in 
this population in large trials in either heart failure or the ESRD population. One small 
study has shown a significant reduction in BNP levels in 14 haemodialysis patients with 
LV dilatation in response to metoprolol therapy, with a corresponding improvement in 
ventricular dimensions(300). 
 
7.4.8  Effect of dialysis on serum BNP   
In considering the effect of haemodialysis therapy on serum BNP levels, there are two 
factors to take into account. Firstly, BNP has a half life in non-uraemic patients of 
approximately  22  minutes,  and  is  cleared  by  endopeptidases.  It  is  likely  that 
ultrafiltration (during dialysis treatment) will lead to reduced ventricular stretch and 
reduced serum BNP levels, due to reduced production. Secondly, any clearance by the 
dialysis process itself must be taken into account.  However BNP is a relatively large 
molecule and there is conflicting evidence for this effect. In one study assessing the 
relationship  between  BNP  and  hydration  status  there  was  no  significant  difference 
observed in pre- and post-dialysis serum BNP(298). Other studies have shown BNP to 
be reduced by haemodialysis and it appears that dialytic clearance is of importance as in 
both  these  studies  greater  clearance  of  BNP  is  achieved  with  a  high  flux  dialyzer. 
Moreover,  whilst  BNP  is  reduced  by  dialysis  with  both  high  and  low  flux  dialysis 
membranes NT-BNP appears to only be significantly reduced by a high flux membrane. 
Crucially, in one of these studies dialysate BNP was measured and both BNP and NT-
BNP were found to be partially cleared by dialysis(301). These results are intriguing 
and it is clear that larger studies of this nature are required to assess thoroughly the 
impact of the dialysis process on serum BNP levels.  
 252 
 
7.4.9  Conclusions 
Serum  BNP  has  emerged  as  a  rapid,  convenient  diagnostic  tool  for  identifying  and 
managing patients with heart failure.  In the ESRD population BNP appears to have a 
role  in  assessing  LVH  and  complementing  echocardiography  or  CMR  in  evaluating 
patients with symptoms or clinical signs of LV dysfunction. A raised BNP carries at 
least  important  diagnostic  value  and  may  provide  further  prognostic  information 
(although not in this study). It may yet have a potential role as a target for intervention 
in the attempt to reduce cardiovascular disease in the ESRD population. It is likely that 
the role of BNP-targeted therapy requires better definition in the general population 
patients with heart failure (in which there is evolving evidence) prior to translating this 
to ESRD. A cut-off point in ESRD needs to be defined for which further assessment of 
ventricular  function  is  required  in  patients  with  ESRD.  Such  cut-points  have  been 
demonstrated  in  this  study  and  these  now  require  prospective  validation.  This  is 
particularly true in asymptomatic patients who may benefit from additional therapeutic 
interventions to prevent the evolution of either progressive LVH or LVSD which are 
associated with reduced survival.   253 
 
 
 
Chapter 8 
 
 
A study of vascular function with cardiovascular magnetic resonance imaging in 
end stage renal disease 254 
 
8.1  INTRODUCTION 
Arterial function is deranged in patients with ESRD. This is due to a combination of 
both  accelerated  arteriosclerosis  and  atherosclerosis.  Epidemiological  studies  have 
shown that increased arterial stiffness, most commonly assessed by measurement of 
pulse wave velocity (PWV) or augmentation index, is independently associated with 
cardiovascular morbidity and mortality in these patients(302;303). However, although 
these studies are generally felt to be robust, using applanation tonometry as an indirect 
measure of central arterial function may be prone to limitations. Cardiac MRI permits 
visualisation of large arteries and blood flow. It thereby facilitates direct measurement 
of aortic compliance and aortic pulse wave velocity. Although blood flow and pulse 
wave  velocity  have  been  extensively  studied  with  MRI  in  healthy  volunteers,  few 
studies have been performed using MRI to assess vascular function in any pathological 
disease state. 
 
CMR potentially offers an integrated method of assessing vascular as well as ventricular 
function during the same examination. Given the strong relationship between vascular 
stiffness  and  outcome  in  ESRD,  CMR  measures  of  vascular  function  may  identify 
patients at increased cardiovascular risk. As patients with ESRD are at extremely high 
cardiovascular risk with an  established link between  altered arterial compliance and 
outcome,  they  represent  an  ideal  patient  population  to  validate  this  technique  for 
translation for use in other patient groups at risk of cardiovascular disease.  
 
The following pilot studies were performed in order to: 
•  develop methods for measuring vascular function using CMR 
•  validate the relationship between CMR measures of vascular function, namely 
aortic distensibilty, aortic volumetric arterial strain(VAS) and PWV 255 
 
•  assess  the  relationship  between  CMR  measures  of  vascular  function  and 
conventional cardiovascular risk factors 
•  establish a cohort of patients to determine the long term prognostic implications 
of CMR measures of vascular function 
 
8.2  METHODS 
 
8.2.1  CMR measures of aortic distensibilty and pulse wave velocity 
All  patients  and  volunteers  underwent  CMR  imaging  of  both  the  left  ventricle  and 
thoracic aorta as described in detail in section 2.3.2. Gd-DTPA-BMA was administered 
to all patients bar exceptions as described as exceptions in section 3.4. Contrast was not 
administered to controls. Scan time to perform only the measures of vascular function 
was 12 minutes. 
 
8.2.2  Measurement of aortic distensibilty 
This was performed as described in detail in section 2.4.3. Briefly aortic distensibilty 
was calculated from change in aortic volume and simultaneous brachial blood pressure 
acquired during the scan using the formula: 
 
where  (Aortic  volume)max  and  (Aortic  volume)min  are  the  maximal  and  minimal 
calculated aortic volumes obtained during the cardiac cycle.  256 
 
Aortic  volumetric  arterial  strain  (VAS),  which  is  non-pressure  dependent,  was 
calculated from the formula: 
 
8.2.3  CMR measurement of pulse wave velocity 
PWV  was  measured  as  described  in  detail  in  section  2.4.3.  Briefly,  velocity  was 
calculated from blood flow along the aorta at three points-  the ascending aorta at the 
level of the bifurcation of the pulmonary trunk, the transversely contiguous position of 
the descending aorta and the junction of the thoracic and abdominal aorta at the level of 
the diaphragm.  
 
PWV was calculated from the distance between these points and the time delay between 
propagation of the flow wave from each point using the equation: 
Pulse wave velocity = Distance/Time 
 
Pulse wave velocity was calculated over two distances- ascending aorta-diaphragmatic 
level aorta (PWV 1-3), and ascending aorta-contiguous descending thoracic aorta (PWV 
1-2). This was to account for cases where PWV from ascending aorta-diaphragmatic 
level aorta measurement was not possible due to the tortuous vessel preventing accurate 
aortic length and flow patterns being recorded.    
 
8.2.4  Applanation tonometry measurement of pulse wave velocity 
Healthy  volunteers  underwent  measurement  of  PWV  was  using  the  SphygmoCor 
system (AtCor Medical, West Ryde, Australia) on the same day as CMR scanning by 
Dr Lukas Zimmerli (University of Glasgow). After 15 minutes of rest in the supine 257 
 
position, pulse wave velocity measurements were performed by applanation tonometry. 
Aortic PWV was assessed by the time difference between pulse wave upstrokes, which 
were consecutively measured at the right carotid artery and right femoral artery and 
aligned by ECG-based trigger. 
 
8.2.5  Follow up 
Follow up data was collected from date of the CMR scan to 9
th November 2006 using 
electronic patient records from the Western Infirmary, Glasgow and Glasgow Royal 
Infirmary Renal Units. With this cohort, death and cardiovascular events (myocardial 
infarction,  cerebrovascular  event,  coronary  revascularisation  and  amputation  for 
peripheral vascular disease) were collected as end points. 
 
8.2.5  Statistical methods 
Correlations between cardiac dimensions, measures of arterial function and continuous 
clinical variables by the various methods were assessed with Pearson and Spearman 
correlation co-efficient as appropriate. Differences between groups were tested by t-test 
and  Mann-Whitney-U  test.  Measures  of  vascular  function  were  compared  between 
patients  who  died  or  had  a  vascular  event  during  the  follow  up  period  with  these 
measures  divided  into  tertiles  or  quartiles  and  subjected  to  an  unadjusted  survival 
analysis by the Kaplan–Meier method. Statistical significance was determined by the 
log-rank  test.  The  data  were  then  analysed  by  Cox  survival  analysis  to  assess  the 
influence of multiple variables on outcome. Variables identified as possibly influential 
on outcome by univariate analysis were then entered into a forward stepwise regression 
model. All analyses were performed using the SPSS 13.0 statistical software package 
(SPSS Inc., Chicago, IL., USA) except comparison between SphygmoCor and CMR 258 
 
measurement of PWV which was performed using Bland-Altman plots on the MedCalc 
8.1 software package (MedCalc Software, Belgium). 
 
8.3  RESULTS 
 
8.3.1  Patient and control demographics  
Patient demographics at the time of scan are shown in Table 5.1. 147 patients with 
advanced renal failure and 20 controls were studied. The groups of controls and uraemic 
patients had a similar age and sex distribution. A total of 144 patients had aortic VAS 
measurement  and  122  patients  had  measurement  of  aortic  distensibilty  available  for 
analysis.  22  patients  did  not  have  blood  pressure  readings  to  calculate  distensibilty 
(either due to bilateral arteriovenous fistulae for dialysis making recording impossible, 
sphygmomanometer failure or due to blood pressure being recorded non-synchronously 
with the aortic distensibilty trace). The automated sphygmomanometer was broken for a 
portion  of  the  study  reducing  the  number  of  successful  blood  pressure  recordings. 
Combined aortic compliance and PWV were available in 19 control subjects and 116 
patients. 28 PWV traces performed with CMR were not of sufficient technical quality 
for analysis either due to tortuous vessels, patient movement or failure of computer 
analysis of the trace.  
 
8.3.2  Measures of vascular function 
Demographic  and  vascular  function  data  are  shown  in  Table  8.1.  No  significant 
differences  in  patient  demographics  or  vascular  function  were  exhibited  between 
patients with advanced renal failure not yet on dialysis therapy (24 patients, 16.3% of 
the uraemic group) and those established on renal replacement therapy (123 patients, 
83.7% of the uraemic group) and therefore these patients were combined as a single 259 
 
‘uraemic’ group. Systolic and diastolic blood pressures were higher in uraemic patients 
than controls as expected.  
 
Cross sectional aortic volume (i.e. cross sectional aortic area multiplied by the slice 
thickness)  was  significant  greater  in  uraemic  patients.  Aortic  distensibilty  and  VAS 
were significantly lower in uraemic patients than controls (median distensibilty 2.4 x 10
-
3 vs. 4.9 x 10
-3 mmHg
-1, p<0.001; VAS 0.13 vs. 0.19, p=0.001), whilst PWV 1-3 was 
non-significantly higher compared to controls (median 7.5 vs. 6.7 m s
-1, p=0.069). PWV 
1-2 was numerically higher in uraemic patients compared to controls (median 7.1 vs. 
6.4 m s
-1, p=0.620).  
 
8.3.3  Comparison between CMR and applanation tonometry for measurement of 
pulse wave velocity 
Combined measurement of PWV by applanation tonometry and CMR was performed in 
14 healthy volunteers.  Mean difference between the two measures was 0.2 m s
-1.   The 
comparison between the two methods of measurement of PWV is shown as a Bland 
Altman plot (Figure 8.1). 
 
8.3.4  Haemodynamic  relationship  between  pulse  wave  velocity,  aortic 
distensibilty and volumetric arterial strain 
As both PWV and aortic distensibilty exhibited skewed distributions log transformation 
was  performed.  Pulse  wave  velocity  displayed  a  significant  negative  correlation 
between  aortic  distensibilty  (PWV  1-3  R=  -0.48,  p<0.001;  PWV  1-2  R=    -0.37, 
p<0.001) and VAS (PWV 1-3 R= -0.47, p<0.001; PWV 1-2 0.38, p<0.001) in uraemic 
patients but not controls (aortic distensibilty-PWV 1-3, R= -0.35, p=0.139; VAS-PWV 
1-3, R= -0.38, p= 0.111). Overall Spearman correlation co-efficient for the whole group 260 
 
(combined  uraemic  and  control)  for  PWV1-3  was  R=  -0.49,  p<0.001  for  aortic 
distensibilty and R= -0.48, p<0.001 for aortic VAS (Figure 8.2).  
 
Assessing  the  relationship  between  central  haemodynamics  and  aortic  vessel 
characteristics, there was a significant correlation between cross sectional aortic volume 
and diastolic blood pressure in both uraemic patients (R = 0.242, p=0.007) and controls 
(R = 0.54, p=0.015), but not between aortic cross sectional area and  either systolic 
blood pressure or pulse pressure. PWV correlated directly with both systolic (PWV 1-3 
R= 0.32, p=0.004, PWV 1-2 R= 0.28, p=0.006) and diastolic blood pressure (PWV 1-3 
R= 0.26, p=0.020, PWV 1-2 R= 0.33, p=0.001).  261 
 
 
  Uraemic  Control  p value 
Number  147    20     
Age  51.5  (11.2)  49.6  (9.4)  0.469 
Male (%)  93  (63.3)  12  (60)  0.777 
Height (m)  169.6  (9.7)  170.7  (8.8)  0.640 
Weight (kg)  76.0  (16.0)  74.9  (10.3)  0.770 
On dialysis (%)  123  (83.7)  -    - 
RRT time (months)  8.0  (55.6)  -    - 
Past history of IHD (%)  24  (16.3)  -    - 
Diabetes (%)  47  (32.0)  -    - 
Smoker (%)           
  Never  85  (57.8)  13  (65.0)   
  Current  39  (26.5)  2  (10.0)  0.220 
    Ex  23  (15.6)  5  (25.0)   
SBP (mmHg)  139.7  (24.6)  116.4  (9.9)  <0.001 
DBP (mmHg)  82.6  (13.0)  74.8  (7.4)  0.010 
Cross sectional aortic volume (mL)  5.0  (2.0)  3.5  (0.9)  <0.001 
Aortic distensibilty (x 10
-3 mmHg
-1)  2.4  (2.0)  4.9  (2.9)  <0.001 
Aortic volumetric arterial strain  0.13  (0.09)  0.19  (0.11)  0.001 
PWV 1-2 (m s
-1)  7.1  (4.5)  6.4  (2.5)  0.620 
PWV 1-3 (m s
-1)  7.5  (3.1)  6.7  (2.9)  0.069 
Table 8.1 
Background demographics for uraemic patients and controls. Results are show as mean 
with  standard  deviation  in  parenthesis  or  number  with  percentage  in  parenthesis  as 
appropriate,  except  for  RRT  time  and  measures  of  vascular  function  which  are 
displayed as median and inter quartile range. Tests of significance are t-test and Chi-
squared  between  groups,  except  for  measures  of  vascular  function  where  Mann-
Whitney-U was used 262 
 
 
 
 
 
 
Figure 8.1 
Bland Altman plot comparing CMR and applanation tonometry (SphygmoCor) methods 
for measuring pulse wave velocity in healthy volunteers 
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8.3.5  Clinical correlates of aortic distensibilty and volumetric arterial strain 
Aortic  distensibilty  demonstrated  a  significant  negative  correlation  with  age  in  both 
uraemic  patients  (aortic  distensibilty  R=  -0.44,  p<0.001,  VAS  R=  -0.44,  p<0.001; 
Figure  8.3)  and  controls  (aortic  distensibilty  R=  -0.55,  p=0.013,  VAS  R=  -0.45, 
p=0.047).  
 
In uraemic patients there were no significant correlations between haemoglobin, dialysis 
adequacy  (either  urea  reduction  rate  in  haemodialysis  or  creatinine  clearance  in 
peritoneal dialysis), time on renal replacement therapy, any lipid parameter, C - reactive 
protein, calcium, phosphate or calcium phosphate product and aortic distensibilty or 
VAS.  There  were  no  significant  differences  in  aortic  distensibilty  or  compliance 
between genders. Aortic distensibilty and VAS were significantly reduced in patients 
with  diabetes  mellitus  (diabetics  –  median  aortic  distensibilty  1.8  x  10
-3    vs.  non-
diabetics 2.8 x 10
-3 mmHg
-1, p=0.001; VAS 0.11 vs. 0.15, p=0.001), patients with a past 
history of ischaemic heart disease (median aortic distensibilty 1.8 x 10
-3  vs. 2.6 x 10
-3  
mmHg
-1,  p=0.028;  VAS  0.11  vs.  0.15,  p=0.009;  Figure  8.4)  or  peripheral  vascular 
disease (median aortic distensibilty 1.2 x 10
-3 vs. 1.8 x 10
-3 mmHg
-1, p=0.005; VAS 
0.14 vs. 0.07, p=0.015).   
 
No significant differences in aortic distensibilty or VAS between patients treated with 
statin therapy, or those requiring antihypertensive therapy. There were no significant 
differences between aortic distensibilty between dialysis modalities nor was there any 
correlation between time on renal replacement therapy and aortic distensibilty or VAS.  264 
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Figure 8.2  Scatter  plot  of  log  transformed  pulse  wave  velocity  plotted  against 
negative log transformed aortic distensibilty 
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Figure 8.3   Scatter  plot  of  negative  log  transformed  aortic  distensibilty  plotted 
against age for normal controls and uraemic patients 
R=0.49, p<0.001 
Uraemic R=0.44, p<0.001 
Normal   R=0.55, p<0.05 265 
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Figure 8.4  
Box  and  whisper  plots  of  log  transformed  aortic  distensibilty  in  patients  with  and 
without a past medical history of diabetes mellitus and ischaemic heart disease 
p=0.001 
p=0.028 266 
 
8.3.6  Relationships between aortic distensibilty and left ventricular dimensions 
and late gadolinium enhancement 
Significant  negative  correlations  were  demonstrated  between  aortic  distensibilty  and 
LVMI (R= -0.21, p=0.021) and end systolic volume (R= -0.18, p=0.048) but no other 
LV  dimension.  Aortic  VAS  correlated  with  markers  of  cardiac  function  -  ejection 
fraction (R= 0.23, p=0.006) and stroke volume (0.19, p=0.024). Of the 119 patients who 
had  combined  vascular  function  measures  with  Gd-DTPA-BMA  contrast  enhanced 
studies, 37 (31.1%) patients had evidence of myocardial fibrosis indicated by LGE as 
described  in  Chapter  3  of  which  20  (14.6%)  patients  had  subendocardial  LGE 
representing previous myocardial infarction and 17 (12.4%) had diffuse LGE. Patients 
who were positive for LGE had lower aortic distensibilty and VAS than LGE negative 
patients (median aortic distensibilty 2.0 x 10
-3 for LGE positive vs. 2.8 x 10
-3 mmHg
-1 
for  LGE  negative  patients,  p=0.027;  VAS  0.11  vs.  0.14,  p=0.056).  Patients  with 
subendocardial  LGE  representing  previous  myocardial  infarction  had  significantly 
lower aortic distensibilty and VAS than patients who were LGE negative (median aortic 
distensibilty 1.6 vs. 2.2 x 10
-3 mmHg
-1 p=0.008; VAS 0.09 vs. 0.14, p=0.006). There 
were no significant differences in aortic distensibilty or  VAS between  patients with 
diffuse  LGE  and  patients  with  subendocardial  LGE.  Additionally  there  were  no 
significant differences between patients with diffuse LGE and LGE negative patients 
(Figure 8.5). 
 
In  patients  with  subendocardial  LGE,  there  was  a  significant  negative  correlation 
between  aortic  distensibilty  and  the  absolute  mass  of  fibrotic  myocardial  tissue 
represented  by  subendocardial  LGE  (R=  -0.57,  p=0.032).  There  was  additionally  a 
negative  correlation  between  percentage  of  the  LV  mass  occupied  by  fibrotic 
myocardium and aortic  distensibilty  (R=  -0.54,  p=0.047; Figure 8.6).    A significant 267 
 
correlation between aortic distensibilty or VAS and mass of myocardial fibrosis was not 
present in patients with diffuse LGE. 
 
8.3.7  Clinical correlates of pulse wave velocity 
In uraemic patients, but not controls, increased PWV correlated significantly with age 
(PWV 1-3 R= 0.41, p<0.001, PWV 1-2 R= 0.34, p<0.001; Figure 8.7).  In uraemic 
patients there were no significant correlations between haemoglobin, dialysis adequacy 
(either  urea  reduction  rate  in  haemodialysis  or  creatinine  clearance  in  peritoneal 
dialysis), time on renal replacement therapy any lipid parameter, C - reactive protein, 
phosphate or calcium phosphate product and PWV. There was however a significant 
negative correlation between serum corrected calcium and PWV (PWV 1-3 R= -0.22, 
p=0.034)  and  with  serum  albumin  (PWV  1-2  R=  -0.25,  p=0.007)  There  were  no 
significant differences in PWV between genders.  
 
Although  PWV  was  numerically  higher  in  patients  with  diabetes,  a  past  history  of 
ischaemic  heart  disease  of  peripheral  vascular  disease  compared  to  those  patients 
without this conditions none of these differences were statistically significant. There 
were no significant relationships demonstrated  between PWV and  cardiac mass  and 
function or between the presence or extent of myocardial fibrosis demonstrated by LGE. 
 
There were no differences in systolic or diastolic blood pressure at the time of scanning 
between patients not requiring antihypertensive therapy (n=68) and those treated with 
either  calcium  channel  antagonist  (n=29)  or  angiotensin  converting  enzyme 
inhibitor/angiotensin receptor blocker monotherapy (n=27) or a combination of these 
agents  (n=19).  However  PWV  was  non-significantly  higher  in  patients  treated  with 
calcium channel antagonist monotherapy compared to those treated with angiotensin 268 
 
converting  enzyme  inhibitor/angiotensin  receptor  blocker  monotherapy  (calcium 
channel antagonist group - median PWV 1-2 7.1 m s
-1 inter quartile range (IQR) 7.3 vs. 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker group - median 
PWV 1-2 7.2 m s
-1 IQR 2.9, p=0.067; Figure 8.8). 269 
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Figure 8.5   
Box and whisper plots of log transformed aortic distensibilty in patients divided by 
pattern of late gadolinium enhancement 
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Figure  8.6  Mass  of  subendocardial  myocardial  fibrosis  indicated  by  LGE  plotted 
against log transformed aortic distensibilty 
p= 0.006 
R = -0.57, p=0.032 270 
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Figure 8.7   Scatter  plot  of  log  transformed  pulse  wave  velocity  plotted  against  age  for 
normal controls and uraemic patients 
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Figure 8.8  Box  and  whisper  plots  of  log  transformed  pulse  wave  velocity  in  patients 
divided by antihypertensive therapy. Abbreviations CA – calcium channel antagonist, MonoRx 
– monotherapy, ACEi - angiotensin converting enzyme inhibitor, ARB - angiotensin receptor 
blocker 
R= 0.41, p<0.001 271 
 
8.3.8  Relationship between CMR measures of vascular function on survival and 
combined mortality and cardiovascular events 
Follow up data combined with vascular function measurements were available for 144 
patients. The median follow up period was 719 days (IQR 375 days). Over the follow 
up period there were 20 deaths, giving an overall mean death rate in this cohort of 76.2 
per 1000 patient years. Patients who died had significantly lower aortic distensibilty 
than those who where alive at the end of the follow up period. There were no significant 
differences in VAS or PWV between survivors and patients who died.  Analysing the 
effect of blood pressure at the time of the scan on survival demonstrated that patients 
who died had significantly higher systolic and pulse pressure than survivors, but there 
were no significant differences in diastolic blood pressure (Table 8.2). The influences of 
the  measures  of  vascular  function  on  survival  are  shown  as  Kaplan-Meier  survival 
curves in Figures 8.9 and 8.10.  
 
During the follow up period there were an additional 12 non-fatal cardiovascular events 
(five  patients  had  a  myocardial  infarction;  four  patients  underwent  coronary 
revascularisation, two patients undergoing amputation for peripheral vascular disease 
and one patient had a cerebrovascular event). These patients had significantly lower 
aortic distensibilty and VAS than survivors who remained event free. Pulse pressure in 
these  patients  was  higher.  There  were  no  significant  difference  in  blood  pressure 
between  than  survivors  who  remained  event  free  and  patients  who  had  a  non-fatal 
cardiovascular event. 
 
Combining death with non fatal cardiovascular events as a combined cardiovascular end 
point, overall patients who reached this combined end point had significantly lower 
aortic distensibilty (median 1.7 x 10
-3 vs. 2.7 x 10
-3 mmHg
-1, p<0.001) and VAS (0.12 272 
 
vs. 0.14, p=0.006) and higher systolic blood pressure (mean 152.9 vs. 136.5 mmHg, 
p=0.001) and pulse pressure (mean 67.0 vs. 54.5 mmHg, p=0.001) than those who did 
not. The influences of the measures of vascular function on cardiovascular vents are 
shown  as  Kaplan-Meier  survival  curves  in  Figures  8.11  and  8.12.  There  were  no 
significant differences in either diastolic blood pressure (mean 85.9 vs. 82.0 mmHg, p= 
0.154) or pulse wave velocity (median PWV 1-2 6.5 vs. 7.1 m s
-1 p=0.387; median 
PWV 1-3 7.4 vs. 7.5 m s
-1, p= 0.711) between those who reached the combined end 
point and those who did.   
 
8.3.9  Multivariate analysis of relationship between CMR measures of vascular 
function and survival 
In  a  Cox  forward  stepwise  regression  model  assessing  patient  survival;  diabetes, 
systolic  blood  pressure  and  aortic  distensibilty  were  identified  as  significant 
independent predictors of patient survival. In a similar analysis assessing the combined 
cardiovascular end point of death or a vascular event; diabetes, aortic distensibilty and 
aortic VAS were significant predictors of events. Due to their close interdependence, 
blood pressure variables and aortic distensibilty were entered individually into the each 
model to determine their influence. Similarly either aortic distensibilty or VAS were 
entered individually to the model but not together.  273 
 
 
  Alive  Dead  p value 
Number  124  (86.1)  20  (13.9)   
Age  51.5  (11.3)  51.9  (11.1)  0.876 
Male (%)  80  (64.5)  10  (50.0)  0.213 
On dialysis (%)  102  (82.3)  18  (18.0)  0.363 
RRT time (months)  3.9  (45.6)  18.4  (83.4)  0.018 
Past history of IHD (%)  19  (15.3)  5  (25.0)  0.281 
Diabetes (%)  34  (27.4)  12  (60.0)  0.004 
Smoker (%)           
  Never  73  (58.9)  10  (50.0)   
  Current  30  (24.2)  8  (40.0)  0.304 
    Ex  21  (16.9)  2  (10.0)   
SBP (mmHg)  137.3  (23.6)  156.3  (21.4)  0.001 
DBP (mmHg)  82.1  (12.9)  87.4  (11.7)  0.092 
PP (mmHg)  55.20  (17.1)  69.0  (17.1)  0.001 
Cross sectional aortic volume (mL)  5.0  (1.9)  5.1  (2.3)  0.634 
Aortic distensibilty (x 10
-3 mmHg
-1)  2.4  (2.0)  2.1  (2.1)  0.009 
Aortic volumetric arterial strain  0.12  (0.09)  0.15  (0.10)  0.176 
PWV 1-2 (m s
-1)  7.1  (4.1)  6.5  (5.8)  0.807 
PWV 1-3 (m s
-1)  7.6  (2.9)  7.3  (2.3)  0.330 
Table 8.2  
Demographic data for patients were alive and dead at the end of the follow up period for 
uraemic patients and controls. Results are show as mean with standard deviation in 
parenthesis or number with percentage in parenthesis as appropriate except for RRT 
time and measures of vascular function which are displayed as median and inter quartile 
range.  Tests  of  significance  are  t-test  and  Chi-squared  between  groups,  except  for 
measures of vascular function where Mann-Whitney-U was used 274 
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Figures 8.9 and 8.10 Kaplan-Meier survival curves for all cause mortality with patients 
stratified by systolic blood pressure tertile and aortic distensibilty tertile  
p=0.186 
 
 
p=0.011 
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Figures 8.11 and 8.12  
Kaplan-Meier survival curves for survival to either CV end point or death with patients 
stratified by aortic VAS quartile and pulse wave velocity tertile 
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Table 8.3 
Cox survival analysis for patient survival. Because of their close correlation SBP aortic 
distensibilty and aortic VAS were entered separately into the model. Results for other 
variables are shown with systolic blood pressure in the model 
  Patient survival 
  Univariate analysis  Multivariate analysis 
Variable  HR         (95.0% CI )  p  HR         (95.0% CI)  p 
Diabetes  3.031  (1.036,  8.866)  0.043  4.214  (1.631,  10.886)  0.003 
SBP (mmHg)  1.015  (0.992,  1.038)  0.197  1.022  (1.000,  1.044)  0.049 
Log aortic distensibilty  0.072  (0.008,  0.694)  0.023  0.135  (0.019,  0.948)  0.044 
Log aortic VAS  0.107  (0.007,  1.732)  0.116         
Duration RRT (days)  1.000  (1.000,  1.000)  0.421         
Age (years)  1.015  (0.969,  1.063)  0.526         
Gender (ref male)  0.833  (0.312,  2.226)  0.716         
Haemoglobin (g/dL)  0.910  (0.670,  1.236)  0.547         
Albumin (g/L)  0.942  (0.839,  1.058)  0.311         277 
 
 
Table 8.4 
Cox  survival  analysis  for  patient  survival  to  either  death  or  cardiovascular  event. 
Because of their close correlation SBP aortic distensibilty and aortic VAS were entered 
separately into the model. Results for other variables are shown with systolic blood 
pressure in the model 
  Combined CV event and death survival 
  Univariate analysis  Multivariate analysis 
Variable  HR         (95.0% CI )  p  HR         (95.0% CI)  p 
Diabetes  2.989  (1.276  7.004)  0.012  2.409  (1.087  5.337)  0.030 
Log aortic distensibilty  0.052  (0.009  0.319)  0.001  0.066  (0.013  0.347)  0.001 
Log aortic VAS  0.021  (0.002  0.206)  0.001  0.026  (0.004  0.175)  <0.001 
Duration RRT (days)  1.000  (1.000  1.000)  0.560         
SBP (mmHg)  1.014  (0.995  1.032)  0.142         
Age (years)  1.023  (0.984  1.062)  0.248         
Gender (ref male)  0.827  (0.368  1.860)  0.646         
Haemoglobin (g/dL)  0.958  (0.748  1.225)  0.731         
Albumin (g/L)  0.984  (0.896  1.080)  0.728         278 
 
8.4  DISCUSSION 
 
8.4.1  Basic physiology of aortic function 
 The aorta as a large artery has two discrete functions. Firstly, as a conduit, it delivers 
blood and hence oxygen to the tissues. This role is expressed by mean blood pressure 
and blood flow. Disruption to this role, primarily by atherosclerosis, potentially results 
in distal ischaemia. Additionally, large arteries have a buffering function, to dampen 
pressure  oscillations  from  intermittent  cardiac  pumping  (the  ‘Windkessel’  effect), 
therefore  transforming  the  pulsatile  blood  flow  into  a  steady  stream  as  required  by 
peripheral  organs  and  tissue.  Alterations  in  shear  stress  or  tensile  stress  within  the 
arterial  wall  lead  to  arterial  remodelling,  with  blood  pressure  being  the  principal 
determinant of these stresses. The characteristics of arterial remodelling are dependant 
on the nature of the haemodynamic stimuli applied to the vessel. Chronic increase in 
arterial blood flow will result in subsequent increase in the vessel lumen whilst increase 
in tensile stress will lead to thickening of the arterial walls, in keeping with the law of 
Laplace,  which  states  that  transmural  stress  directly  proportional  to  the  transmural 
pressure  and  radius  and  inversely  proportional  to  the  arterial  wall  thickness(304).  
Atherosclerosis may further affect arterial remodelling due to alterations in blood flow 
patterns and shear stresses in the vessel wall as well as by direct endothelial injury. 
However this is likely to be of lesser importance in the thoracic aorta, as atherosclerosis 
occurs preferentially in the medium sized conduit vessels.     
 
8.4.2  Alterations of aortic function in ESRD 
The  prime  action  of  atherosclerosis  is  to  disrupt  the  conduit  function  of  the  artery. 
Although patients with ESRD have many risk factors to promote the development of 
atherosclerosis  (diabetes,  hypertension,  age,  dyslipidaemia  and  smoking)  and 279 
 
endothelial function is clearly deranged in uraemia(305), it still remains unclear whether 
the nature of the interactions between the vascular endothelium and atherogenic plaque 
are different to the general population. In any case, these studies focus on the thoracic 
aorta,  and whilst aortic  plaque may  be  found in this region,  as basal blood flow is 
unchanged  until  the  lumen  diameter  is  reduced  by  50%,  altered  conduit  function 
unlikely to be of prime importance as a pathological mechanism in the aorta(304).  
 
In ESRD the large arteries classically undergo remodelling characterised by dilatation 
and  hypertrophy  of  the  arterial  intima-media.  This  remodelling  is  associated  with 
stiffening and the dampening role of the vessel is affected(306). The consequence of 
this  is  primarily  an  increase  in  systolic  and  reduction  in  diastolic  blood  pressure 
resulting  in  higher  pulse  pressure.  This  is  due  to  two  mechanisms.  Firstly  a  higher 
pressure wave is generated by the direct effect of the LV pumping blood into the stiff 
arterial tree. Additionally as vessel stiffness increases this is associated with a rise in the 
PWV over any given arterial segment, in keeping with the Moens-Korteweg equation.  
Thereafter  this  pressure  wave  (forward  travelling)  is  reflected  at  any  point  of 
discontinuity in the arterial tree, generated an echo wave travelling backward toward the 
ascending aorta. The resultant sum of these incident and pressure waves is the measured 
pulse pressure wave and is dependant on their amplitude and timing.  In young healthy 
individuals this reflected wave occurs during diastole and is the associated increase in 
early diastolic pressure augments coronary perfusion. However in conditions where the 
dampening  function  of  the  arterial  tree  is  reduced  such  as  aging  or  uraemia,  this 
beneficial mechanism is disturbed. As PWV increases the reflected waves occur earlier, 
and are more likely to occur during systole than diastole, ‘closer’ in phase with the 
incident wave(307). This therefore leads to an increase in aortic and LV pressure during 280 
 
systole.  This increases cardiac work and the LV after load whilst additionally reducing 
coronary perfusion(308).  
 
Haemodynamic factors which promote arterial remodelling present in ESRD patients, 
although not specific to uraemia, include age and blood pressure. Factors specific to 
uraemia  include  hypervolaemia  due  to  water  and  sodium  retention,  arteriovenous 
shunts, chronic volume and flow overload secondary to anaemia(306).  Arterial medial 
calcification is pronounced in patients in ESRD and is a key mediator of increased 
arterial stiffness(309). This occurs due to changes in the phenotype of vascular smooth 
muscle  cells.  Factors  which  may  affect  this  in  ESRD  include  altered  calcium  and 
phosphate metabolism, chronic inflammation and associated low levels of fetuin-A or 
osteprotegerin  (inhibitors  of  arterial  calcification),  genetic  factors  or  the  presence 
unknown  uraemic  toxins  up  regulating  expression  of  genes  known  to  promote 
calcification in vascular smooth muscle cells(142;147;310;311). 
 
8.4.3  Relationship  between  aortic  distensibilty,  volumetric  arterial  strain  and 
pulse wave velocity 
As different methods of measuring arterial stiffness aortic distensibilty, VAS and PWV 
were  demonstrated  to  be  significantly  correlated  with  each  other.  Using  CMR  to 
measure  aortic  distensibilty  or  VAS  visualises  changes  in  the  aortic  cross  sectional 
volume throughout the cardiac cycle. Therefore these measures are true representations 
of vascular function. This study therefore confirms that PWV (an indirect measure of 
arterial stiffness) and either aortic distensibilty or VAS (direct measures) are directly 
related. To an extent this represents validation of the technique for measurement of 
PWV.  281 
 
8.4.4  Results of studies of aortic distensibilty 
These  data  represent  the  first  report  of  using  CMR  to  assess  vascular  function  in 
uraemic  patients.  The  uraemic  patients  had  significantly  increased  aortic  stiffness 
compared to age matched normal subjects, represented by reduced aortic distensibilty 
and VAS with associated vessel dilatation. In keeping with the relationship between 
increased  arterial  stiffening  and  advancing  age,  there  was  a  significant  relationship 
between  reduced  aortic  distensibilty  and  VAS  and  increasing  age,  both  in  uraemic 
patients and in healthy controls. 
 
In the uraemic patients, aortic distensibilty and VAS were demonstrated to be reduced 
in patients at highest cardiovascular risk, i.e. those with diabetes and/or a past medical 
history of ischaemic heart disease or peripheral vascular disease. No other factors such 
as drug therapy, adequacy of dialysis, duration of renal replacement therapy, dialysis 
modality or any laboratory parameter appeared to be significantly associated with aortic 
distensibilty  or  VAS.  Therefore  overall  increased  aortic  stiffness,  as  indicated  by 
reduced aortic distensibilty or VAS, was demonstrated to be present in uraemic patients 
with the presence of classical cardiovascular risk factors. 
 
The relationship between these markers of aortic function and LV dimensions show a 
weak  but  significant  relationship  between  increased  aortic  stiffness  and  increasing 
LVMI  and  end  systolic  volume,  suggesting  that  reduced  aortic  distensibilty  may 
promote  LV  afterload  and  hence  cardiac  hypertrophy.  Aortic  VAS,  which  is 
independent  of  blood  pressure,  correlated  with  markers  of  cardiac  systolic  function, 
namely ejection function and stroke volume, suggesting that in the failing heart where 
systolic  blood  pressure  is  lower,  increased  arterial  stiffness  remains  deleterious  to 
ventricular performance.  282 
 
Finally  in  the  small  group  of  patients  with  subendocardial  LGE  indicating  previous 
myocardial infarction, the relationship between volume of infarcted tissue and aortic 
distensibilty offers a direct demonstration of the interaction between increased arterial 
stiffness and reduced diastolic coronary artery perfusion(308) leading to increased area 
of  infarction.  This  may  be  one  explanation  long  term  outcome  post  myocardial 
infarction is poor in patients with ESRD. 
 
8.4.5  Limitations  of  studies  with  aortic  distensibilty  and  aortic  volumetric 
arterial strain 
Calculation of aortic distensibilty is based on cross-sectional volume of the vessel wall 
and pulse pressure. For practical reasons, direct aortic blood pressure measurement has 
been  substituted  by  non-invasive  indirect  brachial  blood  pressure  measurement. 
Therefore it is difficult to dissociate any clinical effect associated with changes in aortic 
distensibilty from that due directly to pulse pressure, which is well described as an 
independent predictor of outcome in ESRD. Nonetheless, as it is otherwise impossible 
to  truly  assess  aortic  stiffness,  without  documentation  of  pressure  within  the  vessel 
lumen,  the  approach  used  in  this  study  has  been  used  widely  in  other  patient 
groups(312-314).  For  this  reason  the  aortic  VAS,  the  fractional  increase  in  aortic 
volume during the cardiac cycle was also used. This does not depend on blood pressure 
variables and in this study appeared to display fairly similar relationships with clinical 
variables  and  outcome.  There  is  however  limited  literature  to  support  its  use. 
Additionally, whilst this is the largest study to date using aortic distensibilty in any 
patient group, the number of patients in any subgroup, such as diabetes or with previous 
ischaemic heart disease was small, therefore limiting conclusions that can be drawn 
from this study.  
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Although it is highly likely that arterial calcification is the intricately involved as a 
pathomechanism  for  reduced  aortic  compliance,  CMR  is  unable  to  display  calcific 
lesions  due  to  their  absence  of  water  (and  hence  proton)  content.  This  compares 
relatively  unfavourably  with  multi-slice  computed  tomography  (CT),  which  has 
emerged as a tool for assessing cardiac calcification(144). However, multi-slice CT is 
not able to accurately distinguish between intimal and medial calcification and requires 
ionising radiation. Therefore, serial CT scans to test a therapeutic intervention is an 
unattractive  option  compared  to  using  cardiac  MRI  as  a  surrogate  measure  of 
calcification.  
 
8.4.6  Results of studies of pulse wave velocity 
This represents one of the largest studies of pulse wave velocity  with CMR in any 
pathological disease state. Previous, smaller studies have demonstrated the feasibility of 
measuring PWV in healthy volunteers using CMR(312;315;316). In this study, PWV 
was  numerically  higher  in  uraemic  patients  compared  to  age  matched  controls  in 
keeping with findings of previous studies using alternative methods to measure pulse 
wave velocity(315). Additionally, PWV rose significantly with advancing age in both 
uraemic and control patients. In keeping with the findings for aortic distensibilty and 
VAS, PWV tended to be higher in patients at highest cardiovascular risk (patients with 
diabetes, ischaemic heart disease or peripheral vascular disease), although with PWV 
none  of  these  differences  reached  statistical  significance.    Like  aortic  distensibilty, 
generally there were no associations between PWV and dialysis modality, adequacy, 
time on renal replacement therapy or biochemical or haematological data. It is difficult 
to interpret a negative correlation between serum corrected calcium and PWV as other 
studies have shown the converse to be true. However a negative relationship between 
PWV and albumin may be due to low serum albumin levels reflecting over hydration 284 
 
leading  to  vessel  dilatation,  or  may  indicate  patients  with  the  malnutrition-
inflammation-atherosclerosis complex.  
 
The  differences  in  PWV  between  patients  on  various  classes  of  antihypertensive 
therapy, alludes to potential differences between actions of antihypertensive agents on 
central haemodynamics but due to the limited numbers in each group, firm conclusions 
cannot be drawn. One study however has observed beneficial influences on long term 
survival in similar patient groups with ACE inhibitors compared to other agents(317), 
which  may  reflect  beneficial  haemodynamic  effects.  No  prospective  randomised 
controlled trials exist in this population to confirm this observation. 
 
8.4.7  Limitations of study of PWV with CMR 
Certain limitations of using CMR to measure  PWV were highlighted  by this study. 
Developing the technique required extensive collaboration to develop the Cardiowarp 
analysis software to measure aortic lengths and and interpret flow curves generated with 
CMR imaging of blood flow in the aorta. Although the results for PWV are broadly 
similar  to  the  findings  of  other  studies  of  healthy  volunteers  using  either  CMR  or 
applanation tonometry to measure PWV, PWV in the uraemic patients appears lower 
than found in other studies(303). This was a cohort of uraemic patients being assessed 
for renal transplantation and may be healthier than other cohorts studied in the literature. 
Unfortunately  direct  comparison  of  CMR  derived  PWV  with  applanation  tonometry 
was not possible in the uraemic patients.  
 
Potential sources of error in measurement of PWV include the assessment of aortic 
length. A number of studies were discarded due to unfolding of the aorta taking it out of 
the plane of imaging and therefore not suitable for analysis. Of the scans analysed, 285 
 
although the aorta was entirely visualised in the sagittal plane of imaging, tortuousity of 
the vessel in and out of the sagittal plane used for image acquisition may not have been 
detected. This potentially may have lead to underestimation of aortic length and hence 
PWV.  
 
By assessing flow at three points along the aorta, the technique assumes that all scans 
are  acquired  at  the  same  time  points  relative  to  the  cardiac  cycle.  Although  in  the 
majority of scans this appears to be the case, this represents a further source of error. 
Additionally the aorta itself is regionally heterogeneous and in terms of its composition 
and hence its viscoelastic properties. Finally, the flow sensitive phase contrast CMR 
images were acquired at a temporal resolution of approximately 15ms. This compares 
poorly  to  the  temporal  resolution  of  Doppler  probes  typically  used  for  applanation 
tonometry of 10 MHz. 
 
8.4.8  Prognostic implications of CMR studies of vascular function 
Independent predictors of mortality during the follow up period were diabetes, aortic 
distensibilty and systolic blood pressure. Due to their close interdependence, systolic 
blood pressure and aortic distensibilty could not be independently assessed. However 
when  a  combined  end  point  of    death,  non-fatal  myocardial  infarction,  cardiac 
revascularisation, amputation for peripheral vascular disease and cerebrovascular event 
was used, only diabetes and aortic distensibilty or VAS were independent predictors of 
events. Age was not a predictor of outcome in this group of patients. Therefore aortic 
distensibilty or VAS predict outcome whatever age the patient, rather than merely being 
reflective of older uraemic patients having stiffer vessels as demonstrated earlier. In 
keeping with other studies, time on renal replacement therapy was significantly longer 
in those patients who died during the follow up period(303), but this factor was not 286 
 
independently  associated  with  outcome.  Therefore  in  this  patient  group,  aortic 
distensibilty was a predictor of mortality and/or vascular events whatever the age of the 
patient and even if the CMR was performed long after the patient had started renal 
replacement therapy.  
 
8.4.9  CMR measures of vascular function as surrogate markers of cardiovascular 
risk 
As a potentially novel marker of increased cardiovascular risk, no data exist on the 
natural history of progression of aortic distensibilty in uraemic patients, or whether it 
can  be  improved  by  therapeutic  intervention.  The  assumption  is  that  reduced  aortic 
distensibilty  is  reflective  of  arterial  calcification.  As  arterial  calcification  has  been 
demonstrated by electron beam CT to progress in patients on dialysis therapy and be 
related  to  oral  intake  of  calcium  (primarily  as  calcium  containing  phosphate 
binders)(143), one strategy to improve aortic distensibilty may be to use non-calcium 
containing phosphate binders such as sevelamer hydrochloride or lanthanum chloride to 
reduce to calcium load whilst controlling serum phosphate. Analogues of inhibitors of 
arterial  calcification  are  in  the  early  stages  of  development  and  may  be  of  clinical 
benefit. CMR measures of vascular function, in particular aortic distensibilty, represent 
potentially  useful  surrogate  markers  of  cardiovascular  risk  for  future  trials  of  such 
interventions.        
 
8.4.10  Assessment of vascular function using CMR 
A variety of studies have attempted to address the role of aortic distensibilty as a marker 
of either cardiovascular risk or relating aortic distensibilty to cardiac performance. Like 
the current study, it appears that CMR measures of arterial function represent attractive 
surrogate  markers  for  intervention  for  other  groups  at  high  risk  of  cardiovascular 287 
 
disease.  Currently  data  relating  CMR  measures  of  arterial  function  on  long  term 
outcome are scant and similarly there a few studies to suggest that arterial function 
assessed by this method can be modulated: 
•  In  otherwise  healthy  young  individuals,  obese  subjects  have  been  shown  by 
CMR  to  have  increased  aortic  cross  sectional  area  and  decreased  aortic 
elasticity(318) 
•  In patients with either systolic or diastolic heart failure, aortic distensibilty was 
reduced compared to controls and correlated with exercise capacity as assessed 
by  peak  volume  of  oxygen  consumption  at  cardiopulmonary  exercise 
testing(313) 
•  A small study of 33 hypertensive patients demonstrated that aortic distensibilty 
increased in patients following treatment with either nicardipine or alacepril but 
not trichlormethiazide over a 12 week treatment period. This effect appeared to 
be independent of changes in pulse pressure, which did not significantly differ 
between the three groups(319) 
•  In Marfan syndrome, where the leading cause of death is aortic dissection, both 
aortic  distensibilty  and  aortic  diameter  have  been  shown  to  be  independent 
predictors of progressive aortic dilatation(320). A further CMR study has shown 
that  beta-blocker  therapy  significantly  improves  aortic  distensibilty  in  these 
patients(321) 
•  An interesting pilot study has demonstrated that arterial endothelial function can 
be studied using CMR to by assessing cross sectional flow mediated dilation of 
the brachial artery(316) 
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8.4.11  Other studies using CMR to assess pulse wave velocity 
A  small  number  of  studies  have  used  CMR  to  assess  PWV,  either  validating  the 
technique against established methods or comparing the results to clinical characteristics 
of the subjects studied. Generally, studies assessing validation of CMR measures of 
vascular function have focused on measurements in normal volunteers: 
•  Rogers  et  al  compared  applanation  tonometry  and  CMR  measured  PWV  in 
healthy volunteers across a wide age range. Similar to the current study they 
found  that  PWV  measured  with  both  tonometry  and  CMR  increased  with 
age(315) 
•  One  study  in  healthy  volunteers  validated  aortic  PWV  using  complex 
mathematical derivation of PWV by alternative methods. This study assumes 
that in  young adults, by the time of maximum blood flow, flow direction is 
unidirectional (no reflected waves) and uses fluid dynamic theory to estimate 
PWV from maximum blood flow rates  and changes in aortic cross sectional 
area. Although an attractive concept it is unclear how this translates to older 
patients  (all  subjects  were  21-30  years  old)  as  aortic  stiffening  occurs.  The 
scanning protocol used was similar to the current study(312)  
•  One CMR study of healthy volunteers demonstrated a close correlation between 
aortic compliance and PWV in the thoracic aorta, and again show significant 
correlations between aortic stiffness and age by both methods (322)  
•  PWV assessed by CMR has been show to correlate with age but no other clinical 
parameters in patients with juvenile idiopathic arthritis(314) 
 
8.4.12  Arterial stiffness in uraemia - clinical implications and long term survival  
A  large  number  of  studies  have  been  performed  assessing  both  the  determinants  of 
increased arterial stiffness, measured with alternative methods, and its relation to long 289 
 
term survival in patients with ESRD, using either elastic incremental modulus, PWV or 
augmentation index as markers of arterial stiffness: 
•  Factors  consistently  associated  with  increased  arterial  stiffness  include  age, 
diabetes, and systolic blood pressure (or pulse pressure)(323-325) 
•  A  number  of  studies  have  identified  other  factors  associated  with  increased 
arterial  stiffness  including  serum  calcium  or  the  presence  of  inflammation 
indicated by C-reactive protein(325)  
•  Using electron beam CT, Covic et al have shown that PWV measured with the 
SphygmoCor  apparatus  correlates  with  the  degree  of  coronary  artery 
calcification, even when corrected for confounding variables such as age and 
duration of renal replacement therapy(193) 
•  A number of survival studies from the group of London et al demonstrate that 
PWV is an independent predictor of both all cause and cardiovascular mortality 
in patients on haemodialysis(302;303;326). Interestingly in one of these studies 
in a cohort of 180 dialysis patients followed up for 52 months brachial blood 
pressure  was  a  less  impressive  predictor  of  outcome  compared  to  central 
measures of aortic PWV(326) 
 
8.4.13  Conclusions 
This study has demonstrated that vascular function can be measured using CMR in 
uraemic patients. Increase in aortic stiffness, indicated by reduced aortic distensibilty, 
reduced VAS and increased PWV are all associated with risk factors for cardiovascular 
disease including diabetes, previous ischaemic heart disease, peripheral vascular disease 
and advancing age. Although PWV measured by CMR was not associated with long 
term  outcome,  both  aortic  distensibilty  and  VAS  were  independent  predictors  of 
combined  vascular  events  and  mortality.  Aortic  distensibilty  predicted  all  cause 290 
 
mortality.  It  is  likely  that  these  derangements  in  aortic  function  are  due  to  arterial 
calcification although this requires correlation with conventional methods of assessing 
calcification  such  as  CT  scanning.  CMR  offers  a  novel  non-invasive  tool  to  assess 
vascular function in these patients. Aortic distensibilty and VAS are potential targets for 
therapeutic intervention to reduce cardiovascular risk in uraemia. 291 
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9.1  INTRODUCTION 
The  main  goal  of  the  studies  contained  in  Chapter  3  was  to  assess  the  relationship 
between  myocardial  tissue  abnormalities,  indicated  by  contrast  enhanced  CMR  and 
uraemic  cardiomyopathy  defined  by  CMR.  Furthermore,  these  abnormalities  were 
shown  to  predict  long  term  outcome.  Therefore,  the  next  intention  was  to  use  this 
information  to  power  a  prospective  study  with  the  goal  of  either  preventing  the 
development of myocardial fibrosis or reducing the progression of myocardial fibrosis 
using findings at contrast enhanced CMR as a study end point.  
 
However in April 2006 a case series emerged from Austria postulating a link between 
gadolinium based MRI contrast agents and the development of nephrogenic systemic 
fibrosis (NSF)(327), previously labelled nephrogenic fibrosing dermopathy, in patients 
with advanced chronic kidney disease. This was subsequently followed by a caution 
issued  by  the  United  States  Food  and  Drug  Administration,  regarding  the  use  of 
gadolinium based MRI contrast agents and the development of NSF.  
 
NSF  was  first  identified  in  1997  and  presents  as  a  scleromyxoedema-like  condition 
affecting patients with advanced kidney disease(328). Approximately 200 cases have 
been reported to the NSF registry(329). The clinical manifestations include thickened, 
oedematous, indurated or discoloured skin affecting the limbs and trunk. The face is 
typically spared. Progression may occur over weeks resulting in joint contractures and 
severe  restriction  of  movement.    Multi-organ  involvement  has  been  observed  and 
mortality is high with death occurring often from sepsis as a complication of immobility 
or hypoventilation if lung and diaphragm involvement occurs(330). 
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Although clinical cases of NSF had been documented prior to the commencement of 
these studies at the hospitals from which the patients were recruited, no causative link 
between gadolinium and NSF had been proven. Whilst this uncertainty existed, future 
contrast enhanced CMR studies were suspended and a retrospective case-control study 
was performed to assess any link between exposure to gadolinium based MRI contrast 
agents and development of NSF. 
 
9.2  METHODS 
 
9.2.1  Identification of patients and MRI data 
A retrospective analysis was undertaken of all prevalent patients on renal replacement 
therapy within the renal units of Glasgow Royal Infirmary and the Western Infirmary 
Glasgow between 1
st January 2000 and 1
st July 2006 to identify all cases of NSF. The 
computerised electronic patient record (EPR) was interrogated to using the keywords 
“nephrogenic”,  “dermopathy”,  “fibrosing”,  “scleromyxoedema”  to  identify  all  cases 
(“fibrosis”  and  “systemic”  were  not  used  as  many  more  cases  were  generated  of 
unrelated  conditions  such  as  pulmonary  fibrosis  or  systemic  lupus  erythematosus 
without identifying further cases of NSF).  Additionally all consultant nephrologists 
working at these two units were asked to forward details of any patients they had cared 
for with NSF. Patients with NSF therefore formed the group of cases. Each case was 
reviewed thoroughly with respect to the clinical history and histopathological records. 
 
As controls all patients undergoing dialysis therapy for established renal failure (defined 
as dialysis dependent for >90 days) at the Western Infirmary, Glasgow over the same 
time period were identified via the EPR.  A search was performed of the radiology 
computer system for all records of magnetic resonance imaging with the number of 294 
 
gadolinium-containing  scans  and  cumulative  gadolinium  contrast  dosage  and  type 
recorded for each patient. Doses were recorded in the radiology database. Where this 
was unavailable the MRI logbook was checked. Gadolinium exposure was calculated 
over  the  six  and  a  half-year  period  for  all  non-NSF  patients  and  for  the  period  1
st 
January 2000 until the first presentation of disease for all patients in the NSF group. 
Patients who had functioning renal grafts throughout the study period and thus did not 
receive dialysis were excluded during the time they were not on dialysis therapy. 
 
9.2.2  Statistical Methods 
Non-parametric testing (Mann-Whitney-U test) was used to assess differences between 
median doses of gadolinium contrast and total number of gadolinium-enhanced MRI 
between NSF and non-NSF groups. Statistical analysis was performed by SPSS version 
13.0 (SPSS Inc, IL, USA). 
 
9.3  RESULTS 
 
9.3.1  Demographics  of  patients  undergoing  renal  replacement  therapy  at  the 
Western Infirmary, Glasgow 2000-2006  
A total of 814 patients were identified who had received renal replacement therapy for 
ESRD at the Western Infirmary during the period 01/01/2000 to 01/07/2006.  The mean 
age at starting RRT was 56.5 years and 471 (7.9%) patients were male.  The cause of 
ESRD was diabetic nephropathy in 124 (15.2%), adult polycystic kidney disease in 51 
(6.3%),  glomerulonephritis  in  168  (20.6%),  chronic  pyelonephritis  in  95  (11.7%), 
renovascular disease in 98 (12.0%), miscellaneous other known causes of ESRD in 65 
(8.0%) and 213 (26.2%) with an unknown or unclassifiable cause of their renal failure.  
 295 
 
9.3.2  Cases of nephrogenic systemic fibrosis identified in North Glasgow 
A total of 15 patients were identified with a diagnosis of NSF as evidenced by clinical 
and pathological findings noted within the clinical records.  Four cases were identified 
at the Western Infirmary Glasgow and 11 cases at Glasgow Royal Infirmary. 13 of the 
15 cases were biopsy proven. Compared to the control cohort of patients undergoing 
renal replacement therapy for ESRD at the Western Infirmary, patients with NSF were 
significantly younger at the time of starting renal replacement therapy (median age NSF 
group 51.7 vs. non-NSF group 60.9, p= 0.031). A greater proportion of patients who 
developed NSF were female compared to those who did not (NSF group 66.7% female 
vs. non-NSF group 41.9% female, p=0.054). The demographics of patients with and 
without NSF are shown in Table 9.1. At the end of the study period 6/15 (40.0%) of 
patients with NSF had died.   
 
9.3.3  Contrast  enhanced  magnetic  resonance  imaging  performed  during  the 
period 2000-2006  
Over the six and a half-year period, 204 (24.7%) of the total 825 patient cohort (NSF 
cases from both hospitals plus controls from the Western Infirmary dialysis population) 
patients underwent a total of 248 gadolinium-enhanced MRI scans. Six (2.4%) of these 
MRIs used gadobenate-dimeglumine  (Multihance, Bracco S.p.A., Milan, Italy) as the 
contrast agent with median dose volume of 15ml.  228 (91.9%) of these scans were 
performed with gadodiamide (Omniscan, GE Healthcare, Chalfont St Giles, UK) with a 
median  dose  volume  of  32ml.    11  (4.4%)  scans  used  gadopentetate  dimeglumine 
(Magnevist, Berlex, Canada) as the contrast agent with median dose volume of 15ml, 
and three (1.2%) scans used gadobutrol (Gadovist, Schering, West Sussex, UK) as the 
contrast agent with median dose volume of 15ml. 
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9.3.4  Relationship between exposure to MRI contrast agents and development of 
NSF 
Of the patients who developed NSF only one  patient had not been exposed to MR 
contrast  (Table  9.2).  All  other  patients  who  developed  NSF  had  undergone  MR 
scanning with gadodiamide used as the contrast agent. None of these patients had been 
exposed to other MR contrast agents. When compared to the 190 patients who had 
undergone contrast-enhanced MR and not developed NSF, the 14 NSF patients were 
found to have been exposed to a significantly higher median dose of gadodiamide-based 
contrast  than  their  non-NSF  counterparts  (median  51.5ml  v  32ml,  p<0.001).  
Additionally the median dose of gadodiamide-based contrast used for their first MRI 
scan was significantly higher in patients who developed NSF (45.0 vs. 32ml, p<0.001). 
There  was  additionally  a  significantly  greater  number  of  MRI  scans  performed  on 
patients who developed NSF (median of two scans per patient in the NSF group and one 
per  patient  in  the  non-NSF  patients,  p<0.001).  The  frequency  of  performance  of 
contrast-enhanced MR examinations steadily increased over the study period as shown 
in Figure 9.1 with the cumulative numbers of diagnoses of NSF following a similar 
trend. 
 
9.3.5  Characteristics of patients who developed nephrogenic systemic fibrosis 
The  baseline  demographics  and  outcome  for  the  patients  who  developed  NSF  is 
displayed in Table 8.2. Other than exposure to MR contrast in all but one patient, there 
were no consistent recurrent clinical features present in all these patients, either in terms 
of underlying renal diagnosis, time on dialysis, concurrent medication or co-morbidity 
(data not shown). The median time period from MRI scan to diagnosis of NSF was 70 
days with an interquartile range of 313.5 days. Although one patient (Patient 5) had a 
time interval of 2395 days between first MRI scan and onset of symptoms of NSF, a 297 
 
second MRI was performed after development of skin changes. As a retrospective study 
it is not clear what, if any, exacerbation was related to the first or second scan. Skin 
biopsy was performed after the second scan in this patient. Six patients died during the 
follow  up  period,  one  patient  spontaneously  regained  renal  function  sufficiently  to 
discontinue  dialysis  (Patient  6)  and  one  patient  has  undergone  cadaveric  renal 
transplantation (Patient 12). The patient who has regained renal function has also been 
treated with photophoresis therapy and has experienced improvement but not resolution 
in her skin condition. One patient (Patient 15) has been treated with immunosuppression 
(prednisolone and sirolimus) and at the time of data collection this has been poorly 
tolerated and has not led to any dermatological improvement. 
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Characteristic  Non-NSF  NSF  p 
Number of patients  810    15    - 
Age at start of RRT  60.9  (28.8)  51.7  (20.9)  0.031 
Male (%)  471  (58.1)  5  (33.3)  0.054 
Diagnosis   (%)           
  Diabetes   124  (15.4)  4  (26.7)  - 
  APKD  51  (6.3)  1  (6.7)  - 
  GN  161  (20.0)  5  (33.3)  - 
  CPN  94  (11.7)  3  (20.0)  - 
  Renovascular  98  (12.2)  0  (0.0)  - 
  Other  63  (7.8)  0  (0.0)  - 
  Unknown  213  (26.5)  2  (13.3)  - 
Number undergoing MRI  190  (23.5)  14  (93.3)  <0.001 
Mortality at end of study period  405  (50.0)  6  (40.0)  0.604 
 
 
Table 9.1. Clinical characteristics of the complete of cohort of patients comparing those 
with and without a diagnosis of NSF. All variables expressed as value (%) expect age 
expressed as median and interquartile range.   
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Figure 9.1 
Graph displaying the cumulative number of contrast enhanced MRI scans performed in 
this cohort of patients – left axis (black) with the cumulative frequency of diagnosis of 
nephrogenic systemic fibrosis displayed - right axis (red) 300 
 
CASE  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15 
Sex  M  F  M  F  M  F  F  M  F  F  M  F  F  F  F 
Primary diagnosis  U  CPN  DM  GN  DM  GN  U  U  AP  CPN  DM  CPN  GN  GN  GN 
Skin biopsy  Y  Y  Y  Y  Y  Y  Y  N  Y  Y  Y  Y  N  Y  Y 
Age at diagnosis (years)  63.2  61.0  43.5  54.3  67.1  49.0  63.7  43.7  37.7  20.5  60.4  58.5  59.8  73.2  50.50 
Age starting RRT (years)  61.6  56.6  42.4  22.2  67.0  49.0  56.7  38.9  35.1  17.0  59.9  51.7  59.1  66.2  48.97 
Time on RRT (years)  1.6  4.4  1.1  32.1  0.1  0.0  7.0  4.8  2.6  3.5  0.5  6.8  0.7  7.0  1.53 
RRT modality  PD  HD  HD  HD  HD  HD  HD  HD  HD  HD  HD  HD  PD  HD  PD 
MRI  Y  Y  Y  N  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y  Y 
MRI-NSF time (days)  76  83  477  -  2395  35  2  4  16  52  64  289  99  441  6 
Previous MRI  2  2  1  -  1  1  3  1  1  2  1  1  2  5  0 
MRI post NSF  1  3  0  -  1  1  1  1  0  3  0  0  1  1  0 
HCO3 (mmol/l)  22  24  26  25  18  28  18  36  17  25  23  26  29  21  28 
Treatment  -  Ph  -  -  Ph  -  -  -  -  -  -  -  -  -  Im 
Renal function  -  -  -  -  -  Sp  -  -  -  -  -  Tx  -  -  - 
Outcome  S  I  M  M  S  I  M  M  N/A  M  M  S  S  N/A  D 
Table 9.2 Baseline characteristics of NSF cases. Abbreviations: M - male; F - female; U - unknown; CPN - pyelonephritis; DM - diabetes mellitus; GN - glomerulonephritis; AP - adult 
polycystic kidney disease; Y - yes; N - no; Time on RRT - at diagnosis with NSF; RRT modality - at the time of NSF diagnosis; PD - peritoneal dialysis; HD - haemodialysis; MRI-NSF 
time - time interval between gadolinium-enhanced MRI and NSF onset; Previous MRI - total number of MRI scans prior to NSF diagnosis; MRI post NSF - number of MRI scans 
performed after a diagnosis of NSF; HCO3 - serum bicarbonate level within 30 days of MRI; Ph – photophoresis; Im – immunosuppression; -  no change; Sp - spontaneous improvement; 
Tx - renal transplant; Outcome - of NSF; S - stable; I - improved; M - dead; D  – deteriorating; N/A - not applicable/follow up time too short for comment. 301 
 
9.4  DISCUSSION 
 
9.4.1  Results of this study 
These data support an association between the use of the gadodiamide-based contrast 
agent  (Gd-DTPA-BMA,  Omniscan)  and  the  development  of  nephrogenic  systemic 
fibrosis. Patients who developed NSF were exposed to higher initial and subsequent 
doses of gadodiamide than those who did not and additionally underwent more contrast 
enhanced MRI scans.  However one patient developed NSF without ever undergoing 
contrast enhanced MRI scanning suggesting that gadodiamide is not the sole cause of 
NSF.  Conversely  although  6.6%  in  this  cohort  of  ESRD  patients  undergoing  MRI 
scanning with gadodiamide developed NSF, cases of NSF were over-represented in this 
group by including cases from two hospitals (Western Infirmary, Glasgow and Glasgow 
Royal  Infirmary)  but  only  using  a  control  group  of  a  cohort  of  patients  on  renal 
replacement therapy from one hospital (Western Infirmary, Glasgow). This approach 
was used to ensure accuracy of the data collected regarding contrast agents used for 
MRI scanning. If the entire dialysis population from each centre was selected then there 
would be a prevalence of 15 cases for a total of 1826 patients on maintenance dialysis. 
Between  both  centres  425  contrast  enhanced  MRI  scans  were  performed,  giving  an 
incidence of NSF of 3.5% in patients with ESRD who have undergone previous MRI 
scanning.  
 
None  of  the  alternative  gadolinium  based  contrast  agents  were  associated  with  the 
development of NSF suggesting that it may be properties of the chelating molecule or 
an  interaction  between  the  gadolinium  chelate  and  the  uraemic  milieu  that  leads  to 
development of NSF. Based on these findings, caution should be used in future before 
using gadolinium based contrast agents in the ESRD population, both by reducing the 302 
 
dose  of  contrast  used  and  by  focusing  on  strategies  to  minimize  exposure  to  the 
gadolinium chelate compound.   
 
9.4.2  Pathogenesis of nephrogenic systemic fibrosis 
Currently the pathogenesis of NSF remains unclear. Approximately 90% of patients 
with the condition are established on dialysis therapy. The condition has been described 
in both patients receiving haemodialysis and peritoneal dialysis and no one underlying 
renal  disease,  dialysis  technique;  manufacturer,  dialysate  or  dialysis  unit  has  been 
consistently associated with NSF(331). Hypercoagulable states have been reported in 
NSF including patients experiencing deep vein thrombosis and pulmonary embolus as 
well  as  thrombosed  dialysis  access  (both  femoral  grafts  and  arteriovenous  fistula). 
These have not been a  universal finding(332). Other associated findings reported in 
patients with NSF have included underlying liver disease, most commonly, hepatitis B- 
or C-induced cirrhosis(333). The significance of any of these associations is unclear but 
suggests that vascular injury or thrombosis may set in motion a process of aberrant 
processes akin to early wound healing, leading to abnormal collagen deposition. 
 
More recently the spindle cells present in the dermis of patients with NSF has been 
demonstrated to be a CD34-postive dendritic fibroblast, giving rise to the concept of a 
‘circulating  fibrocyte’  of  bone  marrow  origin  migrating  from  the  circulation  to  the 
dermis  and  differentiating  into  cells  which  histologically  resemble  dermal 
fibroblasts(334). These circulating cells suggest that NSF is a systemic disorder. The 
trigger for the migration and differentiation of these CD34-postive fibrocytes is not 
clear but thrombosis and/or endothelial injury are possibly responsible. 
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9.4.3  Clinical features of nephrogenic systemic fibrosis 
The cutaneous features of NSF include skin-coloured to erythematosus papules which 
classically  coalesce  to  the  characteristic  brawny  plaque  with  peau  d’orange  surface 
changes.  The  skin  becomes  marked  thickened  with  a  woody  texture.  The  condition 
usually follows a symmetrical distribution involving the limbs and trunk, most typically 
between  the  ankles  and  mid-thighs  and  wrists  and  upper  arms.  The  face  is  usually 
spared(332). Patients may complain of pain in the affected areas. Arthritis is not seen 
but joint contractures may develop over a time course of weeks. Loss of function is 
extremely common and patients may become wheelchair bound. 
 
Although  the  condition  was  initially  thought  to  be  confined  to  the  skin,  systemic 
involvement  has  been  described  including  diaphragmatic  and  pleural  involvement 
indicated  by  hypoventilation  and  reduced  gas  transfer  as  well  as  pericardial  and 
myocardial  disease  manifest  as  cardiomyopathy  and  arrhythmia(330).  The  natural 
history  of  the  disease  is  not  yet  well  understood.  Some  patients  report  a  gradual 
improvement in mobility and slight softening of the skin over time, either spontaneously 
or  in  response  to  therapy.  Complete  spontaneous  healing  in  a  patient  with  ongoing 
kidney disease has not yet been reported. Some patients with NSF (approximately 5% 
or less) have an exceedingly rapid and fulminant disease course that may result in death.  
 
9.4.4  Histological findings in nephrogenic systemic fibrosis 
As the disease extends into the subcutaneous fascia a deep biopsy specimen is required. 
Characteristic  biopsy  findings  include  increased  cellularity  in  the  dermis  and  in  the 
subcutaneous  septa.  This  increased  cellularity  consists  of  dermal  spindle-cell 
proliferation  (CD34-postive) with variable mucin deposition and little inflammation; 
occasional  multinucleated  giant  cells,  elongated  elastic  fibres,  and  dystrophic 304 
 
calcification. An Alcian blue stain is often used to highlight the increased deposition of 
acid mucin in the dermis(335). Histological features of NSF are demonstrated from a 
skin biopsy of one of the patients in this study in Figure 9.2. In keeping with the concept 
of  NSF  as  a  deranged  process  of  aberrant  wound  healing  increased  expression  of 
transforming  growth  factor  β1  has  been  demonstrated  in  the  affected  skin  and 
muscle(336).  
 
Differential  diagnoses  of  NSF  include  scleromyxoedema,  eosinophilia–myalgia 
syndrome, eosinophilic fasciitis, systemic sclerosis/morphea, porphyria cutanea tarda, 
fibroblastic rheumatism, Spanish toxic oil syndrome, vinyl chloride exposure and β2-
microglobulin amyloidosis.  305 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.2   
NSF lesions showing normal epidermis, thick collagen bundles with numerous clefts and 
plump fibroblast-like cells, and Alcian blue staining. Photograph courtesy of Dr Michael 
Edward, University of Glasgow 306 
 
9.4.5  Postulated triggers for the development of nephrogenic systemic fibrosis 
As endothelial or vascular injury has previously been implicated in the pathogenesis of 
NSF a number of case reports have suggested a temporal relationship between vascular 
insults, either operations or thrombotic events, and development of NSF. Approximately 
15% of patients report a surgical procedure (other than renal or hepatic transplantation) 
immediately  antecedent  to  the  onset  of  NSF.  If  transplantation  is  included,  the 
percentage climbs to 48%. Inclusion of formation of dialysis fistula and central dialysis 
catheter placement increases the total of patients experiencing a vascular intervention 
prior  to  development  of  NSF  approximately  90%.  However  this  finding  must  be 
interpreted in the context that vascular interventions are extremely common in patients 
with ESRD, irrespective of their NSF status(332).  
 
An alternative proposal has suggested that erythropoietin therapy may be implicated in 
the pathogenesis of NSF. Patients with NSF have been observed to have been treated 
with higher doses of erythropoietin(337). Whether this suggests a common aetiological 
link between erythropoietin resistance (due for example to chronic inflammation) and 
NSF is not clear. Erythropoietin resistance may indicate bone marrow fibrosis as part of 
the  NSF  syndrome,  although  this  has  not  been  demonstrated  in  clinical  practise. 
Moreover  high-level  exposure  to  erythropoietin  may  contribute  to  the  disease  by 
increasing numbers of circulating haematopoietic stem cells and endothelial progenitors 
(and hence CD34-postive circulating fibrocytes). Erythropoietin has also been shown in 
vivo  to  trigger  an  exaggerated  fibrin  induced  wound-healing  response  that  is 
histologically similar to NSF(338). However it will be almost impossible to determine 
the role, if any, of erythropoietin in the development of NSF. 
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9.4.6  Pharmacokinetics of gadolinium based contrast agents in end stage renal 
disease 
Gadodiamide (Gd-DTPA-BMA; Omniscan) is distributed in the extracellular fluid and 
entirely excreted from the body through the kidneys by glomerular filtration, with an 
elimination half-life in normal renal function of 80–100 min. Therefore this compound 
gadolinium  is  excreted  from  the  body  as  a  complex,  i.e.  unchanged  from  the 
administered form. 98% of administered gadodiamide is excreted at 24 hours in normal 
renal  function)(339).  A  number  of  small  studies  have  been  performed  to  assess  the 
pharmacokinetics of gadolinium based contrast agents in end stage renal disease: 
•  In patients with severely reduced renal function (glomerular filtration rate 2-
10ml/min,  not  on  dialysis  therapy),  the  elimination  half-life  of  gadodiamide 
injection is prolonged (34.3 hours +/- 22.9). In the same group of studies 65% of 
the gadodiamide injected was eliminated during a haemodialysis session(340) 
•  In another study using gadopentetate dimeglumine (Gd-DTPA; Magnevist) the 
average  excretory  rates  of  the  total  administered  agent  was  78.2%,  95.6%, 
98.7% and 99.5% in the first to fourth hemodialysis sessions, respectively(341) 
•  Peritoneal clearance appears to much less efficient for removal of gadodiamide. 
Of the studies available it appears that approximately 69% of the gadodiamide is 
excreted over a 22 day period(340) 
•  One concern with gadodiamide compared to the other contrast agents relates to 
the risk of transmetallation. Gadodiamide has excess chelate compared to the 
other agents and is theoretically less stable with a higher risk of transmetallation 
resulting in release of toxic free Gd
3+. Transmetallation has not been observed in 
these pharmacokinetic studies in ESRD patients and its role in development of 
NSF is unproven(342) 308 
 
9.4.7  Adverse  effects  of  gadolinium  based  contrast  agents  in  end  stage  renal 
disease  
Common side effects following administration gadolinium based contrast agents include 
headache,  nausea,  taste  disturbance  and  urticaria.  Typically  with  gadodiamide  the 
incidence of these side effects is approximately 2% for headache and <1% for all other 
effects. As the excretion is delayed these side effects are likely to be exacerbated in 
renal impairment. Anaphylaxis is a rare occurrence. 
•  Reports of nephrotoxicity in patients with advanced renal impairment exist with 
gadolinium based agents. Nonetheless the risk of precipitating dialysis is rare 
and  serum  creatinine  usually  returns  to  baseline.  Risk  factors  for  developing 
gadolinium induced nephrotoxicity include a lower glomerular filtration rate at 
baseline and diabetes(343;344) 
•  Massive life threatening free iron mobilisation has been reported in an ESRD 
patient  with  biochemical  iron  overload  following  administration  of  Gd-
DTPA(345) 
•  Pseudohypocalcaemia  is  commonly  observed  following  administration  of 
gadolinium  based  contrast  agents  due  to  gadolinium’s  interference  with  the 
colorimetric assays used to measure serum calcium. Serum calcium is normal 
when  measured  by  mass  spectrometry.  This  effect  is  prolonged  in  renal 
impairment(346) 
 
9.4.8  Relationship  between gadolinium  based  contrast  agents  and  nephrogenic 
fibrosing dermopathy 
A link between gadolinium based contrast agents, in particular gadodiamide, and NSF 
was first postulated in April 2006 by Grobner(327), with further subsequent reports 
emerging  from  Denmark(347).  To  date  only  gadodiamide  has  been  implicated  with 309 
 
NSF. The findings of the current study are entirely in keeping with these observations 
and  extend  this  association  by  demonstrating  a  dose  dependent  relationship  and 
indicating  a  theoretically  risk  of  developing  NSF  following  administration  of 
gadodiamide of approximately 3.5%. The first report postulating this link suggested that 
acidosis was a prominent feature at the time of MRI scanning in patients who developed 
NSF. This has not been observed in subsequent studies and was not the case in the 
current study. 
 
Two recent studies using spectroscopy have been able to demonstrate the presence of 
gadolinium particles in the skin of patients with NSF(348;349). However gadolinium 
particles were not present in the skin of all affected patients. Therefore these studies, 
along with this work, strengthen the epidemiological association between gadolinium 
based  contrast  agents  and  development  of  NSF  but  do  not  provide  causation  or  a 
mechanism for its pathogenesis. The authors speculate that gadolinium retained in tissue 
is  phagocytosed  by  macrophages  and  this  intracellular  gadolinium  results  in  the  up 
regulation of profibrotic cytokines and/or growth factors that ultimately eventuate in 
dermal or systemic fibrosis. 
 
9.4.9  Treatment of nephrogenic systemic fibrosis 
No consistently successful treatment for NSF has emerged. Various therapies have been 
tried  including  oral  and  topical  corticosteroids,  thalidomide,  ultraviolet  therapy, 
plasmapheresis and intravenous immunoglobulins. Isolated reports suggest that some of 
these interventions are beneficial in individual cases(350). Extracorporeal photophoresis 
has  been  advocated  most  widely  with  a  number  of  reports  published  to  suggest 
benefit(333;351). Whether this is due to a direct effect on the circulating fibrocyte is 
speculative. Restoration of renal function, whether by treatment of the underlying renal 310 
 
disease or by renal transplantation is likely to be of benefit as impaired renal function is 
one consistent finding in all patients with NSF. 
 
9.4.9  Conclusions 
This  study  has  confirmed  an  association  between  used  of  gadodiamide  as  a  MRI 
contrast agent and development of NSF.  This relationship appears to be dose related 
and development of NSF occurs following the demonstration of gadodiamide and is 
exacerbated  by  multiple  further  exposures.  Based  on  these  findings,  in  combination 
other studies, gadodiamide should no longer be considered safe for use in patients with 
advanced  chronic  kidney  disease  or  patients  with  established  ESRD.  If  there  is  no 
alternative to its use, the lowest diagnostic dose should be used and prompt dialysis 
after the scan to remove the gadodiamide. It is not clear is alternative gadolinium based 
agents are safe or it the preponderance of cases of NSF related to gadodiamide merely 
reflect  that  this  agent  accounts  for  >90%  of  the  scans  performed.  Use  of  contrast 
enhanced CMR as a tool for future research in this population has been jeopardised by 
the finding of the association between NSF and gadolinium based contrast agents. 311 
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10.1  Definition  of  uraemic  cardiomyopathy  with  cardiac  magnetic  resonance 
imaging 
The principal aim of this project was to determine whether a cardiomyopathy, specific 
to uraemia could be described in vivo using CMR. The chief method used to investigate 
this was using the contrast agent gadolinium-DTPA-BMA. A further question was to 
unravel the relationship between ischaemic heart disease (or coronary artery disease) 
and  uraemic  cardiomyopathy.  Contrast  enhanced  CMR  allowed  the  identification  of 
myocardial  infarction,  thereby  allowing  a  clear  distinction  between  the  presence  of 
cardiomyopathy potentially related to uraemia and that where the major determinant 
was premature coronary artery disease. 
 
The results contained in Chapter 3 demonstrate two distinct pathological processes or 
subtypes of uraemic cardiomyopathy. Firstly, the presence of left ventricular systolic 
dysfunction is closely associated with subendocardial late gadolinium enhancement, in 
keeping with previous myocardial infarction. This is in keeping with the aetiology of 
the majority of cases of left ventricular systolic dysfunction in the general population. 
The one feature specific to uraemia in this setting is that the progression of coronary 
artery atherosclerosis is accelerated in uraemia, leaving patients with ESRD vulnerable 
to  future  myocardial  ischaemia.  Second,  and  specifically  to  uraemia,  diffuse  LGE 
representing fibrosis through the left ventricular myocardium was observed in some, but 
not all, patients with left ventricular hypertrophy. There were no precedent reports of 
this finding, but this observation is in keeping with histopathological studies of cardiac 
tissue in uraemia. Since these findings have been published, a number of authors have 
commented  on  the  novelty  of  this  observation  using  CMR,  which  appears  to 
demonstrate a further strength of this technique(352;353).  
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10.2  Long  term  implications  of  uraemic  cardiomyopathy  and  other 
cardiovascular risk factors in uraemia 
Both  subtypes  of  uraemic  cardiomyopathy  described  with  contrast  enhanced  CMR 
appeared  to  be  associated  with  poorer  survival.  However  using  the  conventional 
definitions of cardiomyopathy with left ventricular function or dimensions, neither LVH 
nor  left  ventricular  systolic  dysfunction  were  demonstrated  to  be  independently 
associated with poor outcome, although there was a trend towards poorer survival with 
left ventricular systolic dysfunction. This may relate purely to small sample size of the 
cohort of patients. By contrast with other similar studies, all these patients were being 
considered for renal transplantation, and may have by definition been fitter, with less 
severe cardiac abnormalities than studied in other cohorts(75-77). A centre or era effect 
is possible, where patients with left ventricular hypertrophy are less likely to experience 
a  premature  cardiovascular  event  in  the  first  decade  of  the  twenty-first  century 
compared to the last decade of the twentieth.  In the West of Scotland, with such a high 
rate of coronary artery disease, patients with only left ventricular hypertrophy, without 
coronary artery atherosclerosis, may be relatively protected from cardiovascular events 
compared to the rest of the population, although this seems unlikely. Survivor bias may 
be present in patients who survive to commence dialysis therapy as the majority of 
patients with cardiovascular disease and renal impairment will die of cardiovascular 
disease  before  requiring  dialysis.  Ultimately  it  is  less  clear,  why  in  this  cohort  of 
patients,  the  presence  of  uraemic  cardiomyopathy,  detected  by  cardiac  morphology 
appeared to have less of an impact on survival than expected.  
 
The outcome studies contained in Chapter 6, observed that the greater determinants of 
long term outcome were conventional risk factors such as age, diabetes and presence of 
ischaemic  heart  disease.  Clearly  the  ability  to  receive  a  renal  transplant,  the  only 314 
 
definitive treatment to reverse uraemia, improves survival, but there is an inevitable 
selection bias, in choosing relatively fitter patients for transplantation. One practical 
application  emerged  by  studying  this  cohort  of  patients.  An  objective  method  of 
documenting  functional  capacity  using  an  exercise  tolerance  test  conveys  useful 
prognostic information for long term prognosis. This may help indicate which patients 
at much higher risk, who still require invasive investigations with angiography, and in 
whom further cardioprotective strategies may be contemplated, e.g. beta blockade, anti-
platelet  therapy  or  statins.  Unfortunately,  an  evidence  base  for  many  of  these 
interventions is still lacking in this patient group. 
 
10.3  Investigation  of  vascular  function  in  uraemia  using  cardiac  magnetic 
resonance imaging 
At the point of inception of the series of all the studies contained within this project, 
CMR was still a relatively new technique. Although clearly an attractive method for 
studying vascular function, there were very limited data published on the use of CMR 
for assessing vascular function as part of integrated cardiovascular risk assessment in 
any  patient  population(315;316).  As  there  is  a  well  established  link  between 
cardiovascular  outcome  and  arterial  stiffness,  studied  with  alternative 
methods(302;303),  in  patients  with  ESRD;  this  appeared  to  be  an  ideal  cohort  to 
develop this technique with.  
 
The studies contained within Chapter 8 clearly demonstrate arterial stiffness is distorted 
in ESRD compared to normal individuals, and is further reduced by the presence of 
additional cardiovascular risk factors, superimposed upon uraemia. Interestingly, both 
parameters  for  measuring  aortic  stiffness,  aortic  distensibilty  or  aortic  volumetric 
arterial strain, were independent predictors of cardiovascular events in these patients. 315 
 
This finding requires further exploration. One hypothesis would suggest that long term 
dialysis patients have acquired extremely stiff vessels, which may not be amenable to 
intervention with corrective therapy. Study is required to identify ESRD at highest risk 
of  developing  reduced  arterial  stiffness,  perhaps  using  circulating  markers  of  either 
calcification  or  atherosclerosis,  such  as  fetuin-A,  osteprotegerin,  homocysteine  or 
matrix Gla protein(130;310;311).  
 
10.4  Nephrogenic  systemic  fibrosis-  a  devastating  new  disorder  in  uraemic 
patients 
The identification of a link between CMR contrast agents, in particular gadolinium-
DTPA-BMA, and nephrogenic systemic fibrosis was an unexpected and catastrophic 
event. Of the patients in this study, as far as can be identified, no patient who developed 
NSF  received  an  isolated  MRI  scan  for  research  purposes,  with  patients  with  NSF 
undergoing multiple scans, particularly for planning vascular access for dialysis or to 
image  large  vessels  to  assess  peripheral  vascular  disease.  Further  reports  of  the 
association of this condition with gadolinium containing contrast agents have emerged. 
Currently, there are no plans to restart research based MRI scanning in ESRD patients 
using gadolinium based contrast agents until this issue is resolved.  
 
10.5  Limitations of these current studies 
One major goal of this study was to identify the relationship between CMR findings, 
particular  LGE  and  arrhythmia  and  sudden  cardiac  death.  As  part  of  the  initial 
investigation,  a  24-hour  ambulatory  ECG  monitor  recording  was  proposed  in  all 
patients, with the intention of studying minor rhythm abnormalities(78). Unfortunately 
for technical reasons this was not possible, leaving an unexplored gap between CMR 
findings and arrhythmia. Similarly, although details on cardiovascular events, hospital 316 
 
admissions  and  mortality  were  collected  from  the  renal  electronic  patient  records, 
causes of death and cardiovascular event data were not collected. Where this data is 
included  it  is  verified  information.  Potentially  this  information  is  available  for  all 
subjects,  but  was  deemed  too  costly  to  collect,  following  discussions  with  the 
administrative group of the Scottish Renal Registry, who in turn can access records held 
by the Information Services of the National Health Service for Scotland. 
  
Vascular  function  studies  would  have  been  improved  by  detailed  correlation  with 
measures  of  vascular  function  using  established  methods  such  as  the  SphygmoCor 
system, particularly in the ESRD cohort. This was not technically feasible due to the 
geographical  location  of  the  examination  room  used  for  SphygmoCor  examination. 
When piloted on a number of ESRD patients, it was reported to require too long a 
session to make to the study day an acceptable duration to retain patient comfort. One 
solution would have been to perform SphygmoCor examination on a separate occasion 
from CMR, but as vascular dimensions are dependent on hydration status, this may have 
lead to inaccuracies in the correlation between the various methods.  
 
10.5  Cardiac  magnetic  resonance  imaging-  a  novel  surrogate  end  point  for 
clinical trials in end stage renal disease? 
As discussed previously, CMR is ideally placed as an end-point for trials assessing left 
ventricular remodelling both in the ESRD and in other populations(354). Methods to 
reduce  left  ventricular  hypertrophy  include  drug  therapy,  alterations  to  the  dialysis 
schedule or minimising the haemodynamic instability of dialysis with techniques such 
as haemodiafiltration. Methods such as haemodiafiltration are attractive as they may 
increase  clearance  of  ‘uraemic  factors’  responsible  for  promotion  of  left  ventricular 
growth.  Additionally measures of vascular function could be studied in using CMR, 317 
 
using  interventional  strategies  to  reduce  arterial  stiffness,  such  as  calcium  free 
phosphate binders. 
 
10.6  Future work with cardiac magnetic resonance in end stage renal disease 
The initial findings of these studies demonstrating the presence of diffuse LGE as a 
clear marker for uraemic cardiomyopathy along with the suggestion that it may be a 
marker for patients at risk of sudden cardiac death, suggested that a clinical trial aimed 
at either preventing the development or progression of cardiac fibrosis in ESRD would 
be desirable, using the presence and extent of diffuse LGE as an end point. Therapeutic 
agents  which  have  negative  effects  on  myocardial  fibrosis,  which  were  proposed, 
include  angiotensin  receptor  blockers(355),  or  an  aldosterone  antagonist  such  as 
spironolactone  or  eplerenone,  which  may  oppose  the  direct  effect  of  aldosterone  in 
promoting myocardial fibrosis(356).  
 
Similarly from a clinical perspective, the ability to non-invasively detect functionally 
significant coronary artery stenosis using stress perfusion CMR is extremely attractive. 
This  technique  would  be  ideal  for  indicating  which  patients  require  coronary 
angiography as part of work up for renal transplantation, as well as helping to plan 
coronary revascularisation in patients with critical coronary stenosis. One recent study 
had demonstrated that CMR was able to distinguish haemodynamically relevant from 
non-relevant  coronary  lesions,  delineated  by  the  use  of  fractional  flow  reserve  at 
angiography, with a high sensitivity and specificity(357). A prospective trial to assess 
stress perfusion CMR in patients being assessed for renal transplantation was planned, 
comparing findings at CMR with angiography. Unfortunately, with the emergence of 
the link between gadolinium and nephrogenic systemic fibrosis, all plans to perform 
prospective trials using gadolinium contrast were halted.  318 
 
One  CMR  application  which  is  likely  to  provide  further  insight  into  myocardial 
metabolism in uraemia is phosphorous-31 magnetic resonance spectroscopy (
31P-MRS). 
This  does  not  require  a  contrast  agent.  By  analysing  left  ventricular  high-energy 
phosphates the derived phosphocreatine/adenosine triphosphate ratio can be calculated 
which indicates the energy metabolism and the phosphate potential (energy charge) of 
the myocardium. In a cross sectional pilot study, uraemic patients had higher LV mass, 
lower  phosphocreatine/adenosine  triphosphate  ratio  in  compared  to  patients  with  a 
kidney  transplant  and  healthy  controls(204).  The  prognostic  implications  of  these 
findings are unclear, but this may be an attractive target for intervention, with the goal 
of improving myocardial metabolism.   
 
Identifying  vulnerable  coronary  artery  plaque  has  in  patients  with  coronary  artery 
disease has been an area of intense research with CMR. As the coronary arteries are 
difficult  to  image  due  to  motion  artefact,  the  carotid  arteries  offer  the  most  easily 
accessible site for non-invasive assessment of atherosclerotic disease. Assessment of 
atherosclerotic plaque anatomy, size and characterisation by MR is based on the signal 
intensities and morphological appearance of the plaque on T1-weighted, proton dense-
weighted and T2-weighted sequence. Current level of resolution on MRI allows the 
assessment of the composition of the carotid atherosclerotic plaque, between fibrous 
tissue, lipid and necrotic core, calcium, haemorrhage, thrombus, and the state of the 
fibrous cap, based on their different signal intensities(358). This technique would be 
applicable to study in patients with ESRD, where it is not clear if rates of cardiovascular 
events  are  related  to  the  stability  of  the  atherosclerotic  plaque,  or  the  subsequent 
haemodynamic effects which follow plaque rupture and thrombosis, occluding a less 
compliant vessel, where compensatory reperfusion may be harder to achieve. CMR can 319 
 
additionally  assess  plaque  progression  or  regression  with  time  and  in  response  to 
therapy(359).  
 
Finally, there has been a great deal of interest in the use of ultrasmall superparamagnetic 
particles  of  iron  oxide  to  label  macrophages  within  the  vulnerable  atherosclerotic 
plaque. Accumulation of these particles in macrophages in predominantly ruptured and 
rupture-prone human atherosclerotic lesions has been demonstrated in the vessels of 
patients undergoing carotid endarterectomy using CMR(360). Whether this technique is 
safe in ESRD patients is unknown. 
 
10.7  Interventions to reduce cardiovascular risk in end stage renal disease 
There  remains a pressing need to reduce the  risk of future  cardiovascular events in 
patients with ESRD. One clear goal which, although is not currently evidence based is 
likely to benefit all patients is the aggressive treatment of cardiovascular risk factors in 
patients with less severe chronic kidney disease, who do not yet (and may never) require 
dialysis therapy. At this point, these risk factors may still be reversible, and therapies 
directed  at  treating  hypertension,  hypercholesterolaemia,  smoking  and  lifestyle  are 
likely to reduce both cardiovascular risk and progression of renal disease. This strategy 
has  been  adopted  in  the  United  Kingdom  with  the  advent  of  initiatives  aimed  at 
improving management of patients with less severe degrees of chronic kidney disease in 
primary care(361). 
 
Once patients have been established on dialysis therapy randomised placebo-controlled 
clinical trial data on the efficacy
 of cardioprotective medications patients are sparse. 
Cice et al in a prospective
 trial, demonstrated the benefits of beta blockers in dialysis 
patients  with  dilated
  cardiomyopathy  showing  improved
  2-yr  survival  with 320 
 
carvedilol(362).  Using  angiotensin  converting  enzyme  inhibitors,  the  Fosinopril  in 
Dialysis (FOSIDIAL)
 trial however was unable to show a reduction in cardiovascular
 
events with fosinopril in 397 dialysis patients(363), although a smaller Japanese trial of 
80  patients
  found  a  reduction  in  mortality  with  the
  angiotensin  receptor  blocker 
candesartan(364). Larger randomised clinical
 trials to assess the efficacy and safety of 
cardioprotective  agents  for  primary  prevention
  of  cardiovascular  morbidity  and 
mortality  (including  cardiac
  arrest)  in  ESRD  patients  would  be  welcome,  but  their 
design and implementation may be fraught with difficulty both in terms of scale and 
logistics. Many physicians find it hard to withhold beta blockers in patients already 
considered at such high vascular risk, whilst other nephrologists point to better survival 
in centres where patients are maintained with long dialysis schedules and minimal use 
of anti-hypertensives, including beta blocking medication(19).  The evidence, where it 
exists, for lipid lowering therapy in ESRD remains unclear. Although the 4D study 
showed no benefit in treating diabetic dialysis patients with atorvastatin compared to 
placebo(36),  further  large  prospective  randomised  controlled  trials  of  lipid  lowering 
therapy in advanced- or end stage renal disease, such as AURORA (A study to evaluate 
the  Use  of  Rosuvastatin  in  subjects  On  Regular  haemodialysis:  an  Assessment  of 
survival and cardiovascular events) and SHARP (Study of Heart and Renal Protection) 
will report in the next two to five years(365;366). 
 
Perhaps,  rather  than  targeting  conventional  cardiovascular  risk  factors,  trialling 
therapeutic interventions at calcium-phosphate imbalance or hyperparathyroidism, may 
be a more appropriate approach in ESRD. Already, it has been demonstrated that using 
sevelamer carbonate compared to calcium containing phosphate binders results in less 
coronary  calcification  with  a  possible  mortality  benefit(143;148).  The  treatment  of 
secondary  hyperparathyroidism  with  the  calcimimetic  cinacalcet  leads  to  significant 321 
 
improvements in biochemical parameters but patient-based benefits have not yet been 
demonstrated  in  trials(367).  Potentially  this  agent  may  yet  have  benefits  by 
counteracting the adverse cardiovascular effects of parathyroid hormone in uraemia. 
 
Finally,  in  patients  with  a  history  of  cardiac  arrest  or  left  ventricular  systolic 
dysfunction, there is growing evidence that implantable cardiac defibrillators improve 
survival(96).  A primary
 prevention trial of implantable cardiac defibrillators for the 
prevention of sudden cardiac
 death in ESRD may be theoretically feasible, particularly 
among dialysis patients with
 left ventricular ejection fraction <35% who comprise
 a 
high-risk population for sudden death. Potentially the microwave T-wave alternans test 
may used as a method to identify high-risk patients who would require an implantable 
cardiac defibrillator and also classify a low-risk group unlikely to benefit from ICD 
therapy(368). 
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10.8  CONCLUSIONS 
•  Cardiovascular disease is the leading caused of death in patients with chronic 
renal  failure,  both  prior  to  commencing  dialysis  and  on  renal  replacement 
therapy.  The  incidence  is  several  times  greater  than  that  of  age  matched 
individuals from the general population 
•  Increased  risk  of  cardiovascular  disease  in  this  population  is  related  to  both 
changes in cardiac structure and function, as well as to alterations in the major 
blood vessels 
•  CMR  is  the  current  optimal  method  for  assessing  cardiac  morphology  and 
function as well as interrogating myocardial tissue abnormalities 
•  Although previous reports suggest uraemic cardiomyopathy is a combination of 
left ventricular hypertrophy, dilatation and systolic dysfunction, studies in this 
thesis suggest that there are two main forms of uraemic cardiomyopathy; left 
ventricular hypertrophy  is the cardiomyopathy specific to uraemia whilst left 
ventricular  systolic  dysfunction  reflects  underlying  coronary  artery  disease. 
Studies  in  this  thesis  have  demonstrated  the  presence  of  diffuse  myocardial 
fibrosis in the presence of left ventricular hypertrophy 
•  Echocardiography  appears  to  overestimate  left  ventricular  mass  compared  to 
CMR in this population 
•  Although uraemic cardiomyopathy does have an impact on long term survival in 
this patient cohort, conventional cardiovascular risk factors such as advanced 
age, diabetes and a history of ischaemic heart disease confer poorer survival, 
whilst  receiving  a  renal  transplant  is  likely  to  be  protective  for  future 
cardiovascular events 
•  Serum  brain  natriuretic  peptide,  whilst  elevated  in  patients  with  evidence  of 
uraemic  cardiomyopathy  does  not  appear  to  a  sensitive  or  specific  enough 323 
 
biomarker to be used as a diagnostic aid in this patient group and conveys little 
prognostic value 
•  Arterial  function  measured  as  aortic  distensibilty  using  CMR  is  a  powerful 
independent predictor of future cardiovascular events 
•  There appears to be a link between the use of some gadolinium containing CMR 
contrast agents and development of nephrogenic systemic fibrosis, a potentially 
fatal condition, characterised by skin thickening, pain and immobility 
•  Both left ventricular hypertrophy and arterial stiffness measured by CMR are 
potential targets for intervention to reduce cardiovascular risk in patients with 
ESRD. Future work to is required to assess whether it is possible to modify 
arterial stiffness in these patients in which case this parameter may be used as  a 
surrogate marker for treatments to reduce cardiovascular events in this high risk 
group 
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